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Chronic limb-threatening ischemia (CLTI) is the end-stage of peripheral arterial disease 
(PAD), as classified by the Fontaine and Rutherford classifications (Table 1). This disease 
is caused by atherosclerosis. Therefore, the development of CLTI depends on the 
cardiovascular risk factors: age, male gender, diabetes mellitus, smoking, hypertension, 
hyperlipidaemia, genetic abnormalities and family history. (1–4) The yearly incidence 
of CLTI is between 50 and 100 new cases per 100,000 in a Western population. (1) 
Approximately 1% to 3% of PAD patients with an age of 50 or older progress to CLTI. 
(1) The incidence of CLTI is expected to grow due to the increasing elderly population 
(Figure 1). (1,5,6) Therefore, this thesis focuses on CLTI patients older than 70 years. 





Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic




II 2 Moderate 
claudication
III 3 Severe 
claudication
III Ischemic rest pain IV 4 Ischemic rest pain
IV Ulceration or 
gangrene
V 5 Minor tissue loss: 
nonhealing ulcer, 
focal gangrene 
with diffuse pedal 
ischemia








Figure 1. CBS age distribution
Patients with CLTI experience chronic ischemic rest pain (Fontaine III or Rutherford 4) 
and/or tissue necrosis, ulceration or gangrene (Fontaine IV or Rutherford 5-6) in the 
lower extremity. (1,7–9) The diagnosis of CLTI is based on the patient’s medical history, 
physical examination (e.g. discoloration and dependant hyperemia), and ankle-brachial 
index. Diagnostic tools that support the diagnosis are duplex ultrasound, computed 
tomographic angiography, and/or magnetic resonance angiography. In the case of 
ischemic rest pain, the ankle pressure is typically below 50 mmHg. (1,10) Chronic 
limb-threatening ischemia is also suspected in patients with tissue necrosis and an 
ankle pressure less than 70 mmHg. (1) In CLTI patients suitable for revascularisation, 
non-invasive anatomic imaging (computed tomographic angiography, or magnetic 
resonance angiography) is mandatory to evaluate the arterial anatomy in the 
affected lower extremity before committing to invasive angiography. (1) Based on the 
characteristics of the arterial lesions, a decision regarding revascularisation can be 
made. 
Revascularisation is considered the treatment of choice for CLTI patients to prevent 
lower limb amputation. (1,7) Revascularisation options include open vascular surgery, 
endovascular procedures, and hybrid procedures. The main surgical techniques 
to improve limb perfusion include lower extremity bypass and endarterectomy. 
Bypass surgery is preferred for multilevel lesions. (1) In bypass surgery options are an 





















Total population Population, age < 20 years
Population, age 20 - 65 years Population, age ≥ 65 years
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autologous or synthetic bypass. Due to superior patency rates, autologous bypasses 
are favoured. (11) Nowadays, endovascular interventions, such as balloon angioplasty 
or percutaneous atherectomy, are more commonly performed, due to advances in 
endovascular techniques. (12) Largely based on the BASIL trial, current guidelines 
recommend surgical revascularisation in patients with a life expectancy ≥ 2 years. 
(1,13,14)
Still, the management of CLTI in elderly patients remains a challenge. Elderly patients 
are often frail, lack autonomy, and have a shorter life expectancy. (15) The main goal 
in treating the elderly is to do no further harm. (16,17) In patients aged 80 years and 
older, surgical revascularisation is not always possible due to their frailty and existing 
comorbidities. Endovascular revascularisation has shown to achieve better limb 
salvage and survival rates and autonomy levels than surgical revascularisation. (15,18–
20) Therefore, an endovascular revascularisation approach is preferred in elderly CLTI 
patients. (15,18–22) However, as presented in Figure 2, invasive treatment is often not 
achievable because of severe comorbidities and/or the characterization of the arterial 
lesions. (7,16,17,23–25) Consequently, these ‘no-option’ CLTI patients can be managed 
with conservative treatment (analgesics and optimal wound care) or with lower limb 
amputation. (16,17,26–28) Treatment selection depends on the arterial lesion and the 
comorbidities of patients.  Unfortunately, there are no selection criteria that distinguish 
between patients who would benefit from lower limb amputation versus all other 
treatment options. 
 
Traditionally, treatment success has been focussed on objective outcome measures, 
such as bypass patency, limb salvage, and mortality. For CLTI patients, a 2-year 
mortality rate of 40% has been reported. (29) Moreover, CLTI patients with major tissue 
loss (Rutherford 6) have a nearly 3-fold risk of death. (29) The prevention of lower limb 
amputation remains the cornerstone in treating CLTI patients according to health care 
providers today. (30) However, there is a lack of reliable literature to support this in 
terms of mobility or quality of life (QoL). (31) Moreover in 35% to 67% of patients, 
limb salvage cannot be achieved despite all efforts to save the affected limb. (7,32,33) 
Besides that, no differences are found in amputation-free survival, after 3 years, between 
CLTI patients who were surgically revascularized and those who received endovascular 
revascularisation. (34,35) In addition, mortality rates are much higher after lower limb 
amputation. In CLTI patients with a lower-limb amputation, early mortality rates of up 
to 20% are reported. (36,37) Specifically in elderly patients, one-year mortality rates can 




Based on these high mortality and amputation rates, objective outcome measures, 
such as limb salvage and bypass patency, cannot sufficiently evaluate the effectiveness 
of treatments for CLTI. (40) Moreover, objective outcome measures do not assess 
treatment success in an optimal way, due to the multifactorial aspect of the disease 
in the elderly. (41–43) After lower limb amputation, other objective measures, such as 
functional outcome and mobility, are considered important. These measures have been 
described in elderly PAD patients after lower limb amputation. (44,45) Still, it remains 
a challenge to assess mobility outcomes in elderly CLTI patients who already have 
mobility impairments. (44) In fact, there is a lower chance of successful rehabilitation 
and functional improvement in elderly patients with limited preoperative functional 
abilities. (46,47) In these patients, lower limb amputation may be an optional treatment. 
However, this also raises the question of how ‘successful outcome’ is defined after 
lower limb amputation in the elderly. (44) Therefore, primary end points of treatment 
for CLTI have changed from clinical outcome to patient-reported outcome measures 
(PROMS). 













No Option CLI Patients
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Patient-reported outcome measures may be a supplementary measurement to assess 
treatment success. Therefore, this thesis focused on PROMS, which have become 
very important in establishing the best possible treatment in CLTI patients. Quality 
of life and health status (HS) are examples of PROMS. Both measures are believed 
to be impaired in CLTI. (1,13,48,49) Thus, a similarity or an increase in QoL and HS 
is considered a valuable outcome after treatment. There are few studies concerning 
PROMS, such as HS and QoL in elderly CLTI patients. 
Health status questionnaires assess perceived physical, psychological, and social 
functioning. They measure patients’ daily activities and only provide an objective 
assessment of functioning, provided by the patients’ themselves. (42,47,48,50–52) 
Quality of life questionnaires are a subjective appraisal of physical, psychological, 
and social functioning. In other words, QoL concerns patients’ satisfaction with 
functioning. (53) Examples of HS instruments are the 12-Item and 36-Item Short Form 
Health Survey, the European Quality of Life 5D, and the disease-specific VascuQol 
questionnaire. Unfortunately, these questionnaires are often mistakenly interpreted 
as QoL questionnaires. (48,52) But, these HS questionnaires do not incorporate the 
individual’s evaluation or expectations. (48) Therefore, the interpretation of their 
results may influence treatment decisions wrongly. (48,52,54) In contrast with these 
HS questionnaires, the World Health Organization has developed a questionnaire 
that evaluates a complete subjective evaluation of physical, psychological, and social 
functioning: the World Health Organization Quality Of Life-100 (WHOQOL-100) and 
the abbreviated version, the WHOQOL-BREF. (55) In this thesis, QoL and HS are 
investigated in CLTI patients and, more specifically, CLTI patients with a lower-limb 
amputation. Because guidelines are lacking regarding the use of disease specific QoL 
questionnaires for CLTI patients, it will also make a reasonable argument for the use of 
distinctive and subjective QoL questionnaires in future research on CLTI. (30,56)
Depression and anxiety 
In patients with coronary artery disease, depression is associated with poor prognosis. 
(57) In addition to depression, anxiety is associated with an increased risk of mortality 
and adverse cardiac outcome in patients with coronary artery disease. (58) Peripheral 
arterial disease is an atherosclerotic disease as well. The reported prevalence of 
depression in PAD patients varies greatly from 3 to 48%. (57,59) For PAD patients, less 
research is conducted on the prevalence of anxiety that is suggested to be between 
5.7% and 29%. (59,60) However, less research is conducted on the relationship 
between anxiety, depression and adverse outcomes in patients with PAD. (61) Still, 
15
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an association is assumed between depression and worse outcome, such as lower 
limb amputation. (61,62) Cherr et al. demonstrated that in PAD patients, depression 
was associated with worse patency rates and recurrent leg symptoms. (63) However, 
they could not find an association between depression and lower limb amputation. 
(63) McDermott at al. also evaluated depression in PAD patients. (61) They indicated 
an association between depression and increased mortality. (61) However in CLTI 
patients particularly, who are considered the end-stage population of PAD, little is 
known about the association of anxiety and depression with adverse outcomes. (62) 
Recently, Zahner et al. evaluated adverse outcomes for specifically CLTI patients with 
comorbid depression in a retrospective national study. (64) This study demonstrates 
that depression is associated with a 39% increased odds of lower limb amputation in 
CLTI patients. (64)
Cost-effectiveness
Given the rise of health care costs, cost-effective care is a huge priority for the general 
public. (65) The treatment of CLTI is very laborious and costly and despite all efforts 
to salvage the affected limb, limb amputation cannot always be averted. (66–69) Still, 
revascularisation is believed to be a cost-effective alternative to wound care and primary 
amputation, even in patients with a minimal functional status or octogenerians. (68) In 
CLTI patients, primary amputation provided fewer health benefits and increased costs 
due to the need for long-term care institutionalisation. (67,68) So, limb preservation 
needs to be achieved even if only costs are considered. However, not all patients 
are candidates for surgical revascularisation. In these patients, the question remains 
whether endovascular revascularisation is a cost-effective alternative to wound care 
alone. In this thesis, cost-effectiveness is plotted against the willingness-to-pay 
threshold for these two treatments, endovascular revascularisation and conservative 
treatment, in frail CLTI patients. The aim of this analysis is to examine whether 
aggressive revascularisation in patients not suitable for surgery is cost-effective. 
AIM AND THESIS OUTLINE 
The aim of this thesis is to evaluate the QoL and HS in the long-term outcomes of 
elderly patients with CLTI, with special attention to lower limb amputation. The first part 
of this thesis will focus on the long-term outcomes, the PROMS, and cost-effectiveness 
of the various treatments for CLTI. In the second part, the emphasis is on the QoL and 
HS and the role of depression and anxiety after lower limb amputation. 
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Long-term outcome after treatment for chronic limb-threatening ischemia in the 
elderly
Currently, there is a paucity of the best treatment choice in elderly CLTI patients. 
The cornerstone in treating CLTI remains limb salvage, which is often attempted by 
revascularisation. The treatment of CLTI patients is intensive, difficult and costly. The 
survival rates remain limited even with treatment. Along with the increase of the elderly 
age population, health care costs keep rising. Unfortunately, in 35-67% of patients, 
limb salvage cannot be achieved despite all efforts made to save the affected limb. 
(7,32,33) Moreover, not all patients are candidates for surgical revascularisation. For 
these patients, the question rises, which treatment is worthwhile from the patient’s and 
cost-effective point of view. (65) Chapter 2 will elaborate on this topic and the cost-
effectiveness of the two main treatment strategies in frail CLTI patients: endovascular 
revascularisation and conservative therapy. 
Chronic limb-threatening ischemia is associated with a systemic atherosclerotic 
burden and has a massive impact on daily life. (70) Historically, treatment success has 
been measured by objective outcomes, such as bypass patency, mortality, and limb 
salvage. (56) The effects of treatment on the patients themselves can be substantial. 
Consequently, PROMS have become of great importance. As already mentioned, 
HS and QoL are frequently used PROMS. Both measurements are considered to be 
impaired in CLTI patients. Although they have been extensively assessed, long-term 
outcome results in elderly CLTI patients are scarce.  In Chapter 3, QoL and HS, along 
with objective outcomes, are evaluated after two-years of follow-up. A latent class 
analysis will be used to determine if there are certain patient characteristics present 
that can help us recognize which patients are prone to have better or worse QoL and 
HS outcomes.     
Unfortunately, nearly 50% of CLTI patients are expected to die within 2 years after 
diagnosis. Mortality rates are even worse in CLTI patients with tissue loss. (29) 
The question remains if QoL and HS are preserved when treating these patients. 
Chapter 4 elaborates on the QoL and HS outcome of patients who expired during the 
two-year follow-up period.
The effect of lower limb amputation in the elderly patient 
In the elderly, the majority of amputations have a vascular cause. (33,71,72) Chronic 
limb-threatening ischemia has a high risk of lower limb amputation. One year after 
the onset of CLTI, approximately 25% of the patients will have undergone a lower limb 
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amputation. (1,71) Moreover, the four-year amputation rate increases to 35-67%. (7,32) 
Despite high amputation rates, research on PROMS is limited. (73) Though the surgical 
outcome of lower limb amputation in CLTI patients is undesirable, an adequate QoL 
is still possible for patients with a lower limb amputation. (30) Unfortunately, many 
studies claim to assess QoL but their findings are based on HS instruments. (52,73,74) 
In Chapter 5, the changes on questionnaires assessing QoL or HS, in elderly CLTI 
patients who underwent lower limb amputation, are discussed and compared with 
CLTI patients who did not undergo amputation during follow-up. 
In patients with coronary artery disease, depressive disorders adversely affect outcome. 
(75,76) For PAD, in general, an association is assumed between depression and adverse 
outcomes, such as lower limb amputation. (61,62) The prevalence of symptoms of 
depression is as high as 48% in patients with PAD. For CLTI, little is known about the 
association between depressive disorders and poor outcome. (62) Furthermore, lower 
limb amputation can alter a person’s social situation, which can also be associated 
with depression and anxiety, another psychiatric manifestation. (77) Anxiety is also 
known to rise after lower limb amputation in the long-term. In patients with coronary 
artery disease, anxiety is associated with an increased risk of mortality and also an 
adverse cardiac outcome. (58) However, the risks associated with anxiety are lower 
than the risks associated with depression. (58,78) In Chapter 6, the role of anxiety and 
symptoms of depression will be addressed in elderly patients with CLTI. Results will be 
compared between patients who underwent an amputation and patients who did not. 
In Chapter 7, special focus is on the long-term changes of QoL, HS and symptoms of 
depression exclusively in patients after lower limb amputation.
Finally, Chapter 8 will provide a summary of this thesis, a general discussion and 
future perspectives for further research. In Chapter 9, the conclusion of this thesis is 
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Objective: The treatment of chronic limb-threatening ischemia (CLTI), with the intention 
to prevent limb loss, is often an intensive and expensive therapy. The aim of this study 
was to examine the cost-effectiveness of endovascular and conservative treatment of 
elderly CLTI patients unsuitable for surgery.
Methods: In this prospective observational cohort study, data were gathered in 
two Dutch peripheral hospitals. CLTI patients aged 70 years or older were included 
in the outpatient clinic. Exclusion criteria were malignant disease, lack of language 
skills, and cognitive impairment; 195 patients were included and 192 patients were 
excluded. After a multidisciplinary vascular conference, patients were divided into 
three treatment groups (endovascular revascularization, surgical revascularization, or 
conservative therapy). Subanalyses based on age were made (70-79 years and ≥80 
years). The follow-up period was 2 years. Cost-effectiveness of endovascular and 
conservative treatment was quantified using incremental cost-effectiveness ratios 
(ICERs) in euros per quality-adjusted life-years (QALYs).
Results: At baseline, patients allocated to surgical revascularization had better health 
states, but the health states of endovascular revascularization and conservative therapy 
patients were comparable. With an ICER of €38,247.41/QALY (~$50,869/QALY), 
endovascular revascularization was cost-effective compared with conservative therapy. 
This is favourable compared with the Dutch applicable threshold of €80,000/QALY 
(~$106,400/QALY). The subanalyses also established that endovascular revascularization 
is a cost-effective alternative for conservative treatment both in patients aged 70 to 79 
years (ICER €29,898.36/QALY; ~$39,765/QALY) and in octogenarians (ICER €56,810.14/
QALY; ~$75,557/QALY).
Conclusion: Our study has shown that endovascular revascularization is cost-effective 
compared with conservative treatment of CLTI patients older than 70 years and also 
in octogenarians. Given the small absolute differences in costs and effects, physicians 
should also consider individual circumstances that can alter the outcome of the 
intervention. Costeffectiveness remains one of the aspects to take into consideration 




The treatment of chronic limb-threatening ischemia (CLTI), with the intention to prevent 
limb loss, is often an intensive and expensive therapy. (1) Chronic limb-threatening 
ischemia is the end stage of peripheral arterial disease. It is characterized by ischemic 
pain and/or tissue loss (ulcers or gangrene) and causes impaired quality of life (QoL); 
in addition, it has a high morbidity and mortality rate. (2,3) Treatment choices are 
conservative treatment, endovascular revascularization and surgical revascularization. 
Because of a lack of evidence in randomized controlled trials, there is still continuing 
international debate over which treatment is preferred, especially for elderly patients. 
(4–7)
So far, the only randomized controlled trial on this topic is the Bypass vs Angioplasty in 
Severe Ischaemia of the Leg (BASIL) trial. (7) This trial compared a bypass surgery-first 
with a balloon angioplasty-first revascularization strategy for CLTI. It was concluded 
that surgical revascularization was beneficial to the clinical outcome in CLTI patients 
with a life expectancy of at least two years. (7) The BASIL trial also examined the cost-
effectiveness of both treatments, as an individual outcome. According to the BASIL 
trial, surgery may lead to an increase of costs with little effects on health in the short 
to medium term. (7,8) In line with the BASIL trial, Barshes et al. recommended that 
only ambulatory and patients living independently should be treated with surgical 
revascularization, when only taking costs into consideration. 
For elderly patients not suitable for surgery, there is a lack of studies examining the 
cost-effectiveness of other CLTI treatment, notably conservative treatment. It could 
well be that surgical or endovascular revascularization is too invasive for fragile 
patients, leading to a loss of QoL and high costs.  Such concern is particularly relevant 
in view of the increase in patients’ age and the rise of health care costs. 
The purpose of this study was to examine the cost-effectiveness of endovascular and 
conservative treatment for elderly CLTI unsuitable for surgery, or in other words, the 
incremental cost-effectiveness ratio (ICER) between endovascular and conservative 
treatment in elderly patients unsuitable for surgery. The secondary objective was to 




The methods of this prospective observational cohort study have been previously 
published. (9) In summary, data were gathered between January 2012 and February 
2016 in two Dutch hospitals. Patients were included if they were aged 70 years or 
older and suffering from CLTI classified as Rutherford 4 to 6. (10) Exclusion criteria 
were malignant disease, lack of Dutch language skills, and cognitive impairment. The 
follow-up period was 2 years. In line with the findings of Arvela et al, Dosluoglu et al, 
Lejay et al, and Brosi et al, we distinguished between patients aged 80 years and older 
and patients 70 to 79 years of age. (8,11-13)
According to the criteria of the Central Committee on Research Involving Human 
Subjects, this prospective observational cohort study did not require a formal written 
consent for ethical approval. The Institutional Review Board (AMOA) endorsed this. All 
patients included signed an informed consent. 
Patients were divided into three treatment groups at a multidisciplinary vascular 
conference. (9) This treatment selection is in line with current clinical practice and 
resembles the selection of Brosi et al. (13) The treatment options were endovascular 
revascularization, surgical revascularization, and conservative therapy, as published 
previously by Steunenberg et al. (9) Endovascular revascularization was defined as a 
minimally invasive endovascular procedure using intraluminal stents or not. Endovascular 
procedures were performed by either an interventional radiologist or a vascular surgeon. 
Surgical revascularization was described as thromboendarterectomy, surgical bypass, 
or hybrid procedures. A hybrid procedure represented a thromboendarterectomy or 
surgical bypass combined with an endovascular intervention and was fully performed 
by a vascular surgeon. Conservative therapy consisted of local wound care, antibiotics, 
and pain medication with or without minor amputation. Minor amputation was defined 
as amputation distal to the ankle joint. (14) It was scored as a surgical reintervention 
if patency of the bypass had to be restored or an additional thromboendarterectomy, 
bypass surgery, or hybrid procedure in the same vascular area had to be undertaken. 
Endovascular reintervention was an additional minimally invasive endovascular 
procedure with or without the use of intraluminal stents. Conservative treatment 




The mortality and QoL results of this study were recently published. (9) In that publication, 
mortality and QoL were presented as separate items. It could be that mortality and 
QoL have a complicated interaction, as patients with a low QoL die earlier, leaving the 
study arm filled with patients with a high QoL. When QoL and mortality are combined 
in quality-adjusted life-years (QALYs), such complication in the interpretation of the 
results can be avoided. Moreover, QALYs allow an interpretation of the results in terms 
of costs per QALY, which is a preferred outcome in health economics. (15) In relation to 
the calculation of the cost-effectiveness ratio, in-hospital and out-of-hospital costs were 
obtained retrospectively according to the payer’s perspective, in which all inpatient 
and outpatient health care costs and effects were incorporated. (16) The actual costs of 
all services provided in the hospital were retrieved from the financial department. The 
outpatient costs included wound care and rehabilitation stays in nursing facilities and 
were provided by the nursing facilities’ financial departments. Missing cost data were 
estimated according to the Dutch manual for estimating costs. (15) Wound care costs 
were estimated using the same method. Rehabilitation costs of patients entering the 
hospital from nursing facilities were excluded because these patients already received 
nursing care before inclusion. These costs were not considered extra costs due to CLTI 
after inclusion. 
Cost-effectiveness was quantified using ICERs in euros per QALY. All cost values 
reported are in 2017 euros and represent a mean value. The 2017 purchasing power 
parities were used to convert euros to U.S. dollars by multiplying with 1.33.17 ICERs 
were calculated as the ratio of the difference in costs and the effect between different 
strategies. All model parameters were included in a model as distributions rather than 
as point estimates. Using Monte Carlo simulations, the model was evaluated 5000 
times. For each evaluation, the model parameters were randomly drawn from their 
distributions. In this way, all uncertainty from the model parameters was taken into 
account while one can deal with the skewed distributions of the data, most notably 
the costs. The ICERs were then graphically depicted in an ICER scatterplot to visualize 
the uncertainty of the estimates regarding the incremental costs and incremental 
effects. Moreover, the ICER was plotted against the willingness-to-pay threshold. This 
refers to the amount a society is willing to pay to achieve a state of good health or 
to avoid an undesirable state of health. (16) The Dutch willingness-to-pay threshold 
for severe health states is established at V80,000/QALY. (18) Next, the probability 
that endovascular surgery is cost-effective compared with conservative therapy is 
graphically represented using cost-effectiveness acceptability curves. (19) Costs were 
discounted using a rate of 4% and future effects at a rate of 1.5%, as recommended in 
the Dutch guidelines for economic evaluation. (15) 
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The 12-Item Short Form Health Survey (SF-12) was used to estimate EuroQol-5 
Dimension 3-Level (EQ-5D-3L) “utilities” or “values” by mapping Dutch EQ-5D-3L 
values onto the SF-12 scores. (20-23) An EQ-5D-3L score of 1.00 represents the value of 
perfect health; a score of 0.00 represents the value of death. The SF-12 questionnaire was 
measured at baseline (ie, the moment of inclusion in this study), after 5 to 7 days (mostly 
conducted during hospitalization), and at 6 weeks, 6 months, 12 months, and 24 months 
after intervention. It consists of 12 questions that provide information about mental 
and physical functioning. QALYs were calculated per patient during 2 years using the 
mapped EQ-5D-3L values. QALYs were calculated using a standard multiplicative model 
that estimated the area under linear interpolation of the EQ-5D-3L trajectory for each 
individual. The area under the curve was calculated by adding up the areas between 
the successive measurements (ie, trapezoid or, in case of death, a triangle). If the first 
measurement was missing, it was imputed with the second measure (first observation 
carried forward). If the second measure was also missing, it was imputed with the third 
measure, in which case the first measure was also imputed with the third measure. In 
case of death, zero was administered at the death date and at the follow-ups thereafter. 
If the last observations were missing, the last valid observation was carried forward. 
In general, the 24-month measure was not taken at exactly 24 months. Therefore, the 
24-month measure was interpolated or extrapolated to exactly 24 months. 
Statistical analysis was done using SPSS software (version 23; IBM Corp, Armonk, NY). 
Shapiro-Wilks test was used to assess normality of continuous data for the univariate 
comparisons. Gaussian-shaped distributions were analyzed using the Student t-test, 
expressed as mean and standard deviation. Non-normally distributed data were 
analyzed using the Mann-Whitney U test. A P value of <.05 was considered significant.
RESULTS
Between January 2012 and February 2016, a total of 387 elderly patients were 
diagnosed with CLTI. Of this initial cohort, 195 patients were included and 192 patients 
were excluded. There were 187 patients who were excluded from the study because 
of cognitive impairment or refusal to participate; five individuals were excluded on 
the basis of primary amputation. (9) There were 82 patients who were treated with 
endovascular revascularization, 67 patients with surgical revascularization and 46 
patients had conservative therapy. In the Supplementary Table, the revascularization 
procedures are described. Subanalyses based on age were made. The cohort was 




Table I presents an overview of the baseline characteristics of the three subgroups, 
as published earlier by Steunenberg et al. (9) Patients undergoing surgical treatment 
were significantly younger than the other treatment groups for all patients concerning 
median age (76 [73,81], p<.001) and had a Rutherford 4 classification (p<.001) more 
frequently. (9,24) There were no major statistically significant differences in the patients 
who received endovascular and conservative treatment. Therefore, this study focused 
on patients who received endovascular or conservative treatment because their 
characteristics were homogeneous, which allows for a meaningful comparison.
Follow-up
The follow-up characteristics during the first year are summarized in Table II. Hospita-
lization rates were significantly lower for conservative treatment when compared with 
both treatments for the total cohort and in considering both age groups. For stay 
in intensive care unit, readmission, reinterventions and rehabilitation, no statistically 
significant difference was reached. Compared with patients aged between 70 and 79 
years old, there is a tendency towards fewer reinterventions after initial conservative 
treatment for patients aged 80 years and older, but no statistically significant difference 
between all groups was evident. 
Costs and health utilities
Costs are presented in Table III. Costs were divided into four categories: hospital costs, 
rehabilitation or nursing costs, home health nursing costs, and total costs. For the 
total cohort and the octogenarian group, hospital costs were significantly higher in 
the endovascularly revascularized patients compared with the conservatively treated 
patients (p=.008). In the total cohort group, the mean total cost of endovascular 
revascularization was €21,041.93 during a period of 2 years. Endovascular 
revascularization produced a mean of 0.946 QALY per patient. Conservative treatment 
had a mean total cost of €17,103.04 in the same period. Conservative therapy produced 
a mean of 0.846 QALY per patient. 
Cost-utility analysis
Table IV provides an overview of the cost-utility analysis. For the total cohort group, the 
probabilistic ICER is €38,247.41, indicating that endovascular revascularization is cost-
effective compared with conservative therapy. A sub analysis, looking at the costs and 
effects of patients aged 70 to 79 years, gave an ICER of €29,898.36.  The subanalysis 
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Table III Hospital costs, rehabilitation costs, and home health nursing costs 
Endovascular Conservative
Mean Range Mean Range p-value*
Total group
  Hospital costs 13,878.49 (2,378.95  – 64,797.68) 9,770.35 (100.06 – 36,273.49) 0.008
   Rehabilitation or 
nursing home costs
6,239.70 (0 – 66,110.43) 6,467.95 (0 – 40,460.50) 0.960
   Home health nursing 
costs
923.74 (0 – 26,787.93) 864.74 (0 – 15,398.33) 0.807
  Total cost 21,041.93 (2,378.95 – 130,908.11) 17,103.04 (100.06 – 76,016.75) 0.041
Aged 70-79 
  Hospital costs 14,152.12 (2,378.95 – 48,437.60) 10,643.75 (558.46 – 23,959.41) 0.484
   Rehabilitation or 
nursing home costs
6,474.79 (0 – 30,192.80) 8,814.24 (0 – 30,010.33) 0.652
   Home health nursing 
costs
1,171.73 (0 – 26,783.94) 177,37 (0 – 1,132.23) 0.806
  Total cost 21,798.64 (2,378.95 – 79,899.51) 19,635.36 (548 – 52,501.15) 0.484
Aged 80+ 
  Hospital costs 13,684.68 (2,797.50 – 64,797.68) 9,462.09 (100.06 – 36,273.49) 0.008
   Rehabilitation or 
nursing home costs
6,073.17 (0 – 66,110.43) 5,639.84 (0 – 40,460.50) 0.835
   Home health nursing 
costs
748.08 (0 – 11,171.34) 1,107.35 (0 – 15,398.33) 0.696
  Total cost 20,505.93 (2,797.5 – 130,908.11) 16,209.28 (100.06 – 76,016.75) 0.060
Costs are presented in euros 
* Mann-Whitney U test










  Conservative 17,162.14 0.84588
  Endovascular 20,988.12 3,825.99 0.94591 0.10003 38,247.41
  Aged 70-79 
  Conservative 19,602.06 0.93669
  Endovascular 21,823.51 2,221.45 1.01099 0.0743 29,898.36
  Aged 80+ 
  Conservative 16,236.61 0.82064
  Endovascular 20,540.01 4,303.40 0.89640 0.07576 56,810.14
ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year
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Figure 1. The incremental costs and incremental benefits (quality-adjusted life-years 
[QALYs]) are demonstrated for endovascular revascularization and conservative 
treatment. ICERs, Incremental cost-effectiveness ratios
Figure I represents the point estimates of the ICERs of each of the 5000 trials in a 
scatter plot or cost-effectiveness plane. Most dots appear in the upper right quadrant 
of the illustration, indicating that endovascular revascularization is more costly and 
generates more QALYs compared with conservative therapy for elderly CLTI patients. 
The range of the dots is fairly large, indicating the uncertainty around the parameters.
Figure II depicts the cost-effectiveness acceptability curve for endovascular revas-
cularization compared with conservative therapy. The critical 50% level is surpassed at 
€37,350.00 in the total cohort group. In the octogenarian group, 50% of the iterations 
















Figure 2. The cost-effectiveness acceptability curve for endovascular revascularization 
compared with conservative treatment. The critical 50% level is surpassed at 























































In our study, CLTI patients (n=195) aged 70 years and older were included in a 
prospective observational cohort study to quantify the cost-effectiveness of treatment 
for elderly CLTI patients, in whom surgical treatment is not preferred. As presented in 
Table I, patients undergoing surgical treatment had significantly better characteristics 
than the patients who were treated endovascularly or conservatively, which does not 
allow a meaningful comparison. On the other hand, patients who received endovascular 
or conservative treatment had comparable characteristics at inclusion, which thus 
allows a meaningful comparison. In this comparison, we found that endovascular 
revascularization is more expensive but still showed a reasonable cost-effectiveness 
over conservative treatment.
The design and results of the present study are different from results published 
earlier. (1,7) The BASIL trial stated that surgical revascularization is recommended over 
endovascular revascularization after a 3-year follow-up, but has an unfavorable ICER 
of $184,492/QALY (~€138,369/QALY). (13) We could not confirm these results, as our 
patients allocated to surgical revascularization were in better health than the patients 
allocated to endovascular revascularization. Barshes’ probabilistic Markov model 
compared conservative therapy, endovascular revascularization, bypass surgery, and 
primary amputation in CLTI patients. Barshes et al. concluded that surgical bypass, 
with endovascular revision, was the most cost-effective treatment after 1-year follow-
up for ambulatory and patients living independently, ICER $47,738/QALY (~€35,804/
QALY). (1) 
Our assumption at the beginning of the study was that endovascular treatment results 
in fewer admission days and is less harmful than surgery. However, our data suggest 
otherwise. Admission days were similar to those of surgically treated patients, with no 
statistically significant difference between these two groups. Consequently, there was 
no statistically significant difference in the hospital costs between the endovascularly 
and surgically treated patients.  There was also no statistically significant difference 
in readmission and rehabilitation rates or the number of reinterventions after initial 
treatment.
Our study suggests that even for elderly CLTI patients not suitable for surgery, the 
most cost-effective treatment is endovascular revascularization compared with a 
conservative treatment. That is remarkable, as one could expect that the fragile health 
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state of the elderly would complicate endovascular revascularization. Nevertheless, 
our results suggest that despite this assumption, elderly still benefit from endovascular 
revascularization, although with higher costs. The interpretation of our results must 
be done in the light of the observation that both the absolute difference in costs and 
difference in effects are small: €3,825.99 and 0.10003 QALY. Small differences in the 
execution of endovascular revascularization and conservative treatment, local logistics, 
and the characteristic of the patients may therefore easily influence the individual 
outcomes.
Indeed, individual circumstance are often mentioned in the literature in discussing 
treatment allocation. For instance, Lelay et al. stated that the choice of treatment for the 
age group 80 years and older depends on life expectancy. (12) Surgical revascularization 
leads to a longer lasting outcome than endovascular revascularization. However, the 
outcome of surgery is limited in this age group because of a high rate of morbidity 
and mortality. (2,4,25) Moreover, initial costs of surgical revascularization are high. (25) 
All these factors were taken into consideration in choosing a treatment of choice, in 
the multidisciplinary vascular conference, where this study’s treatment selection took 
place. The older age category, octogenarians, was more likely to receive conservative 
or endovascular treatment. Only octogenarians in extremely good health, with a long 
life expectancy, were treated surgically. The difficulty lies in determining which patient 
has a life expectancy <2 years. Soga et al. developed a risk score to identify CLTI 
patients with <50% probability of 2-year survival. (26) However, this risk score was not 
part of the multidisciplinary vascular conference. 
The most obvious limitation of the present study as well the relevant studies in the 
literature is the lack of randomization. As in most hospitals, the allocation to treatment 
was done by a multidisciplinary vascular conference. (13) The allocation for surgical 
treatment during a multidisciplinary vascular conference is usually indisputable 
in patients who are suitable for surgery. This consensus is reflexed in the results of 
the study, as patients suitable for surgery have characteristics different from those 
allocated to conservative or endovascular treatment. Notably, the characteristics of 
the patients allocated to conservative treatment or endovascular revascularization are 
remarkably similar. A possible explanation is the absence of consensus about which 
treatment is preferred. (3,27) In absence of such consensus, treatment will depend on 
personal opinions of physicians and their ability to convince other physicians in the 
multidisciplinary vascular conference. It is thought that the resulting process leads to 
an ad hoc allocation, and indeed the close resemblance of the characteristic of the 
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patients allocated to conservative treatment and endovascular treatment resembles a 
random allocation. Obviously, randomization cannot be guaranteed, which makes that 
the interpretation of our results should be done with care. 
A second limitation of the present study is that in this relatively small sample size. 
Primary amputations had to be excluded because of the small number of patients (n 
= 5). 
A third limitation is that we did not conduct the EQ-5D-3L questionnaire to provide 
us “utility weight” for the calculation of QALYs. Instead we used the SF-12 to estimate 
EQ-5D-3L by mapping. Mapping is done by regression. Any regression will result in 
a smaller range and thus in smaller effects sizes. It is unlikely that this hampers our 
conclusion, as our ICER is already favorable compared to a reasonable willingness-to-
pay threshold. (20–22) 
A fourth limitation is that we did not include all possible costs items beside the medical 
costs. For instance, we did not include private costs to the patients or others (e.g. 
caretakers). Inclusion of these costs items would have given a better cost estimate 
from a societal perspective, but these costs were not recorded in this study. (28) The 
last limitation is that we were unable to obtain the cost of limb prosthesis purchased 
and prosthesis maintenance costs. However, elderly CLTI patients rarely ambulate or 
use prosthesis after lower limb amputation. (29) 
CONCLUSION 
This is one of the first studies that prospectively established cost-effectiveness of 
the treatment of elderly CLTI older than 70 years who were not suitable for surgery. 
Our study has shown that endovascular revascularization is the more cost-effective 
alternative to conservative treatment. Our results suggest that this conclusion also 
holds in octogenarians. Obviously, cost-effectiveness remains one of the aspects to take 
into consideration in making a clinical decision. Given the small absolute differences 
in costs and effects, physicians should also consider individual circumstances that can 




Supplementary table 1 procedure characteristics
Surgical procedures 
 Aorta-iliac 18
 Supraingenual Femoro-popliteal 2
 Infraingenual Femoro-popliteal 21
 Femoro-distal 14
Hybrid procedures
 Aorto-iliac procedure with PTA 4
 Femoro-popliteal bypass with iliac PTA 7
 Femoro-popliteal bypass with crural PTA 1
Endovascular procedures 
 Combined PTA 20
 Iliac
       PTA 8
       Stenting 10
 SFA
       PTA 18
       Stenting 11
 Popliteal arteries
       PTA 3
       Stenting 1
 Crural arteries
       PTA of one artery 2
       PTA of two arteries 4
       PTA of three arteries 2
Failed procedures 3
PTA = percutaneous transluminal angioplasty 
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Objective: In elderly patients, chronic limb-threatening ischemia (CLTI) diminishes 
quality of life (QoL) and health status (HS) considerably prior to treatment. There 
is also little scientific understanding of the long-term changes of QoL and HS 
after the treatment of elderly CLTI patients. Therefore, this was examined in this 
prospective study. The primary therapy was: endovascular revascularization, surgical 
revascularization, or conservative treatment. Furthermore, this study aimed to identify 
the distinctive trajectories of QoL and HS in elderly CLTI patients. 
Methods: Chronic limb-threatening ischemia patients aged 70 years or older were 
included in a prospective observational cohort study with a follow-up period of 2 years. 
The World Health Organization Quality Of Life-BREF (WHOQOL-BREF) was used to 
asses QoL. The 12-Item Short Form Health Survey (SF-12) was used to measure HS. 
These self-report questionnaires were completed six times during follow-up. The QoL 
and HS scores of the elderly sample in this current study were compared to the normal 
scores in the general elderly population. 
Results: In total, 195 patients were included in this study. The 2-year mortality was 
42.1%. After 2 years, in all treatment groups patients showed significantly higher 
physical QoL score compared to baseline: endovascular treatment (13.7 vs. 10.9, 95% 
CI -3.63; -1.74, p<.001), surgical treatment (15.0 vs. 10.4, 95% CI -5.28; -3.64, p<.001), 
and conservative treatment (13.8 vs. 11.6, 95% CI -3.88; -1.14, p<.001). There was no 
significant difference between the physical QoL 2-year results and the corresponding 
normal values in the elderly population for all treatment groups. The physical HS (SF-
12) significantly improved compared to the baseline measurement in the endovascular 
(37.4 vs. 28.9, 95% CI -9.46; -2.53, p=.001) and surgical revascularization group (42.5 vs. 
28.0, 95% CI -16.58; -10.48, p<.001). After two years, only surgically treated patients 
had physical HS scores corresponding with the scores of their peers (mean Δ = -1.69, 
95% CI -4.854; 1.474, p=.287). In the latent class trajectory analysis, there were no 
overlapping risk factors for poorer QoL and/or HS in this patient population.
Conclusion: This study shows that physical and psychological QoL levels in surviving 
elderly CLTI patients on the long-term do not differ from the corresponding norm 
values for elderly people. Moreover, physical QoL increases over the 2-year follow-
up after either revascularisation or conservative treatment. There were no disparities 
in sociodemographic, clinical and treatment characteristics associated with poorer 
QoL and HS. This study wants to encourage further analysis of the influence of 
biopsychosocial characteristics on QoL and HS in elderly CLTI patients in order to 




The end stage of peripheral arterial disease is represented by chronic limb-threatening 
ischemia (CLTI). This disease is characterized by ischemic rest pain and/or tissue necrosis. 
(1–3) Chronic limb-threatening ischemia diminishes quality of life (QoL) considerably 
(4) and is associated with high mortality and morbidity rates. (5–7) Revascularization 
(surgical or endovascular) is the cornerstone in the treatment of CLTI patients. (1) 
However, scientific data is scarce to determine the best revascularization management 
in elderly (aged ≥ 70 years) CLTI patients. (6–8) Moreover, revascularization is not 
always an option in frail elderly patients. In these patients, conservative treatment is 
a possible approach. (9–11) However, objective clinical outcome measures of conser-
vative treatment are poor. 
Lately, primary end points of treatment for CLTI have changed from clinical outcome, 
such as bypass patency and survival, to patient-reported outcome measures, most 
prominently QoL and health status (HS). Some research has been carried out on the 
long-term changes of these patient-reported outcome measures. (12,13) Still, there 
is little scientific understanding of the long-term changes of QoL and HS after the 
treatment of elderly CLTI patients. (13,14) 
Poorer QoL and HS over time can be associated with patient characteristics. (15) The 
course of a measured variable over time, such as QoL and HS, is called a trajectory. 
Latent class trajectory analysis is used to measure the relationship between distinctive 
trajectories and sociodemographic and clinical variables. In elderly CLTI patients, it is 
unclear which of these variables can influence the course of QoL and HS. Intermittent 
claudication (IC) is also a peripheral arterial disease and sometimes a precursor of 
CLTI. In IC patients, we know that poorer HS is associated with younger age, female 
sex, cardiac disease, worsening ankle-brachial index and not having a partner. (17–20) 
To our knowledge, no studies have focused on the course of elderly CLTI patients’ QoL 
or HS after treatment. In elderly CLTI patients, we expect high age, tissue loss (e.g. 
Rutherford 5/6) and comorbidities to result in poorer QoL and HS. Insight in variables, 
that can influence the QoL and HS trajectories of elderly CLTI patients, gives health 
care providers the opportunity to monitor specific patients more carefully. As a result 
of insufficient information concerning these trajectories, health care providers are 
restricted in making evidence-based decisions. 
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The primary goal of the present study was to provide long-term QoL and HS results 
for elderly CLTI patients after primary therapy: endovascular revascularization, 
surgical revascularization, or conservative treatment. The QoL and HS scores of this 
study’s elderly sample were compared to the normal scores in the general elderly 
population. The second goal was to identify within the entire CLTI patient group 
distinctive trajectories of QoL and HS, followed by an assessment of the clinical and 
sociodemographic variables associated with each trajectory.  
METHODS
In this prospective observational cohort study, elderly CLTI patients were included 
between January 2012 and February 2016 in two hospitals. (11) Inclusion criteria 
were diagnosis with CLTI and an age of 70 years or older.  Because of the use of 
questionnaires, patients with a lack of Dutch language skills and cognitive impairment 
were excluded. Patients treated for or with a recent diagnosis of malignancy and 
patients undergoing primary major lower extremity amputation were also excluded. A 
formal written consent for ethical approval was not required according to the criteria 
of the Central Committee on Research Involving Human Subjects. The institutional 
review board (AMOA) approved this. (11) An written informed consent was obtained 
from all included patients.
After careful consideration of standard diagnostics (e.g. duplex ultrasound, computed 
tomographic angiography, and/or magnetic resonance angiography) in the outpatient 
clinic and The Trans-Atlantic Inter-Society Consensus (TASC II) classification, a panel of 
experts recommended each patient a particular treatment in a weekly multidisciplinary 
vascular conference.(11) The recommendation of treatment was based on current 
clinical practice in addition to the patient’s condition. As reported previously, the 
treatment options were endovascular revascularization, surgical revascularization, or 
conservative therapy (local wound care, antibiotics, and analgesics with or without 
minor amputation). (11)
At patient inclusion, sociodemographic and several clinical characteristics were 
obtained from each patient. Sociodemographic characteristics included age, sex, 
marital status, educational level and level of independence (e.g. independent, home 
with help, nursing home or care facility). Clinical characteristics were Rutherford 
classification, current smoking, and chronic comorbidities (renal impairment, diabetes 
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mellitus, cardiac disease). During a period of 24 months, follow-up measurements 
were performed at 5-7 days, 6 weeks, 6 months, 12 months, and 24 months after the 
initial therapy. At baseline and at each follow-up moment, patients completed the 
WHOQOL-BREF questionnaire to determine QoL and the 12-Item Short Form Health 
Survey (SF-12) to measure HS. (16,17) Health status questionnaires evaluate perceived 
physical, psychological, and social functioning. They assess patients’ daily activities 
and only provide an objective assessment of functioning, provided by the patients’ 
themselves. (18–21) Quality of life questionnaires are a subjective appraisal of physical, 
psychological, and social functioning. Hence, QoL concerns patients’ satisfaction with 
functioning. (22) The treatment course (e.g. treatment, complications of treatment, 
time in hospital, time of amputation, time of death, et cetera) was also duly noted 
during follow-up. 
Statistical analysis 
Latent class trajectory analysis is a statistical method for identifying unobservable (e.g. 
latent) subgroups within a population based on the population’s pattern of answers on 
categorical and continuous observed variables. With latent class trajectory analysis, 
a prediction model why patients fall in a certain subgroups can be created. Latent 
class trajectory analysis was used to classify patients into distinctive subgroups, each 
showing a unique QoL or HS trajectory over the 2-year follow-up. (23) Latent class 
trajectory analyses were performed separately for the following outcomes: overall 
QoL, physical QoL, physiological QoL, physical HS, and psychological HS. For each 
outcome, models varying from one to eight distinctive trajectory classes (e.g. similar 
scoring pattern on the measured variable) were estimated. The relative fit measures 
Akaike’s Information Criterion (AIC), Bayesian Information Criterion (BIC), and AIC3 
were used to define the optimal number of classes. (24) If there was any inconsistency 
in the conclusions provided by these fit measures, we chose the number of classes 
that showed the best fit according to AIC3, as this fit measure was shown to perform 
best in selecting the optimal number of classes. (25) After the best fitting model was 
selected, the associations between latent trajectory class membership and the clinical 
and socio-demographic covariates could be determined using a multinomial logistic 
regression analysis. Missing values in the outcome variables were directly handled 
in the latent class model through full information maximum likelihood estimation. 
Latent gold 5.0 (26) was used both to fit the latent class models and to predict class 
membership based on the multinomial logistic regression. 
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The computerized software package IBM SPSS 23.0 performed all other statistical 
analyses. Shapiro Wilks test was used to assess normality of continuous data. Gaussian-
shaped distributions were expressed as mean and standard deviation. Non-normally 
distributed continuous data expressed as median and interquartile range. The change 
of QoL within treatment group was analyzed by linear mixed modelling. Within 
mixed modeling, custom hypothesis tests were used to assess differences between 
the follow-up measurements. One sample t-tests were used to compare the mean 
QoL and HS estimates to corresponding estimates in the general elderly population. 
A p-value below 0.05 (two-sided) indicated a statistically significant result.
RESULTS
Between January 2012 and February 2016, 195 patients were included in this study and 
192 patients were excluded from this study. There were 187 exclusions due to cognitive 
impairment or refusal to participate; five patients were excluded based on primary 
amputation. (11) Included patients were divided into 3 treatment groups. (11) Patients 
were treated with endovascular revascularization (n=82), surgical revascularization 
(n=67), or they received conservative therapy (n=46).
Baseline patient characteristics
The baseline characteristics are presented in Table I. Of the 195 patients, 56% were 
male and 33% had a Rutherford classification of 4. The median age was 80 years old. 
Patients selected for surgical treatment were significantly younger (p=.001) and had 
less comorbidity compared to patients selected for endovascular revascularization 
and conservative therapy. Patients who received conservative therapy had significantly 
higher pre-operative risk scores (ASA-score). (11) The baseline characteristics for the 
treatment groups separately of this study were previously published by Steunenberg 
et al. (11) The flow chart (Figure I) provides an overview of the clinical course of the 
patients included in our study. The overall two-year mortality was 42.1%. At the two years 
follow-up measurement point, 97 patients were eligible for outcome determination. 
For 31 patients out of the initial cohort of 195 patients, there was no follow-up data 
available for QoL and HS questionnaires because of loss to follow-up (mostly due to 








 Male 110 (56)
 Female 85 (44)
Age
 Median age [IQR] 80 [75,84]
Rutherford-class
 Category 4 64 (33)
 Category 5/6 131 (67)
Co-morbidity
 Pulmonary 108 (55)
 Cardiac 134 (69)
 Neurological 63 (32)
 Arthritis 58 (30)
Vascular risk factors 
 Hypertension 130 (57)
 Diabetes mellitus 94 (48)
 Renal impairment 111 (57)
 Currently smoking 45 (23)
Preoperative risk scores
 ASA score 2 53 (27)
 ASA score 3 124 (64)
 ASA score 4 18 (9)
V-POSSUM score
 Median morbidity [IQR] 55 [35,73]
 Median mortality [IQR] 15 [8,25]
Primary Treatment
Surgical revascularisation 67 (34)
Endovascular revascularisation 82 (42)
Conservative treatment 46 (24)




Figure 1. Screened and included patients
387 Elderly With CLI Screened
82 Assigned to Endovascular 
Revascularization
Outcomes at 2 y FU
12  Lost to Follow-up  
(6 Deaths)
  08  Had Received the  
Primary Treatment
  03  Had Received  
Additional Interventions
  01  Had Undergone Lower 
Extremity Amputation
38 Deaths
  20  Had Received the  
Primary Treatment 
 04 Had Received  
Additional Interventions
  14 Had Undergone Lower 
Extremity Amputation
32  Eligible For Outcome 
Determination
  20  Had Received the 
Primary Treatment
 06  Had Received  
Additional Interventions
 06  Had Undergone Lower 
Extremity Amputation
50  Eligible For Outcome 
Determination
 29  Had Received the 
Primary Treatment
 14  Had Received  
Additional Interventions
 07  Had Undergone Lower 
Extremity Amputation
15  Eligible For Outcome 
Determination
 9  Had Received the  
Primary Treatment
 3  Had Received  
Additional Interventions
 3  Had Undergone Lower 
Extremity Amputation
Outcomes at 2 y FU
6 Lost to Follow-up 
 (2 Deaths)
  03  Had Received the  
Primary Treatment
  00  Had Received  
Additional Interventions
  03  Had Undergone Lower 
Extremity Amputation
11 Deaths
  07  Had Received the  
Primary Treatment
  02  Had Received  
Additional Interventions
  02  Had Undergone Lower 
Extremity Amputation
Outcomes at 2 y FU
13 Lost to Follow-up 
 (7 Deaths)
  05  Had Received the  
Primary Treatment
  03  Had Received  
Additional Interventions
  05  Had Undergone Lower  
Extremity Amputation
18 Deaths
  13  Had Received the  
Primary Treatment
  02  Had Received  
Additional Interventions
  03  Had Undergone Lower 
 Extremity Amputation
67 Assigned to Surgical  
Revascularization




            187 Ineligible





Figure II presents the QoL of patients after 1 and 2 years of follow-up. The 1-year 
results were previously published by Steunenberg et al. (27) The overall QoL and social 
relationship scores were significantly improved at the 2-year follow-up measurement 
when compared to the baseline measurement in the surgically treated group 
(respectively 3.7 vs. 3.0, 95% CI 0.34; 0.83, p<.001 and 16.5 vs. 15.4, 95% CI 0.44; 1.78, 
p=.001). Similarly, the overall QoL and social relationship scores were also significantly 
better in the group receiving conservative treatment (respectively 3.3 vs. 3.1, 95% CI 
0.00; 0.78, p=.049 and 16.5 vs. 15.5, 95% CI 0.25; 2.30, p=.016). There were no significant 
differences in QoL scores at the 2-year follow-up measurement for the endovascular 
treated patients, except for physical QoL.  
After 2 years, physical QoL had a significantly higher score than the baseline 
measurement in all treatment groups: endovascular treatment (13.7 vs. 10.9, 95% 
CI 1.74; 3.63, p<.001), surgical treatment (15.0 vs. 10.4, 95% CI 3.64; 5.28, p<.001), 
and conservative treatment (13.8 vs. 11.6, 95% CI 1.14; 3.88, p<.001). However, the 
psychological QoL only showed significant improvement in the surgically treated group 
at 2-year follow-up (15.3 vs. 14.0, 95% CI 0.68; 1.89, p<.001). No statistically significant 
differences between the environmental scores after 2 years and the baseline score 
were found. Moreover, there were also no statistically significant differences between 
the treatment groups for all QoL measurements at 2-year follow-up. All QoL domains 
show no significant changes in scores during the second year of follow-up compared 
to the one-year results. 
In Table II, the mean QoL scores at baseline and 2-year follow-up are compared to the 
mean estimated normal scores in the elderly population. (28) At baseline, physical QoL 
(mean Δ = -3.97, 95% CI -4.36; -3.57, p<.001) and psychological QoL (mean Δ = -0.78, 
95% CI -1.13; -0.44, p<.001) were significantly lower than the normal values of elderly. 
(28) There was no significant difference between physical QoL, psychological QoL or 
environmental 2-year results and the corresponding normal values for elderly for all 
treatment groups. (28) The overall QoL score was significantly lower in comparison 
with normal value for elderly at baseline (mean Δ = -0.81, 95% CI -0.94; -0.69, p<.001) 
and at 2-year follow-up (mean Δ = -0.39, 95% CI -0.55; -0.23, p<.001). The 2-year social 
relationships score was significantly higher in comparison with normal value for elderly 




Data is presented as mean and standard deviation  
+     =  Significant difference between the treatment group and the surgical treatment group (p<0.05) 










































































































































































































































































































Figure 2. Quality of Life
  i ti
+   =  Significant difference between the treatment group and the surgical treat ent group (p<0.05)
*   = Significant difference in the treatment group between this measurement and baseline (p<0.05)
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Table 2. WHOQOL-BREF compared to normal values for elderly
n Mean 
estimate
Mean estimate in 
the general elderly 
population
Mean difference 95% CI p value
Baseline QoL domains
Overall 3.90
Total cohort 193 3.086 -0.815 -0.936; -0.693 <0.001
Endovascular group 81 3.105 -0.795 -0.992; -0.598 <0.001
Surgery group 67 3.045 -0.855 -1.067; -0.643 <0.001
Conservative group 45 3.111 -0.789 -1.024; -0.554 <0.001
Physical 14.869
Total cohort 192 10.903 -3.966 -4.362; -3.570 <0.001
Endovascular group 81 10.899 -3.970 -4.604; -3.337 <0.001
Surgery group 65 10.422 -4.447 -5.074; -3.819 <0.001
Conservative group 46 11.589 -3.280 -4.137; -2.422 <0.001
Psychological 14.871
Total cohort 195 14.088 -0.783 -1.129; -0.437 <0.001
Endovascular group 82 14.175 -0.696 -1.239; -0.154 0.012
Surgery group 67 13.967 -0.904 -1.498; -0.310 0.003
Conservative group 46 14.109 -0.762 -1.501; -0.023 0.43
Social relationship 15.251
Total cohort 191 15.467 0.218 -0.1498; 0.586 0.244
Endovascular group 80 15.500 0.249 -0.312; 0.810 0.380
Surgery group 65 15.426 0.174 -0.416; 0.764 0.557
Conservative group 46 15.478 0.227 -0.656; 1.109 0.006
Environment 15.573
Total cohort 188 15.479 -0.093 -0.386; 0.200 0.531
Endovascular group 79 15.443 -0.130 -0.590; 0.331 0.577
Surgery group 63 15.564 -0.009 -0.478; 0.459 0.969
Conservative group 46 15.427 -0.146 -0.816; 0.524 0.664
QoL domains at 2-year follow-up
Overall 3.90
Total cohort                          87 3.512 -0.388 -0.545; -0.231 <0.001
Endovascular group 28 3.375 -0.525 -0.865; -0.185 0.004
Surgery group 43 3.651 -0.249 -0.422; -0.076 0.006
Conservative group 13 3.346 -0.554 -1.038; -0.070 0.028
Physical 14.869
Total cohort 84 14.364 -0.505 1.094; 0.084 0.092
Endovascular group 28 13.704 -1.165 -2.341; 0.011 0.052
Surgery group 43 14.950 0.081 -0.698; 0.860 0.834
Conservative group 13 13.846 -1.023 -2.419; 0.374 0.137
Psychological 14.871
Total cohort 84 15.071 0.200 -0.226; 0.627 0.353
Endovascular group 28 14.810 -0.062 -0.904; 0.781 0.882
Surgery group 43 15.302 0.431 -0.144; 1.006 0.138
Conservative group 13 14.872 0.001 -1.131; 1.133 0.999
Social relationship 15.251
Total cohort 83 16.137 0.885 0.466; 1.305 <0.001
Endovascular group 28 15.405 0.153 -0.830; 1.137 0.751
Surgery group 42 16.508 1.277 0.810; 1.703 <0.001
Conservative group 13 16.513 1.261 0.437; 2.086 0.006
Environment 15.573
Total cohort 84 15.643 0.070 -0.240; 0.380 0.653
Endovascular group 28 15.571 -0.001 -0.576; 0.574 0.997
Surgery group 43 15.721 0.148 -0.286; 0.583 0.494
Conservative group 13 15.539 -0.034 -0.919; 0.851 0.934
Data presented as mean; n = number of patients




Health status after 1 year and 2 year follow-up is presented in Figure III. After 2 
years, physical HS (SF-12) significantly improved compared to the one-year follow-
up measurement in the surgical revascularization group (42.5 vs. 28.0, 95% CI 2.75; 
7.25, p<.001). The physical HS (SF-12) significantly improved compared to the baseline 
measurement in the endovascular (37.4 vs. 28.9, 95% CI 2.53; 9.46, p=.001) and surgical 
revascularization group (42.5 vs. 28.0, 95% CI 10.48; 16.58, p<.001). For all treatment 
groups, the mental HS scores were significantly better than the baseline measurement. 
The mental HS scores were also improved in comparison with the one-year follow-
up measurement: endovascular treatment (46.8 vs. 42.5, 95% CI 1.90; 7.63, p=.001), 
surgical treatment (51.5 vs. 43.9, 95% CI 4.53; 9.38, p<.001), and conservative treatment 
(45.8 vs. 39.5, 95% CI 1.05; 9.62, p=.009). Also, the endovascular treated patients had 
a significantly lower mental HS score than the surgically treated patients at the 2-years 
follow-up measurement (46.8 vs 51.5, 95% CI -8.47; -0.45, p=.03).  
Table 2. WHOQOL-BREF compared to normal values for elderly
n Mean 
estimate
Mean estimate in 
the general elderly 
population
Mean difference 95% CI p value
Baseline QoL domains
Overall 3.90
Total cohort 193 3.086 -0.815 -0.936; -0.693 <0.001
Endovascular group 81 3.105 -0.795 -0.992; -0.598 <0.001
Surgery group 67 3.045 -0.855 -1.067; -0.643 <0.001
Conservative group 45 3.111 -0.789 -1.024; -0.554 <0.001
Physical 14.869
Total cohort 192 10.903 -3.966 -4.362; -3.570 <0.001
Endovascular group 81 10.899 -3.970 -4.604; -3.337 <0.001
Surgery group 65 10.422 -4.447 -5.074; -3.819 <0.001
Conservative group 46 11.589 -3.280 -4.137; -2.422 <0.001
Psychological 14.871
Total cohort 195 14.088 -0.783 -1.129; -0.437 <0.001
Endovascular group 82 14.175 -0.696 -1.239; -0.154 0.012
Surgery group 67 13.967 -0.904 -1.498; -0.310 0.003
Conservative group 46 14.109 -0.762 -1.501; -0.023 0.43
Social relationship 15.251
Total cohort 191 15.467 0.218 -0.1498; 0.586 0.244
Endovascular group 80 15.500 0.249 -0.312; 0.810 0.380
Surgery group 65 15.426 0.174 -0.416; 0.764 0.557
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Physical 14.869
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Endovascular group 28 13.704 -1.165 -2.341; 0.011 0.052
Surgery group 43 14.950 0.081 -0.698; 0.860 0.834
Conservative group 13 13.846 -1.023 -2.419; 0.374 0.137
Psychological 14.871
Total cohort 84 15.071 0.200 -0.226; 0.627 0.353
Endovascular group 28 14.810 -0.062 -0.904; 0.781 0.882
Surgery group 43 15.302 0.431 -0.144; 1.006 0.138
Conservative group 13 14.872 0.001 -1.131; 1.133 0.999
Social relationship 15.251
Total cohort 83 16.137 0.885 0.466; 1.305 <0.001
Endovascular group 28 15.405 0.153 -0.830; 1.137 0.751
Surgery group 42 16.508 1.277 0.810; 1.703 <0.001
Conservative group 13 16.513 1.261 0.437; 2.086 0.006
Environment 15.573
Total cohort 84 15.643 0.070 -0.240; 0.380 0.653
Endovascular group 28 15.571 -0.001 -0.576; 0.574 0.997
Surgery group 43 15.721 0.148 -0.286; 0.583 0.494
Conservative group 13 15.539 -0.034 -0.919; 0.851 0.934
Data presented as mean; n = number of patients
The value of the general elderly population is based on reference 28
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Figure 3. Health status (SF-12)  
 
Data is presented as mean and standard deviation 
+     =  Significant difference between the treatment group and the surgical treatment group (p<0.05) 






















































































































































i ure 3. Heal h status (SF-12) 
Data is presented as m an and standard deviation
+     Significant diff r ce between the treatment group and the surgical treatment group ( . )
*   = Significant difference in the treatment group between this measurement and baseline (p<0.05)
#   = Significant difference in the treatment group between this measurement and the 12 month measurement (p<0.05)
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Table 3. HS compared to normal values for elderly
n Value Value of general 
elderly population
Mean difference p value 95% CI
Baseline HS domains
Physical 44.22
Total cohort 190 28.87 -15.35 <0.001 -16.596; -14.097
Endovascular group 78 28.88 -15.34 <0.001 -17.427; 13.256
Surgery group 66 27.98 -16.24 <0.001 -17.880; -14.608
Conservative group 46 30.15 -14.07 <0.001 -17.140; -10.999
Mental 47.71
Total cohort 190 37.44 -4.58 <0.001 11.863; -8.670
Endovascular group 78 36.98 -10.73 <0.001 -13.376; -8.090
Surgery group 66 36.13 -11.57 <0.001 -14.103; -9.054
Conservative group 46 40.12 -7.59 <0.001 -10.914; -4.272
HS domains at 2-year follow-up
Physical 44.22
Total cohort 84 39.64 -10.27 <0.001 -6.984; 2.186
Endovascular group 28 37.39 -6.83 0.005 -11.381; -2.275
Surgery group 43 42.53 -1.69 0.287 -4.854; 1.474
Conservative group 13 34.89 -9.33 0.005 -15.345; -3.312
Mental 47.71
Total cohort 84 49.07 1.36 0.209 -0.774; 3.490
Endovascular group 28 46.78 -0.93 0.667 -5.320; 3.457
Surgery group 43 51.54 3.83 0.004 1.289; 6.376
Conservative group 13 45.81 -1.90 0.496 -7.778; 3.984
Data presented as mean; n = number of patients
The value of the general elderly population is based on reference 29
The scores of the physical and mental domains of the SF-12 questionnaire were 
compared to the mean estimated normal scores in the elderly population (Table III). 
(29) At baseline, both domains of the SF-12 were significantly impaired in the elderly 
CLTI population of this study. After two years, only surgically treated patients had 
physical HS scores corresponding with the scores of their peers (mean Δ = -1.69, 95% 
CI -4.854; 1.474, p=.287).
Trajectories
The number of latent trajectory classes was found to be four for the QoL domains and 
five for the HS domains based on the lowest AIC3-value (Supplement A). Trajectories 
of the QoL domains are presented in Figure IV and trajectories of the HS domains 
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Figure 4. Quality of Life Trajectories
are presented in Figure V. In supplement B, an overview of the associations between 
the latent trajectory classes and the sociodemographic and clinical characteristics is 
provided for the overall, physical and psychological domains of QoL and the physical 
and mental domains of HS. Because of the large number of tested associations, a 
Bonferroni correction was applied resulting in an adjusted significance level of .05 / 14 
predictors = .0035. Overall, there were no overlapping risk factors for poorer QoL and/
or HS in this patient population.
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Figure 5. Health Status Trajectories 
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Although QoL and HS are discussed for CLTI patients in current literature (11–13,30–
32), there is a paucity of information about long-term QoL and HS outcomes in 
elderly CLTI patients. In our study, there is a persistent gain in QoL and HS for the 
surgically treated patients after two years. For all treatment groups, the physical 
QoL is significantly better compared to the baseline measurement on the long-term. 
Concerning physical HS, both surgically and endovascular treated patients improve 
significantly on this domain of the SF-12. Interestingly, conservatively treated patients 
do not show any improvements on their physical HS scores during two years of follow-
up. More importantly, physical QoL did not differ from the corresponding normal 
values for patients in all treatment groups after 2-years of follow-up. (28) But then 
again, the overall QoL score was significantly lower in comparison with normal value 
for elderly after 2-years of follow-up.    
Our results are only partly in line with previous studies conducted with CLTI patients. 
The BASIL trial stated that both endovascular and surgical revascularization led to an 
improved long-term QoL. (12) In our study, the surgically treated rose in QoL scores 
and endovascular treated patients only gained in physical QoL. A possible explanation 
for this might be that patients were included in our study despite comorbidities or type 
of anatomic lesion. Due to the latter, patients could only be randomized in the BASIL 
trial if patients were suited for open or endovascular revascularization. Thus, only half 
of the elderly patients with infra-inguinal lesions could be included in the BASIL trial. 
Similar to our study, a significant difference in QoL between the two groups could not 
be detected. (12,33) Still, it remains unsure whether the BASIL trial’s QoL results reflect 
the underlying QoL. It can be argued that the disease-specific VascuQol questionnaire 
does not represent QoL. The measurement of physical function in the VascuQol 
questionnaire represents an ‘objective’ assessment of performing activities instead 
of the patient’s perception of his overall functioning. (34) Therefore, the VascuQol 
questionnaire is an objective assessment of functioning e.q. HS. (4) Additionally, the 
differentiating power in CLTI patients is deficient and therefore it may not be applicable 
to the CLTI patient group. (35)
Van Hattem et al. indicated that HS deteriorates after peripheral bypass surgery on the 
long-term (mean follow-up 11 years). (13) There is a lack of other studies on the long-
term HS of CLTI patients. In our study, surgically and endovascular treated patients 
show a significant improvement of physical and mental HS after 2 years of follow-up. 
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Patients who received conservative treatment do not show any deterioration in the 
physical and mental HS domains during 2 years of follow-up. This study indicated that 
surviving patients do not experience worse HS 2 years after the start of any treatment. 
An understanding of the profile of elderly CLTI patients to identify patients with factors 
that could impair QoL and HS was lacking. In the latent class analysis, patients with the 
lowest and highest QoL and HS trajectories could be identified. The findings of this 
prospective observational cohort study may help us recognize elderly CLTI patients 
that may need a careful reconsideration of the intended treatment.  Consequently, a 
tailored approach in the management of CLTI can be facilitated when there is insight 
into the variables that make a patient prone to better or worse QoL or HS outcomes. 
With respect to shared decision making, these distinctive variables will provide a very 
important facet in personalized medicine. 
In patients with IC, prior reports have focussed on factors that might influence the 
course of HS. Poorer HS in these patients was associated with younger age, female 
sex, the presence of cardiac disease, worsening ankle-brachial index and not having 
a partner. (15,36–38) However, these results do not apply to the elderly CLTI patients 
in this study. No sociodemographic or clinical variables significantly influenced the 
lowest QoL and HS trajectories. 
Our study has limitations. In this observational study, patients were not randomized 
to treatment. Thereby, this study suffers from selection bias. Nevertheless, a selection 
bias even exists when CLTI patients are randomized to treatment. Not all patients 
are suitable for both surgical and endovascular revascularization. Moreover, some 
patients cannot undergo either of these treatments. So in this study, the treatment 
selection after counselling in a multidisciplinary vascular conference resembles current 
clinical practice. Secondly, in this study questionnaires were conducted. In survey 
research a non-response bias is always present. The main reason for loss to follow-up 
was incapability of completing questionnaires during follow-up. Still, response rates 
were high when compared to the BASIL trial and PREVENT trial. At 2-years follow-up 
84.1% patients alive completed the questionnaires. In the BASIL trial, the response 
rate was 70%. (12) Response rate was similar in the PREVENT trial; 62.5% at 1-year 
follow-up. (39) Thirdly, patients with primary amputations were excluded due to the 
low number of patients (n=5). So, this study was underpowered to examine the clinical 
outcome of patients with a primary amputation. Future research will examine QoL 
and HS of primarily amputated CLTI patients. Also, due to of the small number of 
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surviving patients, this study did not differentiate between patients with ischemic rest 
pain and patients with ischemic ulcers or wounds. Previously published data of this 
study shows that patients with ischemic ulcers or wounds were significantly less treated 
with conservative treatment compared to revascularization. (11) In future research, a 
differentiation should be made between patients with ischemic rest pain and patients 
with ischemic ulcers or wounds.  
CONCLUSION
Currently, long-term outcome in elderly CLTI patients are lacking. (40) This study shows 
that physical and psychological QoL levels in surviving elderly CLTI patients do not 
differ from the corresponding normal values of elderly people. Moreover, physical 
QoL increases after revascularisation and conservative treatment after 2 years of 
follow-up. Physical HS only improves in revascularized patients. This was also the first 
study to evaluate the trajectory of elderly CLTI patients’ QoL or HS after treatment. 
Interestingly, no sociodemographic or clinical variables significantly influenced the 
lowest QoL and HS trajectories. This study hopes to encourage further analysis of the 
influence of biopsychosocial characteristics on QoL and HS in elderly CLTI patients in 




Supplement A. Goodness-of-fi t chi-squared statistics compared to analyses of 
Akaike’s Information Criterion (AIC), Bayesian Information Criterion (BIC), and AIC3 
Outcome Trajectories BIC AIC AIC3
WHOQOL overall
1 2050,9379 2028,0269 2035,0269
2 1939,7864 1835,0504 1867,0504
3 1960,7783 1774,2173 1831,2173
4 2009,3766 1740,9906 1822,9906
5 2045,8327 1695,6217 1802,6217
6 2106,3225 1674,2865 1806,2865
7 2172,2746 1658,4137 1815,4137
8 2295,8922 1700,2063 1882,2063
WHOQOL physical
1 4226,8036 4203,8926 4210,8926
2 4196,9836 4092,2476 4124,2476
3 4215,3223 4028,7613 4085,7613
4 4260,188 3991,8021 4073,8021
5 4305,1406 3954,9296 4061,9296
6 4374,4037 3942,3678 4074,3678
7 4404,9565 3891,0956 4048,0956
8 4507,8661 3912,1802 4094,1802
WHOQOL 
psychological
1 3759,5738 3736,6628 3743,6628
2 3590,6399 3485,9039 3517,9039
3 3582,8551 3396,2942 3453,2942
4 3621,8361 3353,4501 3435,4501
5 3692,8281 3342,6171 3449,6171
6 3756,938 3324,9021 3456,9021
7 3792,8459 3278,985 3435,985
8 3904,2628 3308,5769 3490,5769
SF-12 physical
1 6242,8472 6219,9362 6226,9362
2 6069,4557 5964,7197 5996,7197
3 6106,424 5919,863 5976,863
4 6152,971 5884,5851 5966,5851
5 6181,6052 5831,3943 5938,3943
6 6248,8478 5816,8118 5948,8118
7 6288,1592 5774,2983 5931,2983
8 6381,8711 5786,1852 5968,1852
SF-12 psychological
1 6182,1475 6159,2365 6166,2365
2 6073,0493 5968,3133 6000,3133
3 6100,1297 5913,5687 5970,5687
4 6132,388 5864,002 5946,002
5 6166,7158 5816,5048 5923,5048
6 6233,1879 5801,152 5933,152
7 6239,8692 5726,0083 5883,0083
8 6359,1548 5763,4689 5945,4689
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Supplement B1. Characteristics for SF-12
Characteristics for 5 classes on SF-12 physical health



















Age 77.0 81.1 79.1 84.8 78.1 <0.001
Sex
Male 65.0 28.3 76.6 69.8 42.7 <0.001
Female 35.0 71.7 23.4 30.2 57.3
Marital status
With partner 77.0 20.4 41.0 49.6 59.8 <0.001
No partner 23.0 79.6 59.0 50.4 40.2
Educational level
Low 41.3 46.7 29.4 46.3 31.6 0.0049
Intermediate 55.5 36.8 43.7 33.9 47.1
High 2.3 12.4 26.9 18.2 17.1
Level of independence
Independent 62.7 30.7 79.3 55.0 17.0 0.0044
Home Health Care 23.0 59.3 13.9 27.2 64.8
Nursing Facility 4.3 6.0 6.6 14.7 13.9
Clinical characteristics
Rutherford classifi cation
4 36.8 2.0 46.2 56.3 30.5 0.0012
5/6 63.2 98.0 53.8 43.7 69.5
Smoking
Yes 18.5 8.0 37.5 18.2 47.3 0.0012
No 79.4 92.0 58.5 81.2 47.6
Comorbidities
Renal impairment 0.044
Yes 40.2 69.1 38.4 64.4 87.1
No 59.8 30.9 61.6 35.6 12.9
Diabetes mellitus
Yes 57.1 50.3 30.4 38.5 69.7 0.013
No 42.9 49.7 69.6 61.5 30.3
Cardiac disease
Yes 61.6 79.5 46.9 73.3 91.3 0.058
No 38.4 20.5 53.1 26.7 8.7
Treatment 
Surgical 55.4 22.6 46.0 19.6 16.9 0.0066
Endovascular 42.1 32.4 36.3 43.1 70.2
Conservatively 2.5 45.0 17.7 37.3 12.9
Follow-up treatment
Surgical
Yes 20.5 6.5 10.2 14.2 29.3 <0.001
No 79.5 93.5 89.8 85.8 70.7
Endovascular 
Yes 8.1 28.7 15.5 20.1 8.6 0.0019
No 91.9 71.3 84.6 79.9 91.4
Amputation 
Yes 29.9 36.5 2.8 21.5 12.8 0.0053
No 70.1 63.5 97.2 78.5 87.2
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 76.6 79.5 82.0 84.1 78.6 <0.001
Sex
Male 59.8 69.0 56.8 40.8 44.1 0.016
Female 40.2 31.0 43.2 59.2 55.9
Marital status
With partner 67.1 39.1 44.2 37.7 53.0 0.0068
No partner 32.9 60.9 55.8 62.3 47.0
Educational level
Low 22.1 36.6 48.4 43.8 64.8 0.0032
Intermediate 69.3 46.8 21.6 47.0 17.6
High 8.6 16.6 25.4 6.2 13.1
Level of independence
Independent 85.7 70.3 30.3 13.0 30.8 0.0039
Home Health Care 6.0 21.9 62.8 46.3 64.7
Nursing Facility 6.3 7.9 0.0 28.3 0.0
Clinical characteristics
Rutherford classifi cation
4 58.0 38.6 11.7 15.4 30.8 0.073
5/6 42.0 61.4 88.3 84.6 69.2
Smoking
Yes 23.8 19.4 30.4 6.2 39.5 0.0095
No 72.5 78.5 69.7 90.2 60.5
Comorbidities
Renal impairment
Yes 43.7 53.8 71.9 43.8 82.5 <0.001
No 56.3 46.2 28.1 56.2 17.5
Diabetes mellitus
Yes 37.3 37.7 61.6 80.9 22.1 <0.001
No 62.7 62.3 38.4 19.1 77.9
Cardiac disease
Yes 58.8 65.1 74.2 90.7 56.3 0.0033
No 41.3 34.9 25.8 9.3 43.7
Treatment 
Surgical 54.1 51.2 6.8 24.7 22.0 0.0026
Endovascular 41.6 30.4 48.4 44.5 52.1
Conservatively 4.3 18.4 44.9 30.8 26.0
Follow-up treatment
Surgical
Yes 22.4 0.0 25.4 3.1 26.5 <0.001
No 77.6 100.0 74.6 96.9 73.5
Endovascular 
Yes 14.4 25.2 9.3 15.4 21.7 0.004
No 85.6 74.9 90.7 84.6 78.3
Amputation 
Yes 9.1 17.5 42.2 24.7 21.9 0.0014
No 90.9 82.4 57.8 75.3 78.1
Data are presented as %, except for age (mean estimate), A p value < 0.0035 was considered statistically signifi cant
Chapter 3
64
Supplement B1. Characteristics for SF-12
Characteristics for 5 classes on SF-12 physical health



















Age 77.0 81.1 79.1 84.8 78.1 <0.001
Sex
Male 65.0 28.3 76.6 69.8 42.7 <0.001
Female 35.0 71.7 23.4 30.2 57.3
Marital status
With partner 77.0 20.4 41.0 49.6 59.8 <0.001
No partner 23.0 79.6 59.0 50.4 40.2
Educational level
Low 41.3 46.7 29.4 46.3 31.6 0.0049
Intermediate 55.5 36.8 43.7 33.9 47.1
High 2.3 12.4 26.9 18.2 17.1
Level of independence
Independent 62.7 30.7 79.3 55.0 17.0 0.0044
Home Health Care 23.0 59.3 13.9 27.2 64.8
Nursing Facility 4.3 6.0 6.6 14.7 13.9
Clinical characteristics
Rutherford classifi cation
4 36.8 2.0 46.2 56.3 30.5 0.0012
5/6 63.2 98.0 53.8 43.7 69.5
Smoking
Yes 18.5 8.0 37.5 18.2 47.3 0.0012
No 79.4 92.0 58.5 81.2 47.6
Comorbidities
Renal impairment 0.044
Yes 40.2 69.1 38.4 64.4 87.1
No 59.8 30.9 61.6 35.6 12.9
Diabetes mellitus
Yes 57.1 50.3 30.4 38.5 69.7 0.013
No 42.9 49.7 69.6 61.5 30.3
Cardiac disease
Yes 61.6 79.5 46.9 73.3 91.3 0.058
No 38.4 20.5 53.1 26.7 8.7
Treatment 
Surgical 55.4 22.6 46.0 19.6 16.9 0.0066
Endovascular 42.1 32.4 36.3 43.1 70.2
Conservatively 2.5 45.0 17.7 37.3 12.9
Follow-up treatment
Surgical
Yes 20.5 6.5 10.2 14.2 29.3 <0.001
No 79.5 93.5 89.8 85.8 70.7
Endovascular 
Yes 8.1 28.7 15.5 20.1 8.6 0.0019
No 91.9 71.3 84.6 79.9 91.4
Amputation 
Yes 29.9 36.5 2.8 21.5 12.8 0.0053
No 70.1 63.5 97.2 78.5 87.2
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 76.6 79.5 82.0 84.1 78.6 <0.001
Sex
Male 59.8 69.0 56.8 40.8 44.1 0.016
Female 40.2 31.0 43.2 59.2 55.9
Marital status
With partner 67.1 39.1 44.2 37.7 53.0 0.0068
No partner 32.9 60.9 55.8 62.3 47.0
Educational level
Low 22.1 36.6 48.4 43.8 64.8 0.0032
Intermediate 69.3 46.8 21.6 47.0 17.6
High 8.6 16.6 25.4 6.2 13.1
Level of independence
Independent 85.7 70.3 30.3 13.0 30.8 0.0039
Home Health Care 6.0 21.9 62.8 46.3 64.7
Nursing Facility 6.3 7.9 0.0 28.3 0.0
Clinical characteristics
Rutherford classifi cation
4 58.0 38.6 11.7 15.4 30.8 0.073
5/6 42.0 61.4 88.3 84.6 69.2
Smoking
Yes 23.8 19.4 30.4 6.2 39.5 0.0095
No 72.5 78.5 69.7 90.2 60.5
Comorbidities
Renal impairment
Yes 43.7 53.8 71.9 43.8 82.5 <0.001
No 56.3 46.2 28.1 56.2 17.5
Diabetes mellitus
Yes 37.3 37.7 61.6 80.9 22.1 <0.001
No 62.7 62.3 38.4 19.1 77.9
Cardiac disease
Yes 58.8 65.1 74.2 90.7 56.3 0.0033
No 41.3 34.9 25.8 9.3 43.7
Treatment 
Surgical 54.1 51.2 6.8 24.7 22.0 0.0026
Endovascular 41.6 30.4 48.4 44.5 52.1
Conservatively 4.3 18.4 44.9 30.8 26.0
Follow-up treatment
Surgical
Yes 22.4 0.0 25.4 3.1 26.5 <0.001
No 77.6 100.0 74.6 96.9 73.5
Endovascular 
Yes 14.4 25.2 9.3 15.4 21.7 0.004
No 85.6 74.9 90.7 84.6 78.3
Amputation 
Yes 9.1 17.5 42.2 24.7 21.9 0.0014
No 90.9 82.4 57.8 75.3 78.1
Data are presented as %, except for age (mean estimate), A p value < 0.0035 was considered statistically signifi cant
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Age 77.0 81.1 79.1 84.8 78.1 <0.001
Sex
Male 65.0 28.3 76.6 69.8 42.7 <0.001
Female 35.0 71.7 23.4 30.2 57.3
Marital status
With partner 77.0 20.4 41.0 49.6 59.8 <0.001
No partner 23.0 79.6 59.0 50.4 40.2
Educational level
Low 41.3 46.7 29.4 46.3 31.6 0.0049
Intermediate 55.5 36.8 43.7 33.9 47.1
High 2.3 12.4 26.9 18.2 17.1
Level of independence
Independent 62.7 30.7 79.3 55.0 17.0 0.0044
Home Health Care 23.0 59.3 13.9 27.2 64.8
Nursing Facility 4.3 6.0 6.6 14.7 13.9
Clinical characteristics
Rutherford classifi cation
4 36.8 2.0 46.2 56.3 30.5 0.0012
5/6 63.2 98.0 53.8 43.7 69.5
Smoking
Yes 18.5 8.0 37.5 18.2 47.3 0.0012
No 79.4 92.0 58.5 81.2 47.6
Comorbidities
Renal impairment 0.044
Yes 40.2 69.1 38.4 64.4 87.1
No 59.8 30.9 61.6 35.6 12.9
Diabetes mellitus
Yes 57.1 50.3 30.4 38.5 69.7 0.013
No 42.9 49.7 69.6 61.5 30.3
Cardiac disease
Yes 61.6 79.5 46.9 73.3 91.3 0.058
No 38.4 20.5 53.1 26.7 8.7
Treatment 
Surgical 55.4 22.6 46.0 19.6 16.9 0.0066
Endovascular 42.1 32.4 36.3 43.1 70.2
Conservatively 2.5 45.0 17.7 37.3 12.9
Follow-up treatment
Surgical
Yes 20.5 6.5 10.2 14.2 29.3 <0.001
No 79.5 93.5 89.8 85.8 70.7
Endovascular 
Yes 8.1 28.7 15.5 20.1 8.6 0.0019
No 91.9 71.3 84.6 79.9 91.4
Amputation 
Yes 29.9 36.5 2.8 21.5 12.8 0.0053
No 70.1 63.5 97.2 78.5 87.2
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 76.6 79.5 82.0 84.1 78.6 <0.001
Sex
Male 59.8 69.0 56.8 40.8 44.1 0.016
Female 40.2 31.0 43.2 59.2 55.9
Marital status
With partner 67.1 39.1 44.2 37.7 53.0 0.0068
No partner 32.9 60.9 55.8 62.3 47.0
Educational level
Low 22.1 36.6 48.4 43.8 64.8 0.0032
Intermediate 69.3 46.8 21.6 47.0 17.6
High 8.6 16.6 25.4 6.2 13.1
Level of independence
Independent 85.7 70.3 30.3 13.0 30.8 0.0039
Home Health Care 6.0 21.9 62.8 46.3 64.7
Nursing Facility 6.3 7.9 0.0 28.3 0.0
Clinical characteristics
Rutherford classifi cation
4 58.0 38.6 11.7 15.4 30.8 0.073
5/6 42.0 61.4 88.3 84.6 69.2
Smoking
Yes 23.8 19.4 30.4 6.2 39.5 0.0095
No 72.5 78.5 69.7 90.2 60.5
Comorbidities
Renal impairment
Yes 43.7 53.8 71.9 43.8 82.5 <0.001
No 56.3 46.2 28.1 56.2 17.5
Diabetes mellitus
Yes 37.3 37.7 61.6 80.9 22.1 <0.001
No 62.7 62.3 38.4 19.1 77.9
Cardiac disease
Yes 58.8 65.1 74.2 90.7 56.3 0.0033
No 41.3 34.9 25.8 9.3 43.7
Treatment 
Surgical 54.1 51.2 6.8 24.7 22.0 0.0026
Endovascular 41.6 30.4 48.4 44.5 52.1
Conservatively 4.3 18.4 44.9 30.8 26.0
Follow-up treatment
Surgical
Yes 22.4 0.0 25.4 3.1 26.5 <0.001
No 77.6 100.0 74.6 96.9 73.5
Endovascular 
Yes 14.4 25.2 9.3 15.4 21.7 0.004
No 85.6 74.9 90.7 84.6 78.3
Amputation 
Yes 9.1 17.5 42.2 24.7 21.9 0.0014
No 90.9 82.4 57.8 75.3 78.1
Data are presented as %, except for age (mean estimate), A p value < 0.0035 was considered statistically signifi cant
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Age 83.8 79.9 77.2 77.2 77.1 <0.001
Sex
Male 57.7 71.9 43.1 44.5 64.7 0.0073
Female 42.3 28.1 56.9 55.5 35.3
Marital status
With partner 52.2 39.5 55.9 34.1 78.7 0.0052
No partner 47.8 60.5 44.1 65.9 21.3
Educational level 3 missing
Low 53.8 33.4 35.3 33.2 29.1 0.052
Intermediate 30.5 47.3 49.3 57.0 42.2
High 13.0 19.3 15.4 5.9 21.5
Level of independence 3 missing
Independent 31.8 67.5 71.4 45.9 42.8 0.002
Home Health Care 60.0 19.7 7.8 39.4 50.0
Nursing Facility 2.0 10.5 18.2 8.8 0.0
Clinical characteristics
Rutherford classifi cation
4 27.7 36.8 66.5 3.1 21.5 0.0029
5/6 72.3 63.2 33.5 96.9 78.5
Smoking
Yes 88.5 73.6 46.5 91.2 56.5 0.0018
No 11.5 26.4 43.1 8.8 43.5
Comorbidities
Renal impairment
Yes 47.5 57.6 48.1 20.9 14.5 <0.001
No 52.5 42.4 51.9 79.1 85.5
Diabetes mellitus
Yes 51.7 50.9 71.4 28.3 57.6 0.015
No 48.3 49.1 28.6 71.7 42.4
Cardiac disease
Yes 18.5 40.0 53.3 21.9 21.7 0.078
No 81.5 60.0 46.7 78.1 78.3
Treatment 
Surgical 20.6 44.3 69.0 15.2 14.4 0.036
Endovascular 51.0 36.2 23.5 39.6 78.3
Conservatively 28.4 19.5 7.5 45.3 7.4
Follow-up treatment
Surgical
Yes 11.6 12.9 18.0 8.8 42.3 0.064
No 88.4 87.1 82.0 91.2 57.7
Endovascular 
Yes 12.7 17.2 2.6 41.9 14.2 0.01
No 87.3 82.8 97.4 58.1 85.8
Amputation 
Yes 29.8 15.1 0.0 45.4 21.7 0.0091
No 70.2 84.9 100.0 54.6 78.3
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 78.6 80.7 81.6 80.0 80.0 0.0014
Sex
Male 43.6 25.8 83.3 67.5 84.6 <0.001
Female 56.4 74.2 16.7 32.5 15.4
Marital status
With partner 46.7 41.1 40.6 52.5 73.0 0.0021
No partner 53.3 58.9 59.4 47.5 27.0
Educational level 3 missing
Low 34.1 31.0 40.9 45.5 61.5 0.019
Intermediate 44.3 58.5 45.5 37.4 23.1
High 17.1 10.5 13.7 13.4 15.4
Level of independence 3 missing
Independent 57.1 30.9 67.6 45.1 50.1 0.0089
Home Health Care 38.3 41.5 13.3 47.3 42.2
Nursing Facility 3.0 22.4 13.8 0.1 0
Clinical characteristics
Rutherford classifi cation
4 30.3 15.3 42.9 26.2 57.7 <0.001
5/6 69.7 84.7 57.1 73.8 42.3
Smoking
Yes 67.2 98.8 53.4 68.7 96.2 <0.001
No 29.8 0 42.9 31.3 42.3
Comorbidities
Renal impairment
Yes 44.3 58.9 48.4 85.0 69.4 <0.001
No 55.7 41.1 51.6 15.0 30.6
Diabetes mellitus
Yes 55.1 45.0 21.4 49.6 73.0 0.035
No 44.9 55.0 78.6 50.4 27.0
Cardiac disease
Yes 61.2 87.4 57.0 72.1 73.2 0.021
No 38.8 12.6 43.0 27.9 26.8
Treatment 
Surgical 45.5 23.2 45.5 0.0 42.3 0.025
Endovascular 43.2 42.2 27.8 55.2 46.1
Conservatively 11.3 34.7 26.7 44.8 11.6
Follow-up treatment
Surgical
Yes 25.9 5.1 0.0 26.3 11.5 0.005
No 74.1 94.9 100.0 73.7 88.5
Endovascular 
Yes 4.6 19.9 21.2 38.2 15.4 <0.001
No 95.4 80.1 78.7 61.8 84.6
Amputation 
Yes 23.7 17.4 29.8 39.0 0.0 0.099
No 76.3 82.6 70.2 61.0 100.0
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant















Age 75.9 84.7 80.6 78.8 <0.001
Sex
Male 62.0 46.1 62.6 49.2 0.15
Female 38.0 53.9 37.4 50.8
Marital status
With partner 63.6 35.7 38.7 62.0 0.041
No partner 36.4 64.3 61.3 38.0
Educational level
Low 25.3 54.1 38.7 57.3 0.075
Intermediate 59.5 35.1 38.0 23.8
High 11.5 10.5 23.2 12.0
Level of independence
Independent 61.4 35.2 62.0 30.5 0.011
Home Health Care 37.0 31.3 36.1 46.1
Nursing Facility 0 24.9 1.9 5.9
Clinical characteristics
Rutherford classifi cation
4 34.8 28.4 37.0 26.2 0.035
5/6 65.2 71.6 63.0 73.8
Smoking
Yes 29.6 23.0 10.9 34.2 0.020
No 70.4 71.7 89.1 60.0
Comorbidities
Renal impairment
Yes 45.2 66.5 56.5 74.5 0.054
No 54.8 33.5 43.6 25.5
Diabetes mellitus
Yes 64.1 25.1 54.8 39.5 0.0094
No 35.9 74.9 45.2 60.5
Cardiac disease
Yes 68.4 79.0 61.8 57.2 0.011
No 31.6 21.0 38.2 42.8
Treatment 
Surgical 45.5 17.8 38.2 32.1 0.11
Endovascular 39.4 40.6 44.5 50.4
Conservatively 15.1 41.6 17.3 17.5
Follow-up treatment
Surgical
Yes 10.0 20.6 8.5 35.2 0.020
No 90.0 79.4 91.5 64.8
Endovascular 
Yes 11.2 31.8 10.1 11.7 0.0057
No 88.8 68.2 89.9 88.3
Amputation 
Yes 26.7 31.8 7.7 20.5 0.0068
No 73.3 68.2 92.3 79.5
Data are presented as %, except for age (mean estimate), A p value < 0.0035 was considered statistically signifi cant
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Age 83.8 79.9 77.2 77.2 77.1 <0.001
Sex
Male 57.7 71.9 43.1 44.5 64.7 0.0073
Female 42.3 28.1 56.9 55.5 35.3
Marital status
With partner 52.2 39.5 55.9 34.1 78.7 0.0052
No partner 47.8 60.5 44.1 65.9 21.3
Educational level 3 missing
Low 53.8 33.4 35.3 33.2 29.1 0.052
Intermediate 30.5 47.3 49.3 57.0 42.2
High 13.0 19.3 15.4 5.9 21.5
Level of independence 3 missing
Independent 31.8 67.5 71.4 45.9 42.8 0.002
Home Health Care 60.0 19.7 7.8 39.4 50.0
Nursing Facility 2.0 10.5 18.2 8.8 0.0
Clinical characteristics
Rutherford classifi cation
4 27.7 36.8 66.5 3.1 21.5 0.0029
5/6 72.3 63.2 33.5 96.9 78.5
Smoking
Yes 88.5 73.6 46.5 91.2 56.5 0.0018
No 11.5 26.4 43.1 8.8 43.5
Comorbidities
Renal impairment
Yes 47.5 57.6 48.1 20.9 14.5 <0.001
No 52.5 42.4 51.9 79.1 85.5
Diabetes mellitus
Yes 51.7 50.9 71.4 28.3 57.6 0.015
No 48.3 49.1 28.6 71.7 42.4
Cardiac disease
Yes 18.5 40.0 53.3 21.9 21.7 0.078
No 81.5 60.0 46.7 78.1 78.3
Treatment 
Surgical 20.6 44.3 69.0 15.2 14.4 0.036
Endovascular 51.0 36.2 23.5 39.6 78.3
Conservatively 28.4 19.5 7.5 45.3 7.4
Follow-up treatment
Surgical
Yes 11.6 12.9 18.0 8.8 42.3 0.064
No 88.4 87.1 82.0 91.2 57.7
Endovascular 
Yes 12.7 17.2 2.6 41.9 14.2 0.01
No 87.3 82.8 97.4 58.1 85.8
Amputation 
Yes 29.8 15.1 0.0 45.4 21.7 0.0091
No 70.2 84.9 100.0 54.6 78.3
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 78.6 80.7 81.6 80.0 80.0 0.0014
Sex
Male 43.6 25.8 83.3 67.5 84.6 <0.001
Female 56.4 74.2 16.7 32.5 15.4
Marital status
With partner 46.7 41.1 40.6 52.5 73.0 0.0021
No partner 53.3 58.9 59.4 47.5 27.0
Educational level 3 missing
Low 34.1 31.0 40.9 45.5 61.5 0.019
Intermediate 44.3 58.5 45.5 37.4 23.1
High 17.1 10.5 13.7 13.4 15.4
Level of independence 3 missing
Independent 57.1 30.9 67.6 45.1 50.1 0.0089
Home Health Care 38.3 41.5 13.3 47.3 42.2
Nursing Facility 3.0 22.4 13.8 0.1 0
Clinical characteristics
Rutherford classifi cation
4 30.3 15.3 42.9 26.2 57.7 <0.001
5/6 69.7 84.7 57.1 73.8 42.3
Smoking
Yes 67.2 98.8 53.4 68.7 96.2 <0.001
No 29.8 0 42.9 31.3 42.3
Comorbidities
Renal impairment
Yes 44.3 58.9 48.4 85.0 69.4 <0.001
No 55.7 41.1 51.6 15.0 30.6
Diabetes mellitus
Yes 55.1 45.0 21.4 49.6 73.0 0.035
No 44.9 55.0 78.6 50.4 27.0
Cardiac disease
Yes 61.2 87.4 57.0 72.1 73.2 0.021
No 38.8 12.6 43.0 27.9 26.8
Treatment 
Surgical 45.5 23.2 45.5 0.0 42.3 0.025
Endovascular 43.2 42.2 27.8 55.2 46.1
Conservatively 11.3 34.7 26.7 44.8 11.6
Follow-up treatment
Surgical
Yes 25.9 5.1 0.0 26.3 11.5 0.005
No 74.1 94.9 100.0 73.7 88.5
Endovascular 
Yes 4.6 19.9 21.2 38.2 15.4 <0.001
No 95.4 80.1 78.7 61.8 84.6
Amputation 
Yes 23.7 17.4 29.8 39.0 0.0 0.099
No 76.3 82.6 70.2 61.0 100.0
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant















Age 75.9 84.7 80.6 78.8 <0.001
Sex
Male 62.0 46.1 62.6 49.2 0.15
Female 38.0 53.9 37.4 50.8
Marital status
With partner 63.6 35.7 38.7 62.0 0.041
No partner 36.4 64.3 61.3 38.0
Educational level
Low 25.3 54.1 38.7 57.3 0.075
Intermediate 59.5 35.1 38.0 23.8
High 11.5 10.5 23.2 12.0
Level of independence
Independent 61.4 35.2 62.0 30.5 0.011
Home Health Care 37.0 31.3 36.1 46.1
Nursing Facility 0 24.9 1.9 5.9
Clinical characteristics
Rutherford classifi cation
4 34.8 28.4 37.0 26.2 0.035
5/6 65.2 71.6 63.0 73.8
Smoking
Yes 29.6 23.0 10.9 34.2 0.020
No 70.4 71.7 89.1 60.0
Comorbidities
Renal impairment
Yes 45.2 66.5 56.5 74.5 0.054
No 54.8 33.5 43.6 25.5
Diabetes mellitus
Yes 64.1 25.1 54.8 39.5 0.0094
No 35.9 74.9 45.2 60.5
Cardiac disease
Yes 68.4 79.0 61.8 57.2 0.011
No 31.6 21.0 38.2 42.8
Treatment 
Surgical 45.5 17.8 38.2 32.1 0.11
Endovascular 39.4 40.6 44.5 50.4
Conservatively 15.1 41.6 17.3 17.5
Follow-up treatment
Surgical
Yes 10.0 20.6 8.5 35.2 0.020
No 90.0 79.4 91.5 64.8
Endovascular 
Yes 11.2 31.8 10.1 11.7 0.0057
No 88.8 68.2 89.9 88.3
Amputation 
Yes 26.7 31.8 7.7 20.5 0.0068
No 73.3 68.2 92.3 79.5
Data are presented as %, except for age (mean estimate), A p value < 0.0035 was considered statistically signifi cant
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Age 83.8 79.9 77.2 77.2 77.1 <0.001
Sex
Male 57.7 71.9 43.1 44.5 64.7 0.0073
Female 42.3 28.1 56.9 55.5 35.3
Marital status
With partner 52.2 39.5 55.9 34.1 78.7 0.0052
No partner 47.8 60.5 44.1 65.9 21.3
Educational level 3 missing
Low 53.8 33.4 35.3 33.2 29.1 0.052
Intermediate 30.5 47.3 49.3 57.0 42.2
High 13.0 19.3 15.4 5.9 21.5
Level of independence 3 missing
Independent 31.8 67.5 71.4 45.9 42.8 0.002
Home Health Care 60.0 19.7 7.8 39.4 50.0
Nursing Facility 2.0 10.5 18.2 8.8 0.0
Clinical characteristics
Rutherford classifi cation
4 27.7 36.8 66.5 3.1 21.5 0.0029
5/6 72.3 63.2 33.5 96.9 78.5
Smoking
Yes 88.5 73.6 46.5 91.2 56.5 0.0018
No 11.5 26.4 43.1 8.8 43.5
Comorbidities
Renal impairment
Yes 47.5 57.6 48.1 20.9 14.5 <0.001
No 52.5 42.4 51.9 79.1 85.5
Diabetes mellitus
Yes 51.7 50.9 71.4 28.3 57.6 0.015
No 48.3 49.1 28.6 71.7 42.4
Cardiac disease
Yes 18.5 40.0 53.3 21.9 21.7 0.078
No 81.5 60.0 46.7 78.1 78.3
Treatment 
Surgical 20.6 44.3 69.0 15.2 14.4 0.036
Endovascular 51.0 36.2 23.5 39.6 78.3
Conservatively 28.4 19.5 7.5 45.3 7.4
Follow-up treatment
Surgical
Yes 11.6 12.9 18.0 8.8 42.3 0.064
No 88.4 87.1 82.0 91.2 57.7
Endovascular 
Yes 12.7 17.2 2.6 41.9 14.2 0.01
No 87.3 82.8 97.4 58.1 85.8
Amputation 
Yes 29.8 15.1 0.0 45.4 21.7 0.0091
No 70.2 84.9 100.0 54.6 78.3
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 78.6 80.7 81.6 80.0 80.0 0.0014
Sex
Male 43.6 25.8 83.3 67.5 84.6 <0.001
Female 56.4 74.2 16.7 32.5 15.4
Marital status
With partner 46.7 41.1 40.6 52.5 73.0 0.0021
No partner 53.3 58.9 59.4 47.5 27.0
Educational level 3 missing
Low 34.1 31.0 40.9 45.5 61.5 0.019
Intermediate 44.3 58.5 45.5 37.4 23.1
High 17.1 10.5 13.7 13.4 15.4
Level of independence 3 missing
Independent 57.1 30.9 67.6 45.1 50.1 0.0089
Home Health Care 38.3 41.5 13.3 47.3 42.2
Nursing Facility 3.0 22.4 13.8 0.1 0
Clinical characteristics
Rutherford classifi cation
4 30.3 15.3 42.9 26.2 57.7 <0.001
5/6 69.7 84.7 57.1 73.8 42.3
Smoking
Yes 67.2 98.8 53.4 68.7 96.2 <0.001
No 29.8 0 42.9 31.3 42.3
Comorbidities
Renal impairment
Yes 44.3 58.9 48.4 85.0 69.4 <0.001
No 55.7 41.1 51.6 15.0 30.6
Diabetes mellitus
Yes 55.1 45.0 21.4 49.6 73.0 0.035
No 44.9 55.0 78.6 50.4 27.0
Cardiac disease
Yes 61.2 87.4 57.0 72.1 73.2 0.021
No 38.8 12.6 43.0 27.9 26.8
Treatment 
Surgical 45.5 23.2 45.5 0.0 42.3 0.025
Endovascular 43.2 42.2 27.8 55.2 46.1
Conservatively 11.3 34.7 26.7 44.8 11.6
Follow-up treatment
Surgical
Yes 25.9 5.1 0.0 26.3 11.5 0.005
No 74.1 94.9 100.0 73.7 88.5
Endovascular 
Yes 4.6 19.9 21.2 38.2 15.4 <0.001
No 95.4 80.1 78.7 61.8 84.6
Amputation 
Yes 23.7 17.4 29.8 39.0 0.0 0.099
No 76.3 82.6 70.2 61.0 100.0
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant















Age 75.9 84.7 80.6 78.8 <0.001
Sex
Male 62.0 46.1 62.6 49.2 0.15
Female 38.0 53.9 37.4 50.8
Marital status
With partner 63.6 35.7 38.7 62.0 0.041
No partner 36.4 64.3 61.3 38.0
Educational level
Low 25.3 54.1 38.7 57.3 0.075
Intermediate 59.5 35.1 38.0 23.8
High 11.5 10.5 23.2 12.0
Level of independence
Independent 61.4 35.2 62.0 30.5 0.011
Home Health Care 37.0 31.3 36.1 46.1
Nursing Facility 0 24.9 1.9 5.9
Clinical characteristics
Rutherford classifi cation
4 34.8 28.4 37.0 26.2 0.035
5/6 65.2 71.6 63.0 73.8
Smoking
Yes 29.6 23.0 10.9 34.2 0.020
No 70.4 71.7 89.1 60.0
Comorbidities
Renal impairment
Yes 45.2 66.5 56.5 74.5 0.054
No 54.8 33.5 43.6 25.5
Diabetes mellitus
Yes 64.1 25.1 54.8 39.5 0.0094
No 35.9 74.9 45.2 60.5
Cardiac disease
Yes 68.4 79.0 61.8 57.2 0.011
No 31.6 21.0 38.2 42.8
Treatment 
Surgical 45.5 17.8 38.2 32.1 0.11
Endovascular 39.4 40.6 44.5 50.4
Conservatively 15.1 41.6 17.3 17.5
Follow-up treatment
Surgical
Yes 10.0 20.6 8.5 35.2 0.020
No 90.0 79.4 91.5 64.8
Endovascular 
Yes 11.2 31.8 10.1 11.7 0.0057
No 88.8 68.2 89.9 88.3
Amputation 
Yes 26.7 31.8 7.7 20.5 0.0068
No 73.3 68.2 92.3 79.5
Data are presented as %, except for age (mean estimate), A p value < 0.0035 was considered statistically signifi cant
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Supplement B2. Characteristics for WHOQOL





















Age 83.8 79.9 77.2 77.2 77.1 <0.001
Sex
Male 57.7 71.9 43.1 44.5 64.7 0.0073
Female 42.3 28.1 56.9 55.5 35.3
Marital status
With partner 52.2 39.5 55.9 34.1 78.7 0.0052
No partner 47.8 60.5 44.1 65.9 21.3
Educational level 3 missing
Low 53.8 33.4 35.3 33.2 29.1 0.052
Intermediate 30.5 47.3 49.3 57.0 42.2
High 13.0 19.3 15.4 5.9 21.5
Level of independence 3 missing
Independent 31.8 67.5 71.4 45.9 42.8 0.002
Home Health Care 60.0 19.7 7.8 39.4 50.0
Nursing Facility 2.0 10.5 18.2 8.8 0.0
Clinical characteristics
Rutherford classifi cation
4 27.7 36.8 66.5 3.1 21.5 0.0029
5/6 72.3 63.2 33.5 96.9 78.5
Smoking
Yes 88.5 73.6 46.5 91.2 56.5 0.0018
No 11.5 26.4 43.1 8.8 43.5
Comorbidities
Renal impairment
Yes 47.5 57.6 48.1 20.9 14.5 <0.001
No 52.5 42.4 51.9 79.1 85.5
Diabetes mellitus
Yes 51.7 50.9 71.4 28.3 57.6 0.015
No 48.3 49.1 28.6 71.7 42.4
Cardiac disease
Yes 18.5 40.0 53.3 21.9 21.7 0.078
No 81.5 60.0 46.7 78.1 78.3
Treatment 
Surgical 20.6 44.3 69.0 15.2 14.4 0.036
Endovascular 51.0 36.2 23.5 39.6 78.3
Conservatively 28.4 19.5 7.5 45.3 7.4
Follow-up treatment
Surgical
Yes 11.6 12.9 18.0 8.8 42.3 0.064
No 88.4 87.1 82.0 91.2 57.7
Endovascular 
Yes 12.7 17.2 2.6 41.9 14.2 0.01
No 87.3 82.8 97.4 58.1 85.8
Amputation 
Yes 29.8 15.1 0.0 45.4 21.7 0.0091
No 70.2 84.9 100.0 54.6 78.3
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant




















Age 78.6 80.7 81.6 80.0 80.0 0.0014
Sex
Male 43.6 25.8 83.3 67.5 84.6 <0.001
Female 56.4 74.2 16.7 32.5 15.4
Marital status
With partner 46.7 41.1 40.6 52.5 73.0 0.0021
No partner 53.3 58.9 59.4 47.5 27.0
Educational level 3 missing
Low 34.1 31.0 40.9 45.5 61.5 0.019
Intermediate 44.3 58.5 45.5 37.4 23.1
High 17.1 10.5 13.7 13.4 15.4
Level of independence 3 missing
Independent 57.1 30.9 67.6 45.1 50.1 0.0089
Home Health Care 38.3 41.5 13.3 47.3 42.2
Nursing Facility 3.0 22.4 13.8 0.1 0
Clinical characteristics
Rutherford classifi cation
4 30.3 15.3 42.9 26.2 57.7 <0.001
5/6 69.7 84.7 57.1 73.8 42.3
Smoking
Yes 67.2 98.8 53.4 68.7 96.2 <0.001
No 29.8 0 42.9 31.3 42.3
Comorbidities
Renal impairment
Yes 44.3 58.9 48.4 85.0 69.4 <0.001
No 55.7 41.1 51.6 15.0 30.6
Diabetes mellitus
Yes 55.1 45.0 21.4 49.6 73.0 0.035
No 44.9 55.0 78.6 50.4 27.0
Cardiac disease
Yes 61.2 87.4 57.0 72.1 73.2 0.021
No 38.8 12.6 43.0 27.9 26.8
Treatment 
Surgical 45.5 23.2 45.5 0.0 42.3 0.025
Endovascular 43.2 42.2 27.8 55.2 46.1
Conservatively 11.3 34.7 26.7 44.8 11.6
Follow-up treatment
Surgical
Yes 25.9 5.1 0.0 26.3 11.5 0.005
No 74.1 94.9 100.0 73.7 88.5
Endovascular 
Yes 4.6 19.9 21.2 38.2 15.4 <0.001
No 95.4 80.1 78.7 61.8 84.6
Amputation 
Yes 23.7 17.4 29.8 39.0 0.0 0.099
No 76.3 82.6 70.2 61.0 100.0
Data are presented as %, except for age (mean estimate)
A p value < 0.0035 was considered statistically signifi cant















Age 75.9 84.7 80.6 78.8 <0.001
Sex
Male 62.0 46.1 62.6 49.2 0.15
Female 38.0 53.9 37.4 50.8
Marital status
With partner 63.6 35.7 38.7 62.0 0.041
No partner 36.4 64.3 61.3 38.0
Educational level
Low 25.3 54.1 38.7 57.3 0.075
Intermediate 59.5 35.1 38.0 23.8
High 11.5 10.5 23.2 12.0
Level of independence
Independent 61.4 35.2 62.0 30.5 0.011
Home Health Care 37.0 31.3 36.1 46.1
Nursing Facility 0 24.9 1.9 5.9
Clinical characteristics
Rutherford classifi cation
4 34.8 28.4 37.0 26.2 0.035
5/6 65.2 71.6 63.0 73.8
Smoking
Yes 29.6 23.0 10.9 34.2 0.020
No 70.4 71.7 89.1 60.0
Comorbidities
Renal impairment
Yes 45.2 66.5 56.5 74.5 0.054
No 54.8 33.5 43.6 25.5
Diabetes mellitus
Yes 64.1 25.1 54.8 39.5 0.0094
No 35.9 74.9 45.2 60.5
Cardiac disease
Yes 68.4 79.0 61.8 57.2 0.011
No 31.6 21.0 38.2 42.8
Treatment 
Surgical 45.5 17.8 38.2 32.1 0.11
Endovascular 39.4 40.6 44.5 50.4
Conservatively 15.1 41.6 17.3 17.5
Follow-up treatment
Surgical
Yes 10.0 20.6 8.5 35.2 0.020
No 90.0 79.4 91.5 64.8
Endovascular 
Yes 11.2 31.8 10.1 11.7 0.0057
No 88.8 68.2 89.9 88.3
Amputation 
Yes 26.7 31.8 7.7 20.5 0.0068
No 73.3 68.2 92.3 79.5
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Objective: Revascularization is the cornerstone in the treatment of patients with 
critical limb-threatening ischemia (CLTI). However, the 2-year mortality rate is up to 
50% in these patients.  Therefore, the clinical benefit of revascularization needs to be 
considered carefully. The question emerges if there are changes in quality of life (QoL) 
and health status (HS) in the end-of life phase of CLTI in older patients.
Methods: Patients with CLTI and of an age of 70 years or older were included in 
a prospective observational cohort study. Treatment consisted of endovascular 
revascularization, surgical revascularization, or conservative therapy. The follow-up 
period was 2 years. Within this follow-up period, patients completed the following 
questionnaires at six specified time intervals: the WHOQOL-BREF and the SF-12. 
Patients who died within 2 years after inclusion were analyzed. Final scores were 
defined as the last measurement at end of follow-up or death.
Results: Eighty two patients (42.1%) died during the 24-month follow-up. Quality 
of life and HS before death did not decrease with treatment (option: endovascular 
intervention, surgical revascularization, or conservative therapy).
Conclusion: Older patients with CLTI and a life expectancy less than 2 years had no 
differences in QoL and HS before death compared to their previous measurement. 
Except for the mental HS domain, no differences in the percentage of patients showing 
significant individual change in QoL and HS were found between the treatments. For 
clinicians, it is important to use patient-reported outcome measure when discussing 




Critical limb-threatening ischemia (CLTI) is the end stage of peripheral artery disease 
(PAD). Up to 10% of patients with PAD will evolve or newly present with CLTI. (1) 
Revascularization (endovascular or surgical) is the treatment of choice for patients with 
CLTI. (2) Overall, endovascular procedures are performed on a larger scale due to 
innovations in this field. The outcome of both types of revascularization is similar in 
terms of amputation-free survival and mortality. (3) However, mortality rates in older 
patients with CLTI are higher due to a higher incidence of comorbidity. (4) Therefore, 
in these patients, the clinical benefit of revascularization may be limited. In addition, 
conservative treatment avoids periprocedural mortality, and there is evidence of 
complete wound healing in more than half of patients with CLTI and tissue loss who 
had no revascularization. (5) The question emerges if quality of life (QoL) and health 
status (HS) are preserved when treating older patients with CLTI who die within 2 years 
of diagnosis. The aim of this study was to investigate changes in QoL and HS in the 
end-of-life phase of CLTI.
METHODS
A prospective observational study of 195 patients with CLTI and over 70 years of age 
was conducted. (6) Patients who die within 2 years after inclusion were analyzed in 
this study. The hospitals ethics committee approved this study’s protocol. Informed 
consent was obtained from all patients included in this study. Patients treated for 
malignancy and patients with low Dutch-speaking proficiency or cognitive impairment 
were excluded. Treatment consisted of endovascular revascularization, surgical 
revascularization, or conservative therapy. A panel of experts assigned patients to 
primary treatment after case review in a multidisciplinary vascular conference. In the 
24-month follow-up period, patients completed the WHOQOL-BREF questionnaire 
to determine QoL and the 12-Item Short Form Health Survey (SF-12) to measure HS. 
The questionnaires were repeated at the following times after inclusion: 5-7 days, 6 
weeks, 6 months, 12 months, and 24 months; for a total of 6 times. Statistical analyses 
were performed through a computerized software package, using IBM SPSS 23.0. 
Last known measurements were defined as last measurement before end of follow-
up period or death. The mean difference was calculated between the last known 
measurements (Mean 2) and the previous measurements (Mean 1) for all domains of 
the questionnaires. This mean difference was divided by the corresponding standard 
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deviation of the mean difference, resulting in the standardized individual difference 
(SID). (7) A result higher or lower than 1.96 indicated significant improvements or 
significant decreases in the QoL and HS domains. Gaussianshaped distributions were 
analyzed using the Student’s t-test. Nonnormal distributed data were analyzed using 
the ManneWhitney U-test. Chisquared and Fisher’s exact tests (in case of expected cell 
counts <5) were used to assess the allocation between categorical variables. A P-value 
< 0.05 (twosided) was considered significant.
RESULTS
One hundred ninety-five patients were included between January 2012 and February 
2016. In total, 82 patients (42.1%) died during the 24-month followup period. Treatment 
for this subgroup consisted of endovascular revascularization (n = 44), surgical 
revascularization (n = 13), or conservative therapy (n = 25). In Table I, the patient 
characteristics are presented. 
Quality of life and HS of the patients from the final sample were analyzed from 
the period just before these patients died. The two last known QoL and HS scores 
were compared with each other (Table II). The vast majority of patients showed no 
significant changes in their personal QoL and HS scores based on the SID. There were 
no significant differences in change of QoL and HS between treatment groups, except 
for the mental HS domain. Patients who received surgery experienced significantly 
more improvement of their mental HS than patients treated with endovascular 
revascularization (P = 0.034) and patients treated conservatively (P = 0.034).
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Table 1. Patient characteristics
Deceased patients (n=82)
Sex (male) 45 (55)
Age; median (IQR) 82 (77;86)
Rutherford-class 4 15 (18)
Rutherford-class 5/6 67 (82)
Comorbidity
Cardiac comorbidity 69 (82)
Neurologic comorbidity 29 (35)
Pulmonary comorbidity 57 (68)
Vascular risk factors
Renal impairment 58 (69)
Diabetes mellitus 50 (60)
Hypertension 57 (68)
Current smoking 16 (19)
Initially selected therapy
Endovascular revascularization 44 (54)
Surgical revascularization 13 (16)
Conservative therapy 25 (30)
Data are presented as n and (%), unless otherwise specifi ed
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Mean 1 Mean 2 Decrease No change Increase
QoL domains
Overall
Endovascular group 2.91 (0.84) 2.63 (0.89) 2% 98% -
Surgery group 3.01 (0.87) 3.23 (0.99) 7% 85% 7%
Conservative group 3.30 (0.63) 3.29 (0.64) - 100% -
Physical
Endovascular group 11.18 (3.59) 11.29 (2.86) 4% 96% -
Surgery group 11.29 (3.59) 12.40 (2.04) - 92% 8%
Conservative group 12.56 (2.57) 12.29 (2.56) - 100% -
Psychological
Endovascular group 14.39 (2.18) 14.33 (1.87) 4% 96% -
Surgery group 14.18 (2.80) 14.10 (2.85) 8% 92% -
Conservative group 15.28 (1.33) 14.11 (1.81) 8% 92% -
Social relationship
Endovascular group 16.22 (2.14) 16.24 (1.89) 4% 96% -
Surgery group 16.56 (1.47) 16.82 (1.59) - 100% -
Conservative group 16.45 (1.77) 17.25 (1.65) - 92% 8%
Environment
Endovascular group 15.10 (2.01) 14.65 (1.54) 7% 89% 4%
Surgery group 14.96 (2.44) 14.85 (2.20) 15% 85% -
Conservative group 15.40 (1.99) 14.38 (1.52) 16% 84% -
HS domains
Physical
Endovascular group 27.73 (9.33) 26.24 (7.22) 4% 96% -
Surgery group 27.60 (9.55) 26.23 (5.27) - 100% -
Conservative group 30.70 (8.81) 27.14 (7.38) 4% 96% -
Mental
Endovascular group 37.04 (10.31) 39.20 (9.60) 2% 98% -
Surgery group* 34.38 (11.81) 36.29 (8.24) 8% 77% 15%
Conservative group 42.67 (7.88) 40.41 (6.29) - 100% -
Data presented as mean (standard deviation) 




An important goal in treating older patients with CLTI is to do no further harm to frail 
older patients. High mortality rates of up to 50% have been reported 2 years after onset 
of CLTI. (1,6,8-10) In our study, a 2-year mortality rate of 42.1% is similar to previously 
reported mortality rates. (1,8) Patients selected for surgery are usually in a better state 
of health than patients managed nonsurgically. In older patients with CLTI not suitable 
for surgery, the question remains as to what we want to achieve with other treatment 
options. Moreover, nonrevascularization methods are unsupported by evidence due 
to high mortality and amputation rates, despite common use in clinical practice. (1) 
Supplementary to traditional treatment outcomes are patient-reported outcomes, 
such as QoL and HS. An analysis of the last known QoL and HS scores may provide an 
important insight in the effects of treatment on QoL or HS. In this study, the last known 
QoL and HS scores before death did not significantly differ from their previous QoL and 
HS scores regardless of treatment. There were no differences between treatment groups 
in QoL and HS, except for the mental domain of HS. This study may provide support for 
conservative management of older patients with CLTI and a limited life expectancy. The 
challenge remains to identify this subgroup of patients for whom conservative therapy 
is suitable. With these results, patient-reported outcome measure can be discussed 
in a shared decision-making process to facilitate individualized treatment. This study 
has limitations. First, the patient selection is based on predicted death within 2 years. 
Secondly, there was no control group used to compare changes in QoL and HS, which 
may be confounded by other factors unrelated to death. These results indicate that 
starting any kind of treatment does not worsen the QoL or HS in patients with a life 
expectancy of less than 2 years. It is important to discuss these aspects when selecting 
treatment in a shared decision-making process, especially in elderly frail patients with 
CLTI and a limited life expectancy.
CONCLUSION
In older patients with CLTI and a life expectancy less than 2 years, there were no differences 
in QoL and HS scores before death compared to previous measurement. Except for the 
mental HS domain, no differences in patients showing individual change in QoL and HS 
were found between the treatment groups: endovascular revascularization, surgery, and 
conservative therapy. In older frail patients with CLTI, it is important to consider patient-
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Objective: A patient-oriented appraisal of treatment has become extremely important, 
particularly in elderly patients with chronic limb-threatening ischemia (CLTI). Quality of 
life (QoL) is an important patient-reported outcome in vascular surgery. Frequently, 
the physical domain of QoL questionnaires represents an ‘objective’ evaluation of 
performing activities, which is expected to be impaired after lower limb amputation. 
However, an objective appraisal of physical function is an assessment of health status 
(HS) and not of QoL. Little is known about the subjective appraisal of physical health 
(QoL). The goal of this study was to evaluate, prospectively, QoL in relation to HS in 
elderly CLTI patients undergoing lower limb amputation.
Methods: Patients suffering from CLTI aged 70 years or older were included in a 
prospective observational cohort study with a follow-up period of 1 year. Patients were 
divided according to having had an amputation or not. The World Health Organization 
Quality Of Life-BREF (WHOQOL-BREF) was used to asses QoL. The 12-ItemShort Form 
Health Survey (SF-12) was used to measure HS. These self-reported questionnaires 
were completed five times during follow-up.
Results: Two-hundred patients were included of whom 46 underwent a lower limb 
amputation within one year. Patients with a lower limb amputation had a statistically 
significant improvement of their physical QoL after six months (14.0 vs. 9.0 (95% CI 
-7.84;-1.45),p = 0.005) and after a one-year follow-up (14.0 vs. 9.0 (95% CI -9.58;-
1.46),p = 0.008). They did not however show any statistically significant difference 
in HS. For patients without an amputation, both physical QoL and HS improved. An 
instant statistically significant improvement of the physical QoL appeared 1 week after 
inclusion (12.0 vs. 10.9 (95% CI -1.57;-0.63),p<0.001). Similarly, statistically significant 
improvement in the physical HS first occurred at 1 week follow-up (29.0 vs. 28.9 (95% 
CI -5.78; 2.23),p = 0.003).
Conclusion: There is a clear difference between patients’ functioning (HS) and the 
patients’ appraisal of functioning (QoL). In elderly CLTI patients, this study clearly 
suggests a discrepancy between the physical QoL (WHOQOL-BREF) and HS (SF-
12) measurements in vascular patients with a lower limb amputation. This raises the 
question, which outcome measurement is the most relevant for elderly CLTI patients. 
Individual treatment goals should be kept in mind when assessing the HS or QoL 
outcome of patients undergoing hospital care. With respect to shared decision making, 
distinctive and subjective QoL questionnaires, like the WHOQOL-BREF, provide a very 




Chronic limb-threatening ischemia (CLTI) is characterised by impaired mobility, which 
can negatively affect quality of life (QoL). (1) Chronic limb-threatening ischemia, the 
end stage of peripheral arterial disease, is also the most common cause of lower 
limb amputation in elderly patients. (2,3) Because lower limb amputation is usually 
associated with poor physical function, high mortality, and assumed high revalidation 
costs, it is an outcome that health care providers fear. (3-6) However, in the elderly CLTI 
patients, revascularization is not always possible and lower limb amputation is often 
necessary, due to infection or severe pain in selected patients. (7) 
Due to a lack of randomized controlled trials, no recommendation for therapy can be 
made in CLTI patients. (7,8) Consequently, a patient-oriented appraisal of treatment 
is becoming increasingly important. (9-11) The importance of the patient-reported 
outcome measure, QoL, is broadly recognized. Unfortunately, the term QoL is used 
inconsistently and confusingly, possibly explaining some contradictory results. (11-
14) Many studies claim to evaluate QoL but their findings are based on health status 
(HS) instruments. (9,15) Health status is solely a patient’s assessment of objective 
functioning having to do with the patient’s functional status, that is associated with 
a certain disease. (16-20) Perceived health does not convey a patient’s subjective 
wellbeing and QoL. (9,15) Particularly for CLTI patients this can lead, for instance, to 
incorrect conclusions concerning what should be an adequate treatment. (9,21) 
Accordingly HS questionnaires, like the 12-Item Short Form Health Survey (SF-12), 
measure a patient’s daily activities and provide an arguably objective assessment. Health 
status questionnaires, take a functional approach by assessing physical, psychological 
and social functioning (e.g. whether a patient is able to adequately engage in specific 
activities, such as climbing stairs or using a vacuum cleaner). In contrast with HS, the 
WHOQOL (World Health Organization Quality Of Life) definition of QoL assesses 
a complete subjective appraisal or evaluation of physical, psychological, and social 
functioning and therefore takes into account a subjective evaluation of health. (9,22) 
The WHOQOL-BREF questionnaire asks patients if they are satisfied with their ability to 
perform their daily living activities. So in our opinion, the importance of HS measures in 
CLTI patients is doubtful when approximately half of the vascular patients with a lower 
limb amputation are not able to walk one year after amputation. (11) 
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At the moment, prospective data related to suitable patient-oriented outcomes is 
missing in elderly vascular patients with a lower limb amputation. (7,11) In clinical 
practice a subjective appraisal of wellbeing would be more valuable to patients and 
health care providers. As mentioned above, the WHOQOL-BREF gives more insight 
into the patient’s opinion about QoL. The goal of this study was to evaluate QoL 
(WHOQOL-BREF) in relation to HS (SF-12) in elderly CLTI patients who underwent 
lower limb amputation in comparison to elder CLTI patients who did not. 
METHODS
Between January 2012 and February 2016, elderly patients with CLTI in two peripheral 
hospitals (Amphia hospital and Bravis hospital, The Netherlands) were included in a 
prospective observational cohort study, as published previously. (23) Inclusion criteria 
were a diagnosis with CLTI and an age of 70 years or older. Chronic limb-threatening 
ischemia was defined as chronic ischemic rest pain with or without the presence of 
ulcers or gangrene. The diagnosis was confirmed by the anklebrachial index or toe 
systolic pressure measurement when appropriate. Patients with malignancy, lack of 
Dutch language skills, or cognitive impairment were excluded from the study. A formal 
written waiver for ethical approval was not required according to the criteria of the 
Central Committee on Research Involving Human Subjects. This was confirmed by the 
institutional review board (AMOA). All patients included signed an informed consent. 
A panel of experts at a weekly multidisciplinary vascular conference determined 
patients’ inclusion. After inclusion, patients received a treatment that consisted of 
either surgical or endovascular revascularisation, conservative therapy or primary 
amputation. (23) Patients were selected for a treatment while taking into account 
comorbidities and TransAtlantic Inter-Society Consensus (TASC) lesion classification. 
Methods of patient inclusion and treatment selection have previously been described 
by Steunenberg et al. (23) Lower limb amputation was defined as an amputation 
proximal to the ankle joint. All additional treatment received during follow-up was 
duly recorded. 
Quality of life and HS were prospectively measured using the WHOQOL-BREF and the 
SF-12, respectively. These self-report questionnaires were completed at the moment of 
inclusion, five to seven days after inclusion (mostly conducted during hospitalisation), 
and at six weeks, six months and 12 months.
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The validated WHOQOL-BREF questionnaire is the shortened version of the 
WHOQOL-100. Studies using the WHOQOL-BREF have shown good validity in the 
elderly. (24) This patient-completed measurement of health-related QoL contains 
26 items with a 5-point Likert type response scale. The following broad domains are 
measured: physical health, psychological health, social relationships, and environment. 
(11,25) In this study, the physical and psychological domains are used, which together 
consist of 13 items. The validated SF-12 was used to determine HS. (26,27) It is the 
short version of the 36-Item Short Form Health Survey and provides information about 
physical and mental functioning. (11) Patients who did not answer all questions of a 
domain did not reach an overall score for that particular questionnaire. 
In this study, patients were classified into two groups at one-year follow-up: patients 
who had undergone lower limb amputation and patients who had not, during the 
first year after inclusion. Results of the questionnaires were recoded to ensure that 
for each patient the first completed questionnaire, after lower limb amputation, was 
considered the first measurement after baseline and so forth. Patients who did not get 
an amputation were considered the control group.
As reported previously, a sample size calculation was performed for an ANOVA. Given 
a power of 0.80, an alpha of 0.05, and an effect size of 0.25, the total sample should be 
at least 159 persons. (23) Statistical analyses were performed through a computerized 
software package, using IBM SPSS 23.0. Linear mixed models were used to assess 
the change of QoL and HS for both treatment groups at four specified times. Within 
mixed modeling, custom hypothesis tests were used to assess differences between 
baseline and follow-up measurements within each treatment group. An advantage of 
mixed modeling is that it analyzes all available data for each participant when some of 
the measurements are missing. Additionally, mixed models can take into account the 
fact that the time intervals separating the measurements differed across participants. 
Computing Pearson correlations assessed the association between QoL and HS. 
Common variance of the two questionnaires was determined using the scores of these 




During the study period (January 2012 through February 2016), 387 elderly patients 
were diagnosed with CLTI. One hundred and eighty-seven CLTI patients were excluded 
from our study because of cognitive impairment or refusal to participate, resulting in 
200 included CLTI patients. Of those patients, five were treated with a primary lower 
limb amputation. One hundred and ninety-five CLTI patients did not undergo lower 
limb amputation as a primary treatment, but instead were treated with  endovascular 
revascularisation (n = 82), surgical revascularisation (n = 67), or received conservative 
therapy (n = 46).





Sex (male) 82 (53) 30 (65)
Age; median (IQR) 79.5 (9) 82 (10)
Rutherford-class 4 58 (38) 6 (13)*
Rutherford-class 5/6 96 (62) 40 (87)*
Comorbidity
Cardiac comorbidity 101 (66) 38 (83)*
Neurologic comorbidity 49 (32) 16 (35)
Pulmonary comorbidity 80 (52) 33 (72)*
Vascular risk factors
Renal impairment 86 (56) 28 (61)
Diabetes mellitus 69 (45) 27 (59)
Hypertension 106 (69) 28 (61)
Current smoking 37 (24) 9 (20)
Type of amputation
Above knee amputation 14 (30)
Below knee amputation 32 (70)
Data are presented as n and (%), unless otherwise specifi ed. IQR= interquartile range




At one-year follow-up, all patients were reclassified as patients with and without a lower 
limb amputation. An additional 41 patients had received lower limb amputation during 
the follow-up period. Hence, a total of 46 patients had a lower limb amputation and 
154 patients had not undergone lower limb amputation. The patients’ characteristics 
are presented in Table 1. In the group with patients undergoing a lower limb 
amputation, there were more patients with Rutherford 5 or 6, e.g. minor tissue loss 
or gangrene. Additionally, there were no statistically significant differences between 
the characteristics of patients that had a major amputation after a revascularization 
attempt or conservative therapy and the ones that had a primary major amputation 
done. 
Non-amputated patients
In Table 2, patients were grouped according to whoever received amputation as 
primary treatment and those who did not. Of those patients, 195 were treated 
without a primary lower limb amputation. There was an instant statistically significant 
improvement in the physical QoL domain scores after five to seven days (12.0 vs. 10.9 
(95% CI-1.57; -0.63), p<0.001). This statistically significant improvement persisted 
during the one-year follow-up (14.2 vs. 10.9 (95% CI -3.70; -2.50), p<0.001). 
As presented in Table 3, these results remained the same for patients who did not 
underwent lower limb amputation within the first year. Patients without a lower limb 
amputation showed an immediate increase of the physical QoL domain scores occurred 
after five to seven days (12.1 vs. 10.7 (95% CI -1.95; -0.90), p<0.001) and persisted after 
one-year follow-up (14.2 vs. 10.7 (95% CI -3.98; -2.65), p<0.001). However, statistically 
significant improvement in the physical HS domain only occurred after one week of 
follow up for primarily non-amputated CLTI patients (29.0 vs. 28.9 (95% CI -0.80; -0.17), 
p = 0.003) and after six weeks for patients who did not undergo secondary amputation 
(32.8 vs. 28.3 (95% CI -5.78; -2.23), p<0.001), as presented respectively in Tables 2 and 
3. These results remained statistically significant over time for both groups. 
As presented in Table 2, statistically significant changes were present in both the 
psychological QoL domain (14.6 vs. 14.1 (95% CI -4.14; -0.89), p = 0.003) as well as the 
psychological HS domain (40.4 vs. 37.4 (95% CI -4.37; -1.16), p<0.001) in the primarily 
non-amputated group. These results did not differ for patients who remained their 
lower limbs during follow-up (Table 3). Also, all measurements remained statistically 
significant over time. 
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Table 2. WHOQOL-BREF vs. SF12 according to received amputation as intention to treat
n Non-amputees n Amputees
WHOQOL-BREF physical 
Baseline 192 10.9 (2.8) 5 9.0 (2.8)
5-7 days 169 12.0 (2.8)* 3 8.3 (2.3)
6 weeks 160 12.7 (3.2)* 5 9.8 (2.5)
6 months 131 13.9 (2.7)* 4 14.0 (2.0)*
12 months 115 14.2 (2.7)* 2 14.0 (0.4)*
SF-physical
Baseline 190 28.9 (8.7) 5 23.9 (7.0)
5-7 days 166 29.0 (8.7)* 3 23.5 (12.0)
6 weeks 160 31.9 (9.8)* 5 25.1 (8.7)
6 months 131 35.7 (9.6)* 4 33.2 (7.2)
12 months 115 35.7 (10.2)* 2 33.2 (3.9)
WHOQOL-BREF Psychological
Baseline 195 14.1 (2.5) 5 14.4 (3.5)
5-7 days 169 14.6 (2.0) 3 12.0 (4.0)
6 weeks 160 14.6 (2.3)* 5 12.7 (4.1)
6 months 131 14.9 (1.9)* 4 14.8 (2.9)
12 months 115 14.9 (2.1)* 2 15.3 (2.8)
SF-mental
Baseline 190 37.4 (11.1) 5 36.7 (13.5)
5-7 days 166 40.4 (8.4)* 3 33.8 (9.2)
6 weeks 160 40.8 (8.4)* 5 34.8 (8.8)
6 months 131 42.2 (7.7)* 4 38.7 (8.4)
12 months 115 42.7 (8.6)* 2 35.2 (5.0)
Data is presented as mean and standard deviation
n =number of patients
* = Signifi cant difference in the treatment group between this measurement and baseline, p<.05
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Table 3. WHOQOL-BREF vs. SF12 according to received lower limb amputation 








Baseline 151 10.7 (2.8) Baseline 46 11.3 (2.7)
5-7 days 133 12.1 (2.8)* Measurement 1 27 12.1 (3.1)
6 weeks 125 13.1 (3.2)* Measurement 2 23 13.0 (3.1)*
6 months 106 14.0 (2.7)* Measurement 3 14 14.7 (1.6)*
12 months 97 14.2 (2.8)* Measurement 4 4 14.4 (1.1)*
SF-physical SF-physical
Baseline 150 28.3 (8.5) Baseline 45 30.2 (9.5)
5-7 days 131 29.4 (8.7) Measurement 1 26 31.1 (8.6)
6 weeks 125 32.8 (10.0)* Measurement 2 23 31.8 (8.0)
6 months 106 36.3 (10.1)* Measurement 3 14 35.2 (5.7)





Baseline 154 14.1 (2.5) Baseline 46 14.0 (2.4)
5-7 days 133 14.7 (2.2)* Measurement 1 27 13.5 (2.5)
6 weeks 125 14.8 (2.2)* Measurement 2 23 13.8 (2.7)
6 months 106 14.9 (1.9)* Measurement 3 14 15.2 (2.1)
12 months 97 14.9 (2.2)* Measurement 4 4 14.8 (1.8)
SF-mental SF-mental
Baseline 150 37.1 (11.1) Baseline 45 38.5 (11.6)
5-7 days 131 40.7 (8.7)* Measurement 1 26 39.6 (7.9)
6 weeks 125 41.2 (8.3)* Measurement 2 23 39.6 (8.2)
6 months 106 42.3 (7.7)* Measurement 3 14 43.0 (10.1)
12 months 97 42.3 (8.8)* Measurement 4 4 38.3 (6.3)
Data is presented as mean and standard deviation
n = number of patients
* = Signifi cant difference in the treatment group between this measurement and baseline, p< .05
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Patients with a lower limb amputation
Patients who underwent a primary lower limb amputation showed statistically signi-
ficant improvements in their physical QoL domain scores after six months (14.0 vs. 9.0 
(95% CI -7.84; -1.45), p = 0.005) and after one year (14.0 vs. 9.0 (95% CI -9.58; -1.46), 
p = 0.008) follow-up (Table 2). No other domains showed a statistically significant 
change over time. Table 3 presents the results of the physical and psychological QoL 
and HS domains after reclassifying the groups at one-year follow-up. Patients with 
a lower limb amputation showed statistically significant improvement of the physical 
QoL domain after a median follow-up time of 182 days (measurement 2; 13.0 vs. 11.3 
(95% CI -7.84; -1.45), p = 0.005) and these results stayed statistically significant in the 
following measurements. Again, no other domains showed any statistically significant 
changes for these patients. 
Overall, our results indicated a discrepancy for the physical QoL and HS domains of 
the WHOQOL-BREF and SF- 12 questionnaires. The Pearson correlation was used to 
measure the strength and direction of association that exists between the WHOQOL-
BREF and SF-12 questionnaires. There was a strong positive relationship between 
the physical and psychological domains of both questionnaires for patients with and 
without a lower limb amputation. These results were statistically significant after one 
year in the patient group without amputation, respectively r(95)=.78, p<0.001 and 
r(95)=.73,p<0.001. After six months, there was a strong statistically significant positive 
relationship between the physical and psychological domains of both questionnaires 
in the patients with a lower limb amputation, r(12)=.60, p=0.023 and r(12)=.81,p<0.001. 
However, these results did not stay statistically significant after one year, r(2)=-.42, p = 





The goal of this prospective observational cohort study was to evaluate QoL in 
relation to HS in 200 CLTI patients aged 70 years and older undergoing lower limb 
amputation. Quality of life is an important outcome in vascular surgery. The data shows 
that patients without a lower limb amputation had statistically significant improvement 
of both physical domains of QoL and HS. Patients with a lower limb amputation only 
had statistically significant improvement of the physical domain of the QoL and did 
not show any statistically significant difference in HS. Although, health care providers 
presume that disability in physical functioning, such as walking and climbing chairs, 
equals impaired QoL, we found something different. Instead, QoL (measured by 
WHOQOLBREF) improved whereas HS did not. In our opinion, the explanation for this 
difference should be found in the questionnaire design. 
Health status is an assessment that measures objective functioning (e.g. whether a 
patient is able to adequately engage in specific activities). Health status is an objective 
indicator of functional outcome, but does not measure a patient’s subjective wellbeing. 
(16-20) The WHOQOL-BREF questionnaire provides the opportunity to assess the 
patient’s evaluation of physical, psychological, and social functioning. (9,22) In contrast 
to HS questionnaires, the WHOQOL-BREF questionnaire does not express the level of 
functioning, but evaluates the patient’s perception thereof. Rather than asking a patient 
whether he is able to perform daily activities, the WHOQOL-BREF questionnaire asks 
patients if they are satisfied with their ability to perform certain daily living activities. 
The systematic review of Hawkins et al. showed that the SF-12 questionnaire was 
extensively validated to measure HS, including in vascular patients receiving a lower 
limb amputation. But then again HS is a generic measurement tool that does not 
adequately identify the physical, psychological, and social functioning of CLTI patients. 
(1,28,29) The SF-12 questionnaire is based on health professionals’ definitions of QoL. 
(13) Therefore, HS accesses disabilities in life whereas QoL accesses if patients are 
subjectively restricted in daily life. In CLTI patients and especially in vascular patients 
with a lower limb amputation living without pain is prioritised over mobility. This 
results in a different perspective on QoL, which is difficult to measure. (1) Breek et 
al. stated an important difference between HS and QoL in patients with intermittent 
claudication (IC). (9) Our results endorse these findings in patients with CLTI. Because 
of high amputation rates (35%-67%) in CLTI, a valid QoL outcome and HS is important 
in vascular patients with a lower limb amputation. In our study, these patients (with a 
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one-year mortality of 35%) showed statistically significant improvement in the physical 
QoL domain at one-year follow-up (survey response 67%, n = 20). (3,8,30)
Frans et al. analysed the QoL in 150 CLTI patients using the VascuQol questionnaire, 
of which 14 patients underwent lower limb amputation. (18) After one-year follow up 
the overall QoL improved. The disease-specific VascuQol questionnaire is considered 
an accurate instrument to measure QoL in IC patients. (29) Nonetheless, the physical 
domain of the VascuQol questionnaire represents an ‘objective’ evaluation of 
performing activities instead of the patient’s perception of his overall functioning. 
(31,32) Therefore the VascuQol questionnaire should be classified as a HS and not as a 
QoL measurement. Additionally, the differentiating power in CLTI patients is poor and 
therefore it may not be generalizable to this specific patient group. (1,31) 
Our study clearly suggests a discrepancy between the physical QoL (WHOQOL-BREF) 
and HS (SF-12) measurements. Currently, there is no consensus about which instruments 
are appropriate to measure QoL in elderly CLTI patients. (9,33) We advocate the use 
of the validated WHOQOL-BREF questionnaire because it is a more precise method 
to describe QoL in CLTI patients and it reveals whether a patient is satisfied with his/
her overall functioning. (22) With respect to shared decision making, distinctive and 
subjective QoL questionnaires provide a very important outcome measurement and 
should be used in future research.
Clearly, this study has several limitations. Health status and QoL are measured with 
the use of self-report questionnaires. Inaccurate reporting of patients can compromise 
self-reported information. In order to limit this risk, we excluded cognitively impaired 
patients. These patients combined with the patients who refused to participate resulted 
in the exclusion of 50% of the elderly CLTI patients. This could cause a selection bias. 
Nonresponse bias was also present. Eighty-two included patients did not complete 
the questionnaires at the one-year follow-up because of decease (n = 59, 30%) and loss 
to follow-up (n = 13, 7%). The reason for loss to follow-up was mostly due to cognitive 
impairment. All patients lost to follow-up did not receive lower limb amputation 
during the first year. Finally, this study represents the entire clinical course of CLTI 
patients. Comorbid conditions and treatment received during follow-up could have 
had an influence on HS and QoL. Future studies could examine the repercussion of 
comorbidities and repetitive treatment on HS and QoL. Furthermore, a patient’s view 
on QoL can also change over time. These changes can be a response to treatment, but 
can also be a result of adaptation to a chronic illness. Therefore, changes in QoL over 




There is a clear difference between patients’ functioning and the patients’ appraisal of 
functioning. In this study, elderly CLTI patients who underwent lower limb amputation 
showed an increase of QoL, but showed no changes in HS. This raises the question 
of what do we want to achieve for the elderly CLTI patient population. Individual 
treatment goals should be kept in mind when assessing the HS or QoL outcome of 
patients undergoing hospital care. With respect to shared decision making, distinctive 
and subjective QoL questionnaires, like the WHOQOL-BREF, provide a very important 
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patient with chronic limb-
threatening ischemia, 
especially after major 
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Objective: In chronic limb-threatening ischemia patients, an association is assumed 
between depression and worse outcome for morbidity, such as lower limb amputation. 
After major amputation, anxiety and depression are common. We aimed to determine 
the association of depressive and anxiety symptoms in the elderly with chronic limb-
threatening ischemia, especially after lower limb amputation.
Methods: Chronic limb-threatening ischemia patients aged ≥70 years were included 
in this prospective observational cohort study between January 2012 and February 
2016 in two Dutch hospitals. After a multidisciplinary vascular conference, patients 
were divided into four treatment groups: endovascular revascularisation, surgical 
revascularisation, conservative therapy, or primary major amputation. In a one-year 
follow-up period, depression and anxiety were measured four times using the Dutch 
versions of the Center for Epidemiological Studies Depression Scale and the State-
Trait Anxiety Inventory.
Results: 187 patients were included. Within one year, 44 patients underwent a lower 
limb amputation. Lower amputation free survival did not differ significantly for 
patients with versus without greater anxiety (X2 (1)=0.689, p=0.407), and also not for 
patients with versus without more depressive symptoms (X2 (1)=0.614, p=0.433). For 
both groups, there were no significant changes in anxiety scores over time. After a 
median follow-up time of 336.5 days and 365 days, depressive symptoms significantly 
decreased in patients with a lower limb amputation, respectively 8.5 vs. 4.5 ((95% CI 
1.76-7.48), p=0.002) and  8.5 vs. 4.3 ((95% CI 0.61-9.82), p=0.027) when compared to 
the baseline measurement. Similarly, patients without a lower limb amputation had 
significantly lower overall score for depressive symptoms after a median follow-up time 
of 365 days (10.1 vs. 4.1, (95% CI 4.49-6.90), p<.001).
Conclusion: In the opinion of the medical health care provider, amputation is a severe 
and unwanted end phase of chronic limb-threatening ischemia. However, depressive 
symptoms seem to decrease over time and anxiety symptoms do not seem to be 
affected in patients after lower limb amputation. Also, patients with greater trait 
anxiety or more depressive symptoms at baseline did not have significantly higher 
amputation rates. These findings are similar to the course of depressive and anxiety 




Chronic limb-threatening ischemia (CLTI) represents the end stage of peripheral 
arterial disease (PAD) and is characterized by ischemic rest pain and ischemic wounds. 
(1) It is associated with high mortality and morbidity, such as lower limb amputation in 
35% to 67% of mainly elderly CLTI patients. (1-3) An association is assumed between 
depression and worse outcome, such as lower limb amputation, for PAD in general. (4) 
Moreover, a higher incidence of lower limb amputation has been described in diabetes 
patients with depression. (4)
A recent review identified a prevalence of depression or depressive symptoms 
ranging from 3-48% in PAD patients. (5) This prevalence is in the range of the reported 
prevalence for another atherosclerotic disease, coronary artery disease (CAD). (5-7) 
In CAD patients, depression is associated with worse outcomes for morbidity and 
mortality. (8-13) After major amputation, anxiety and depression are common. (14-16) 
Moreover, some studies report an association between depression and lower mobility 
levels in amputated patients, but others did not. (7-19) For CLTI little is known about the 
association between depression and major amputation. (4) To our knowledge, there 
are no previous studies that have prospectively examined depression and anxiety after 
major amputation for elderly CLTI patients alone. (5,8)
The objective of this study was to determine the course of depressive and anxiety 
symptoms for elderly CLTI patients, especially after lower limb amputation as clinical 
outcome. Because lower limb amputation is an undesirable outcome in CLTI, our 
hypothesis was that lower limb amputation results in more depressive and/or anxiety 
symptoms. Our second hypothesis was that elderly CLTI patients with primarily higher 




The methods of this study have been published previously. (20) Between January 
2012 and February 2016, 387 elderly patients were treated for CLTI in two peripheral 
hospitals, Amphia hospital and Bravis hospital, the Netherlands. Patients were identified 
and recruited in outpatient clinic. Chronic limb-threatening ischemia was defined 
as ischemic pain and/or tissue loss (Rutherford classification 4 to 6). Diagnosis was 
based on the patient’s medical history, physical examination and ankle-brachial index. 
In patients with incompressible arteries, toe pressure measurements were performed 
instead of a measurement of the ankle-brachial index. Inclusion criteria were diagnosis 
with CLTI, and an age of 70 years and older. Patients were excluded from the study if 
one of the following criteria applied: malignancy, lack of Dutch language skills, and 
cognitive impairment. The follow-up period was one year.
A formal written waiver for ethical approval was not required according to the criteria 
of the Central Committee on Research Involving Human Subjects. The institutional 
review board (AMOA) approved this. All included patients provided written informed 
consent. Patients were not financially compensated in this study.
In a weekly multidisciplinary vascular conference, patients were included and divided 
into four treatment groups. The treatment options were endovascular revascularisation, 
surgical revascularisation, conservative therapy, or primary major amputation. 
Endovascular revascularisation was defined as minimally invasive endovascular 
procedures with or without the use of intraluminal stents. An interventional radiologist 
or a vascular surgeon performed these procedures. Surgical revascularisation was 
described as endarterectomy, lower extremity bypass, or hybrid procedures. A hybrid 
procedure was performed by vascular surgeons and represented an endarterectomy, or 
bypass combined with an endovascular intervention. Conservative therapy consisted 
of local wound care, antibiotics, pain medication and minor amputation (distal of the 
tarsometatarsal joint). Primary major amputation was an amputation proximal to the 
tarsometatarsal joint. Treatment received during follow-up was scored according to 
the same definitions. 
Depressive and anxiety symptoms were measured prospectively using the Dutch 
versions of the Center for Epidemiological Studies Depression Scale (CES-D) and of the 
State-Trait Anxiety Inventory (STAI). These self-report questionnaires were completed 
at the following moments: at inclusion, five to seven days, six weeks, six months, and 
12 months after inclusion.
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The CES-D assesses the presence of depressive symptoms, especially in the elderly 
population. (21,22) In this study, the simplified and shortened 16-item version was 
used. In this questionnaire patients were enquired to specify if and how much time 
they had experienced each depressive symptom during the past week. A CES-D cut 
off score of ≥12 specified patients with depressive symptoms. (23) 
The STAI was used to measure the presence and severity of anxiety symptoms. (24,25) 
At moment of inclusion, the validated 10-item STAI Trait Scale was used to indicate 
how prone patients were to experiencing anxiety. At the subsequent measurement 
points, the six-item STAI State Scale was used to indicate anxiety at the moment 
of completion. (26-29) The six-item short-form was not part of the questionnaire 
conducted at inclusion because of the length of the multiple questionnaires and 
time limitation. A STAI trait cut off score of ≥22 classified patients with greater anxiety 
proneness. (27) A STAI state cut off score of ≥12 classified patients with greater anxiety.
Missing values on the CES-D, STAI-trait and STAI-state questionnaires were handled 
with imputation of the mean of the non-missing items for each participant, but only if 
no more than three (CES-D), two (STAI-trait), or one (STAI-state) item(s) were missing. 
Patients who did not meet this requirement were excluded from analyses involving 
that particular questionnaire.
The use of pain medication, antidepressants and sleeping pills was registered. 
Preoperative variables and outcome variables were gathered at moment of inclusion 
from the electronic medical records. Amputation-free survival was defined as survival 
without a lower limb amputation of the index limb or death. Dates of the deceased 
were confirmed by the Dutch national death registry database (CompeT&T Eindhoven) 
after the follow-up period of one year. The visual analogue scale (VAS) was used at 
each measurement occasion to assess the level of pain. (30)
The treatment groups were classified at baseline according to first treatment approach. 
These groups were reclassified after one-year follow-up as received lower limb 
amputation or not. Results of CESD, STAI and VAS measurements were redefined after 
receiving lower limb amputation. The first completed questionnaire after amputation 
resembled the first measurement after baseline. The second completed questionnaire 
after amputation was defined as the second measurement and so forth.
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Sample size calculation was performed for repeated measures analysis. The power 
was set at 0.80. For a medium effect size (d=0.5) with 5 measurements and an alpha of 
0.05, a total sample size of at least 24 patients would be required. Statistical analyses 
were done using SPSS software, version 23. Chi-squared and Fisher’s exact tests were 
used for univariate analysis. Linear mixed models were performed to examine the 
longitudinal outcome differences of the continuous variables CES-D, STAI and VAS. 
The five measurement points (level 1) were nested within patients (level 2). Test for 
within group difference between baseline and specific follow-up measurements were 
derived directly from the mixed model via a custom hypothesis test programmed in 
the SPSS syntax. Analysis of variance (ANCOVA) with repeated measures was used 
for the outcome differences of CES-D, STAI and VAS after lower limb amputation. 
Amputation free survival (AFS) was estimated by means of Kaplan-Meier curves and 
compared between groups with the Log-rank test. All p-values (two-sided) < 0.05 were 
considered statistically significant. 
RESULTS
Between January 2012 and February 2016, 387 elderly patients were diagnosed with 
CLTI. Of these patients, 187 patients were included and 200 patients were excluded. One 
hundred and eighty-seven patients were excluded from the study because of cognitive 
impairment or patients’ refusal to participate. Thirteen patients were excluded from 
analysis on basis of inability to complete the depression and/or anxiety questionnaire 
at baseline. Seventy-five patients were treated with endovascular revascularisation, 63 
patients with surgical revascularisation, 45 patients had conservative therapy, and 4 
patients had a primary major amputation. 
After 12 months, 105 of 187 patients completed the STAI and CES-D questionnaire. 
For the questionnaires, there was no follow-up data available for 78 of 187 patients 
because 65 patients (83%) died and 13 patients (17%) were lost to follow-up within 
one year. For clinical outcomes, follow-up could be completed for the latter patient 
group. Loss to follow-up was the result of noncompliance of patients on completing 
questionnaires. Median follow-up time was 365 days (interquartile range 201).
In our study, the prevalence of depressive symptoms was 36% at the baseline measure-
ment. The prevalence of anxiety proneness (trait anxiety) was 95% in the elderly CLTI 
patients. There was no correlation between depressive symptoms or anxiety proneness 
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and the comorbidities (e.g. cardiac, neurologic, and pulmonary comorbidities, renal 
impairment, and diabetes mellitus) at baseline. Forty-three patients (the four patients 
with a primarily lower limb amputation included) underwent a lower limb amputation 
within one year (Kaplan-Meier Survival Probability Estimate = 0.77 95% CI 0.701-
0.8269). Figure 1 represents the moment of amputation. Most lower limb amputations 
occurred within three months after inclusion. The median time period from treatment 
to lower limb amputation was 41 days (interquartile range 139).  
Table 1 presents the patients characteristics of patients who underwent lower limb 
amputations and patients who did not during one-year follow-up. At baseline, there 
were no significant differences in depressive and anxiety symptoms for the amputated 
and non-amputated group. There was also no significant difference in sex, age, 
comorbidities, and use of antidepressants and sleeping pills at baseline. There were 
significantly more patients who received a lower limb amputation with Rutherford 
classification 5 or 6 (86%, p=0.005) and a lower mean toe-brachial index (0.05, p=.001). 
Figure 1. The moment of amputation
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Sex (male) 79 (55%) 28 (65%) 0.292
Median Age (IQR) 80 (10) 82 (11) 0.991
Education lever 0.827
- Low 56 (39%) 18 (43%)
- Inbetween 65 (46%) 19 (45%)
- High 22 (15%) 5 (12%)
Having no partner 77 (47%) 22 (48%) 0.790
Living situation 0.692
- Independent 74 (53%) 19 (48%)
- With home care 52 (38%) 16 (40%)
- Nursing home 12 (9%) 5 (12%)
Nicotine abuse 0.509
- Non-smoker 28 (20%) 11 (26%)
- Smoker 35 (24%) 12 (28%)
- Previous smoker 81 (56%) 20 (46%)
Cardiac comorbidity 101 (70%) 29 (67%) 0.736
Neurologic comorbidity 42 (29%) 16 (37%) 0.317
Pulmonary comorbidity 80 (6%) 25 (58%) 0.764
Renal impairment 85 (59%) 24 (56%) 0.708
Diabetes mellitus 69 (48%) 21 (49%) 0.916
Hypertension 100 (69%) 28 (65%) 0.592
Rutherford-class 4 53 (37%) 6 (14%) 0.005
Rutherford-class 5/6 91 (63%) 37 (86%) 0.005
Mean ankle-brachial index ± SD 0.37 ± 0.2 0.32 ± 0.2 0.394
Mean toe-brachial index ± SD 0.22 ± 0.2 0.05 ± 0.1 0.001
Medication use at inclusion
- Beta blocker 77 (54%) 28 (65%) 0.177
- Statin 103 (72%) 30 (70%) 0.823
- Paracetamol/NSAID 10 (7%) 6 (14%) 0.209
- Tramadol/morphine/ pregabalin 59 (41%) 26 (61%) 0.024
- Antidepressants 6 (4%) 5 (12%) 0.130
- Sleeping pills 24 (17%) 3 (7%) 0.113
Medication use at one year follow-up
- Paracetamol/NSAID 23 (40%) 5 (26%) 0.294
- Tramadol/morphine/ pregabalin 7 (13%) 1 (6%) 0.670
- Antidepressants 6 (23%) 0 (0%) 0.304
- Sleeping pills 10 (37%) 2 (22%) 0.685
Mean CESD baseline ± SD 10.1 ± 6.9 8.5 ± 6.9 0.817
Mean STAI baseline ± SD 36.1 ± 10.7 37.6 ± 11.9 0.081
Mean visual analogue scale ± SD 6.5 ± 2.7 5.2 ± 3.2 0.036
Data is presented as n (%) unless otherwise specifi ed
IQR = interquartile range. SD = standard deviation. LLA = lower limb amputation
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Figure 2. Limb free survival between patients with and without anxiety proneness
Figure 2 demonstrates the amputation free survival curves for patients with and for 
patients without greater trait anxiety. Lower amputation free survival did not differ 
significantly for patients with versus without greater anxiety (log rank test X2 (1)=0.689, 
p=0.407) However, the sample size of patients without greater treat anxiety was low. 
Therefore, this study was underpowered to detect true effects in anxiety scores. 
Similarly, the amputation free survival curves (Figure 3) for patients with and without 
depressive symptoms indicated no significant difference between the survival curves 
of both groups (log rank test X2 (1)=0.614, p=0.433).
Results concerning depressive and anxiety symptoms are presented in Table 2, 
stratified by initial treatment. Primarily amputated patients did not show any significant 
difference between depressive or anxiety symptoms during follow-up and the baseline 
measurements. The overall score for depressive symptoms was significantly lower at 
one year for surgical revascularisation (mean 10.2 vs. 3.3, (95% CI 4.69-8.15), p<.001), 
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Figure 3. Limb free survival between patients with and without depressive symptoms
endovascular revascularisation (mean 10.5 vs. 4.9, (95% CI 2.91-6.47), p<.001), and 
conservative therapy (mean 8.0 vs. 6.2, (95% CI -0.02-6.04), p=0.025). However, the 
fraction of patients with depressive symptoms at baseline only significantly decreased 
for endovascular revascularisation (41.3% vs. 14%, (95% CI -2.40--0.42), p=0.005) 
and surgical revascularisation (36.4% vs. 7.4%, (95% CI -2.59--0.45), p=0.006). For all 
treatment groups, there were no significant changes in anxiety scores or number 
of anxious patients. The overall VAS score was significantly lower at one year for 
endovascular revascularisation (6.3 vs. 2.7, (95% CI 1.49-4.31), p<.001) and surgical 
revascularisation (7.2 vs. 3.7, (95% CI 1.70-4.55), p<.001) and primary major amputation 
(6.0 vs. 7.0, (95% CI 0.126-6.56), p=0.042). No significant differences were found 
between the overall VAS scores during follow-up and the baseline measurement in the 
conservative treated patients. 
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Baseline 75 10.5 (7.1) 63 10.2 (6.9) 45 8.0 (7.1) 4 10.4 (5.8)
5-7 days 61 6.9 (5.8)* 57 5.7 (5.5)* 39 6.4 (4.5) 3 14.0 (9.6)
6 weeks 58 6.3 (5.8)* 58 5.5 (5.8)* 34 6.3 (4.7)* 3 14.0 (5.2)
6 months 49 5.8 (5.1)* 52 3.8 (5.2)* 23 7.1 (5.2) 2 11.5 (0.7)
1 year 41 4.9 (5.2)* 50 3.3 (4.5)* 17 6.2 (6.1)* 1 8.0 (-)
STAI
5-7 days 61 39.8 (9.9) 56 37.6 (8.8) 38 37.7 (7.9) 3 40.0 (8.8)
6 weeks 57 38.4 (8.7) 58 37.5 (10.1) 34 39.2 (9.1) 3 42.2 (7.7)
6 months 49 37.1 (7.1) 52 40.0 (8.0) 23 39.8 (9.8) 2 41.7 (2.4)
1 year 41 36.7 (7.9) 50 35.1 (8.5) 17 37.0 (9.9) 1 41.7 (-)
VAS
Baseline 73 6.3 (2.8) 62 7.2 (2.2) 44 4.9 (3.4) 4 6.0 (4.1)
5-7 days 59 4.4 (3.3)* 58 4.3 (3.1)* 39 4.4 (3.4) 3 8.7 (1.2)
6 weeks 58 3.8 (3.6)* 58 3.5 (2.9)* 34 4.6 (3.2)* 3 5.0 (4.4)
6 months 49 2.5 (3.2)* 52 2.8 (3.1)* 23 3.0 (3.2) 2 3.3 (2.5)*
1 year 29 2.7 (3.4) 30 3.7 (3.4)* 11 5.6 (3.3) 1 7 (-) *
Data is presented as mean and standard deviation
n = number of patients
* = Signifi cant difference in the treatment group between baseline and this time point, p<0.05
At one-year follow-up, patients were reclassified as patients without a lower limb 
amputation and patient with a lower limb amputation (as shown in table 3). After a 
median follow-up time of 336.5 days (measurement 3) and 365 days (measurement 4), 
depressive symptoms significantly decreased in patients with a lower limb amputation. 
They reported lower overall scores for depressive symptoms at measurement 3 (8.5 vs. 
4.5, (95% CI 1.76-7.48), p=0.002) and measurement 4 (8.5 vs. 4.3, (95% CI 0.61-9.82), 
p=0.027) when compared to the baseline measurement. Similarly, patients without a 
lower limb amputation had significantly lower overall score for depressive symptoms 
after a median follow-up time of 365 days (10.1 vs. 4.1, (95% CI 4.49-6.90), p<.001). 
Depression scores on the long-term were similar between both patient groups. 
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Table 3. Depressive and anxiety symptoms for patients with and without a lower limb 
amputation at one year follow-up
n Patients without 
LLA (n=144)
n Patients with 
LLA (n=43)
CESD CESD 
Baseline 144 10.1 (6.9) Baseline 43 8.5 (6.9)
5-7 days 124 5.7 (4.9)* Measurement 1 25 8.5 (6.7)+
6 weeks 117 5.1 (4.9)* Measurement 2 21 8.4 (6.1)+
6 months 99 4.6 (5.0)* Measurement 3 12 4.5 (3.7)*
1 year 90 4.1 (5.0)* Measurement 4 3 4.3 (3.5)*
STAI STAI
5-7 days 122 37.4 (8.6) Measurement 1 25 39.5 (7.7)
6 weeks 116 36.5 (8.2) Measurement 2 21 39.8 (8.8)
6 months 99 35.4 (8.4) Measurement 3 12 36.9 (4.4)
1 year 90 37.4 (9.1) Measurement 4 3 38.9 (1.9)
VAS VAS
Baseline 140 6.5 (2.7) Baseline 43 5.2 (3.2)
5-7 days 122 4.2 (3.2)* Measurement 1 26 3.7 (3.7)*
6 weeks 117 3.6 (3.2)* Measurement 2 20 3.7 (3.6)*
6 months 99 2.8 (3.1)* Measurement 3 10 1.6 (2.5)*
1 year 55 4.0 (3.5)* Measurement 4 3 2.3 (4.0)
Data is presented as mean and standard deviation. LLA = lower limb amputation
* = Signifi cant difference in the treatment group between baseline and this time point, p<0.05
+ = Signifi cant difference between patient groups, p< 0.05
For patients with as well as patients without a lower limb amputation, there were 
no significant changes in anxiety scores. After one year follow-up, VAS scores were 
significantly lower in the patient group without a lower limb amputation (6.5 vs. 4.0, 
(95% CI 1.55-3.60), p<.001). For patients with a lower limb amputation significance was 




In our study, CLTI patients (n=187) aged 70 years and older were included in a 
prospective observational cohort study. We aimed to explore the course of depressive 
and anxiety symptoms during treatment for CLTI, with special interest for lower limb 
amputation as clinical outcome. The first hypothesis was that lower limb amputation 
results in more depressive and/or anxiety symptoms. The second hypothesis was that 
elderly CLTI patients with primarily higher depressive or anxiety scores underwent 
more lower limb amputation during follow-up.
Based on our data, we did not find support for both hypotheses. At baseline, patients 
exceeding the cut off scores for both questionnaires were labelled as patients with 
greater trait anxiety of more depressive symptoms. These patients did not have a 
significantly higher amputation rate. Furthermore, depressive and anxiety symptoms 
did not increase after lower limb amputation. In fact, the contrary was true in our 
study cohort. Overall scores for depressive symptoms were significantly lower after 
lower limb amputation during follow-up. This significant difference was also reached 
for endovascular, surgical of conservative treated patients. However, anxiety scores 
remained the same as before treatment.  Also, after lower limb amputation there was 
no significant difference for anxiety symptoms. The overall VAS score was significantly 
lower after every endovascular, surgical, or conservative treatment. For patients with 
a lower limb amputation, the overall VAS demonstrates a downward trend over time.  
At baseline, the prevalence of depressive symptoms in our patient cohort was 36%. 
This finding is in line with that of previous studies. (5,8) Cherr et al. is the only study that 
compared major amputation rates of non-depressed patients and depressed patients 
as a clinical outcome. (8) They included 216 patients. Sixty-two of these patients had 
disabling claudication, 48 patients had ischemic rest pain and 106 patients had tissue 
loss. (8) At two years follow-up they found no significant difference in amputation rates 
between the non-depressed and depressed group. (8) Similarly, our study also did not 
demonstrate any significant difference in amputation rates between CLTI patients with 
or without depressive symptoms.
To our knowledge no research has been done on anxiety symptoms after amputation 
for CLTI. However, there is data on this subject for amputation after traumatic injuries. 
These studies report a high level of anxiety directly after traumatic amputation. (15,16) 
Still, our study implies the opposite after amputation for CLTI. 
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When other revascularisation options fail and conservative treatment is not sufficient 
enough, lower limb amputation is the end stage of CLTI. Current clinical practice is 
to prevent this end stage. A possible explanation for less depressive symptoms after 
lower limb amputation may be the fact that our patient cohort experienced chronic 
ischemic limb pain prior to amputation. So based on our results, lower limb amputation 
is maybe not as bad as we thought for the patient’s wellbeing. It is important to provide 
patients with this information in the shared decision-making process when the choice 
to amputate or not is approaching. Still, there is little known about mood disorders 
after amputation for CLTI. However, the awareness and treatment of possible mood 
disorders in CLTI patients should rise. 
Despite the significant differences in depressive symptoms and VAS scores, these 
results should be interpreted with caution for the secondary patients with a lower limb 
amputation at the last two measurement points during follow-up. The sample size of 
amputated participants decreases over time. Still, the sample size is relatively large 
for an elderly CLTI population of a two-centre study. Moreover, the decrease of the 
sample size resembles the clinical course of elderly CLTI patients with high mortality 
rates. Our study also has other limitations. First, depressive and anxiety symptoms 
were reported by self-report questionnaires. The gold standard in diagnosing 
depression and anxiety disorders is the use of diagnostics interview. (31,32) This may 
lead to lower rates of depression and anxiety. Second, our study inclusion resembles 
current clinical treatment practice, but patients were not randomized to treatment. 
Moreover, approximately half of the patients refused to participate in this study. This 
may have caused a selection bias in our study. Third, the small sample size of primarily 
amputated patients and patients without anxiety proneness causes low statistical 
power. This reduces the chance of detecting a true effect. 
CONCLUSION
In the opinion of medical health care provider, lower limb amputation is a severe end 
phase of CLTI that needs to be prevented. In contrast to this opinion of the health care 
provider, depressive symptoms seem to decrease over time and anxiety symptoms do 
not seem to be affected in patients after lower limb amputation in our study cohort. 
These findings are similar to the course of depressive and anxiety symptoms for the 
elderly CLTI patients without lower limb amputation. Also, patients with greater trait 
anxiety or more depressive symptoms at baseline did not have significant higher 
amputation rates. Of course, amputation choice cannot be made on the consideration 
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of depressive and anxiety symptoms alone. But especially in the elderly, expectations 
and demands after lower limb amputation are lower. Future studies are warranted 
to further elucidate the association between lower limb amputation and anxiety and 
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Is amputation in the 
elderly patient with 
chronic limb-threatening 
ischemia acceptable in 
the long term?
C.M.L. Peters, J. de Vries, E.J. Veen, G.H. Ho, P. Lodder,  
S.L. Steunenberg, L. van der Laan




Objective: Despite high amputation rates, data on patient-reported outcomes is 
scarce in the elderly population with chronic limb-threatening ischemia (CLTI). The aim 
of this study was to provide mortality rates and long-term changes of the following 
patient-reported outcomes in elderly CLTI patients with a lower limb amputation: 
quality of life (QoL), health status (HS), and symptoms of depression.
Methods: In this prospective observational cohort study, amputated CLTI patients ≥70 
years were included. The follow-up period was two years. Within the follow-up period 
patients completed the following questionnaires: the World Health Organization 
Quality Of Life -abbreviated version of the WHOQOL 100 (WHOQOLBREF), the 12-
Item Short Form Health Survey, and the Center for Epidemiological Studies Depression 
Scale.
Results: A total of 49 elderly patients with CLTI had undergone lower limb amputation 
within two years after inclusion. In these patients, the one-year mortality rate was 39% 
and the two-year mortality rate was 55%. The physical QoL was the only domain of 
the WHOQOL-BREF that improved significantly across time after amputation (p≤.001). 
In the long-term, there was no difference in the ability to enjoy life (p=0.380) or the 
satisfaction in performing daily living activities (p=0.231) compared to the scores of 
the general elderly population. After amputation, the physical HS domain (p≤.001) and 
the mental HS domain (p=0.002) improved. In the first year, patients with a lower limb 
amputation experienced less symptoms of depression (p=0.004).
Conclusion: Elderly CLTI patients with a lower limb amputation are a fragile population 
with high mortality rates. Their QoL and HS increased after lower limb amputation as 
compared to the baseline situation and they experienced less symptoms of depression. 
Moreover, our results show that, in the long-term, lower limb amputation in the elderly 
patients with CLTI shows an acceptable QoL, which, in some aspects, is comparable to 
the QoL of their peers. These results can improve the shared-decision making process 




Chronic limb-threatening ischemia (CLTI) is the most severe stage of peripheral arterial 
disease (PAD) and is characterized by ischemic rest pain and/or tissue loss. In patients 
with CLTI, the main goal of treatment is to salvage the affected limb. (1,2) The success 
of treatment for CLTI is measured by amputation free survival (AFS). (2) In order to 
achieve this desired outcome, patients with CLTI are aggressively revascularized by 
endovascular or surgical procedures, if possible. (1,2) However, despite these efforts, 
amputation rates remain high. One year after the onset of CLTI, 25% of patients will 
have to undergo a lower limb amputation and approximately 35–67% of CLTI patients 
undergoes lower limb amputation within four years. (2-4) Moreover, early post-
operative mortality rates range from 4% to 22% after lower limb amputation from any 
cause. (5) Early mortality rates of up to 20% are reported in CLTI patients with a lower 
limb amputation. (6,7) 
Because of high amputation and mortality rates functional status and mobility success 
have been studied. (8,9) Norvell et al and Taylor et al report that successful outcome 
is associated with mobility capacity. (8,9) However, mobility is often impaired in elderly 
patients with CLTI. This raises the question whether an assessment of objective 
functioning, which is expected to be impaired, can be considered a good patient-
reported outcome of treatment success. Other patient-reported outcomes (PROs), 
such as quality of life (QoL) and health status (HS), are increasingly relevant in CLTI 
patients. (10–12) Quality of life and HS are supplementary, in the sense that HS 
questionnaires, like the SF-12, focus on physical, psychological, and social objective 
functioning and QoL questionnaires measure the patients’ own satisfaction or 
evaluation of functioning. (11,13,14) 
Furthermore, little is known about the QoL and HS of CLTI patients with a lower limb 
amputation. (15) The lack of literature on long-term results is due to high mortality 
rates. Besides, the absolute number of amputations per hospital is low. Additionally, 
reports on changes in other mental health disorders, like depression, after lower limb 
amputation for CLTI patients, is lacking in literature. (16) 
Therefore, the aim of this prospective observational cohort study was to provide short-
term and long-term changes of the following patient-reported outcomes in elderly 
CLTI patients with a lower limb amputation: QoL, HS, and symptoms of depression. 
The scores of specified World Health Organization Quality Of Life -abbreviated 
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version of the WHOQOL 100 (WHOQOL-BREF) questions of the elderly sample in the 
current study were compared to the normal scores in the general elderly population. 
In addition, the thirty-days, six-month, one-year and two-year mortality rates of elderly 
CLTI patients after lower limb amputation will be addressed.
METHODS
In this prospective observational cohort study, patients with CLTI aged 70 years and 
older undergoing a lower limb amputation, were included between January 2012 and 
February 2016. (17) Exclusion criteria were a diagnosis of malignancy, lack of Dutch 
language skills, or cognitive impairment. This study was conducted in accordance 
with the Declaration of Helsinki. Based on the criteria of the Central Committee on 
Research Involving Human Subjects, a formal written waiver for ethical approval was 
not required. The institutional medical ethical committee (AMOA) approved this. All 
patients included signed an informed consent. 
At a weekly multidisciplinary vascular conference, a panel of experts placed the 
patients into one of four treatment groups: surgical revascularisation, endovascular 
revascularisation, conservative therapy, or lower limb amputation. During follow-up, 
secondary lower limb amputation was recorded. The follow-up period was two years 
after inclusion. 
Within this follow-up period patients completed the following self-report questionnaires 
at six specified times: WHOQOL-BREF, the 12-Item Short Form Health Survey (SF-12), 
and the Center for Epidemiological Studies Depression Scale (CES-D). Patients who 
underwent lower limb amputation during the 2-year follow-up period were selected 
for this study. Questionnaires were gathered that were completed six months, one 
year, and between one-and-a-half years and two years after lower limb amputation.
WHOQOL-BREF
In the elderly, the validated WHOQOL-BREF questionnaire was utilized to measure 
QoL. (18,19) This patient-completed measurement of health-related QoL is the 
short version of the WHOQOL-100 and contains 26 items with a 5-point Likert type 
response scale. These 26 questions are grouped into four domains (physical health, 
psychological health, social relationships, and environment) and a general QoL facet. 
The WHOQOL-BREF is reliable and valid instrument for measuring quality of life in the 




The SF-12 is a reliable and valid instrument for measuring HS of the elderly population. 
(21) The SF-12 is a shortened version of the RAND 36-Item Short Form Health Survey. 
(22) The questionnaire consists of 12 questions with three to five response levels, which 
are completed by patients. It determines HS, which can be divided into the Physical 
Component Summary (PCS) scale and the Mental Component Summary (MCS) scale. 
(10,22,23)
CES-D
Symptoms of depression were measured by means of the CES-D questionnaire. (24,25) 
In this study, the abbreviated 16-item version was applied, which is both widely used 
and easy in use, especially in the elderly population. (25) In this questionnaire, patients 
were presented with 16 symptoms of depression and asked if they experienced any 
of them. If they had experienced any of the sixteen symptoms, the frequency and 
duration within the past week was asked to be noted. A CES-D cut off score of ≥12 
specified patients with symptoms of depression. (26)
Statistical analysis
Statistical analyses were done using a computerized software package: SPSS version 23 
(IBM, Chicago IL, USA). Continuous and normally distributed variables were expressed 
in terms of means and standard deviations. Continuous and non-normally distributed 
variables were expressed in terms of medians and interquartile ranges. The Shapiro-
Wilk test was used to assess whether continuous variables were normally distributed. 
Categorical variables were expressed in terms of frequencies and percentages. 
Item-level missing data was imputed according to the guidelines of the particular 
questionnaire. Scale-level missing data was directly handled through maximum 
likelihood estimation, as implemented in the mixed modeling procedure. Linear mixed 
models were used to assess the change of QoL, HS, and symptoms of depression at 
three specified times. Within mixed modeling, custom hypothesis tests were used to 
assess differences between baseline and follow-up measurements. Lastly, one sample 
t-tests were used to compare the mean QoL estimates to corresponding estimates 





A total of 387 patients of 70 years or older were diagnosed with CLTI during the 
inclusion period of which 195 patients were excluded based on the criteria previously 
stated. Two years after inclusion in this study, a total of 49 elderly CLTI patients had 
undergone lower limb amputation of the affected limb. These patients were selected 
from a cohort initially treated with surgical revascularisation (n=12), endovascular 
revascularisation (n=21), conservative therapy (n=11), or primary lower limb amputation 
(n=5). In Table 1, the patient characteristics of all patients with a lower limb amputation 
are presented.
Clinical outcome & mortality
Place of discharge is shown in Table 2. A small proportion of patients (n=9, 18%) 
were able to go home after lower limb amputation. To the best of our knowledge, 
17 patients with a lower limb amputation (35%) used a prosthesis at some point after 
lower limb amputation. The thirty-day mortality rate was 16%. After 6 months, 31% of 
the patients with a lower limb amputation had deceased. The one-year mortality rate 
was 39% and the two-year mortality rate increased to 55%.
Patient-reported outcome
Table 3 gives an overview of the median time between amputation and the conduction 
of the CES-D, the WHOQOL-BREF and the SF-12. As presented in Table 4, the physical 
QoL was the only domain of the WHOQOLBREF that significantly improved in time, 
after amputation. This improvement occurred at the 6-month measurement compared 
with the baseline measurement (11.29 vs 14.44;p≤.001,  95% CI 1.61; 4.29) and remained 
significant after 1.5–2 years (11.29 vs 14.75; p≤.001, 95% CI 2.49; 4.96). There were 
no significant differences in time for the overall, psychological, environmental, and 
social domains of the WHOQOL-BREF. The SF-12 also showed improvement in their 
physical HS domain, after 6 months compared with the baseline measurement (29.73 
vs 34.97; p=0.015, 95% CI 0.91; 7.82). This improvement remained significant after 
1.5–2 years compared with the baseline measurement (29.73 vs 35.72; p≤.001, 95% CI 
3.02; 9.10). The mental HS domain only showed a significant improvement after 1.5–2 
years compared with the baseline measurement (38.64 vs 44.46; p=0.002, 95% CI 3.88; 
12.59). Patients with lower limb amputation experienced less symptoms of depression 
after 6 months (8.69 vs 4.45; p=0.004, 95% CI −5.91; −1.22) and after 12 months (8.69 
vs 4.56; p=0.004, 95% CI −6.62; −1.40), compared with their baseline measurement. 
Table 5 compares the scores of specified WHOQOLBREF questions at baseline and 
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- Previous minor amputation
Type of amputation
- Above knee amputation
- Knee disarticulation





































Data are presented as n and (%), unless otherwise specifi ed 
n =  number of patients; IQR = interquartile range; ASA = American Society of Anesthesiologists; 
LLA = lower limb amputation
* = Signifi cant difference between age groups (p< .05)
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after amputation to normal scores in the general elderly population. (27) While at 
baseline the current elderly sample showed significantly higher pain scores than the 
general elderly population (mean Δ=0.769; p<.001; 95% CI 0.47; 1.06), the pain scores 
significantly improved and reached a level significantly lower than the normal values 
of the elderly, both in the short-term (mean Δ=−0.603; p=0.022; 95% CI −1.11; −0.10) 
and in the long-term (mean Δ=−0.824; p=0.024; 95% CI −1.51; −0.13). Elderly CLTI 
patients with a lower limb amputation were able to accept their bodily appearance 
less, compared to the corresponding elderly. However, their scores did not differ from 
their pre-amputation scores. Overall, patients with a lower limb amputation rated their 
own quality of life significantly lower than the corresponding elderly in the long-term 
(mean Δ=−0.605; p=0.003, 95% CI −0.96; −0.25). 














Data are presented as n and (%). LLA = lower limb amputation
Table 3. Time to Conduction of the Questionnaires
n Median time IQR
Baseline 49
Half year 23 167 148 - 185
1 year 16 357 336.5 - 362.75
1.5 - 2 years 11 697 651 - 726
Data presented as median; n = number of patients; IQR = interquartile range
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7Table 4. Patient-Reported Outcomes for patients with a lower limb amputation (n=49)
n Mean SD p value 95% CI
WHOQOL-BREF overall QoL
Baseline 49 3.18 0.85
Half year 23 3.47 0.59 0.342 -0.1796; 0.4947
1 year 16 3.63 0.56 0.121 -0.0843; 0.6814
1.5 - 2 years 11 3.55 0.42 0.198 -0.1439; 0.6368
WHOQOL-BREF 
physical health
Baseline 49 11.29 2.67
Half year 23 14.44 2.33 ≤ 0.001 1.6123; 4.2901
1 year 16 14.46 2.34 ≤ 0.001 1.6320; 4.1622
1.5 - 2 years 11 14.75 1.86 ≤ 0.001 2.4949; 4.9603
WHOQOL-BREF 
Psychological health
Baseline 49 14.00 2.36
Half year 23 14.89 1.90 0.162 -0.2052; 1.1654
1 year 16 15.17 1.57 0.199 -0.3819; 1.7532 
1.5 - 2 years 11 14.73 1.28 0.269 -0.3395; 1.1448
WHOQOL-BREF 
social relationships
Baseline 49 15.99 2.23
Half year 23 16.17 2.00 0.897 -0.7205; 0.8220
1 year 15 16.36 1.55 0.978 -0.9858; 0.9587
1.5 - 2 years 11 15.76 1.59 0.163 -1.7996; 0.3037
WHOQOL-
BREF environment
Baseline 49 15.57 2.07
Half year 23 14.96 1.45 0.067 -1.3431; 0.0463
1 year 16 15.34 1.42 0.702 -0.8126; 0.5473
1.5 - 2 years 11 15.36 0.74 0.125 -1.0256; 0.1248
SF-physical
Baseline 48 29.73 9.36
Half year 23 34.98 6.54 0.015 0.9095; 7.8204
1 year 16 34.97 5.40 0.022 0.6319; 7.7767
1.5 - 2 years 11 35.72 4.77 ≤ 0.001 3.0249; 9.1026
SF-mental
Baseline 48 38.64 11.37
Half year 23 43.21 6.97 0.063 -0.2088; 7.69795
1 year 16 43.66 8.55 0.262 -2.4686; 8.7032
1.5 - 2 years 11 44.46 9.07 0.002 3.8787; 12.5862
CESD
Baseline 48 8.69 7.05
Half year 22 4.45 4.72 0.004 -5.9119; -1.2185
1 year 16 4.56 3.44 0.004 -6.6151; -1.3993
1.5 - 2 years 11 5.00 4.90 0.050 -6.3459; 0.0027
Data presented as mean; n = number of patients; SD = standard deviation; CI = confi dence interval
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However in the long-term, there was no difference in the ability to enjoy life (mean 
Δ=0.145; p=0.380; 95% CI −0.21; 0.50), the amount of energy the elderly had (mean 
Δ=−0.545; p=0.052; 95% CI −1.10; 0.01), or the satisfaction in performing daily living 
activities (mean Δ=−0.265; p=0.231; 95% CI −0.73; 0.20).
 Table 5. WHOQOL-BREF compared to normal values for elderly




p value 95% CI
Item 1. How would you rate your quality of life?
Very poor (1) – poor (2) – neither poor nor good (3) – good (4) – very good (5)
Baseline 49 3.33 4.06 -0.733 <0.001 -1.01; -0.46
Half year 22 3.27 -0.787 <0.001 -1.10; -0.48
1 year 17 3.65 -0.413 0.027 -0.77; -0.05
1.5-2 years 11 3.45 -0.605 0.003 -0.96; -0.25
Item 3. To what extend do you feel that physical pain prevents you from doing what you 
need to do? 
Not at all (1) – a little (2) – a moderate amount (3) – very much (4) – an extreme amount (5)
Baseline 48 3.23 2.46 0.769 <0.001 0.47; 1.06
Half year 21 1.86 -0.603 0.022 -1.11; -0.10
1 year 16 1.56 -0.898 0.002 -1.41; -0.38
1.5-2 years 11 1.64 -0.824 0.024 -1.51; -0.13
Item 5. How much do you enjoy life?
Not at all (1) – a little (2) – a moderate amount (3) – very much (4) – an extreme amount (5)
Baseline 49 3.10 3.31 -0.208 0.083 -0.44; 0.03
Half year 22 3.48 0.166 0.360 -0.20; 0.54
1 year 17 3.35 0.043 0.852 -0.44; 0.52
1.5-2 years 11 3.45 0.145 0.380 -0.21; 0.50
Item 10. Do you have enough energy for everyday life?
Not at all (1) – a little (2) – moderately (3) – mostly (4) – completely (5)
Baseline 49 3.29 4.09 -0.804 <0.001 -1.10; -0.51
Half year 22 3.64 -0.454 <0.001 -0.67; -0.24
1 year 17 3.41 -0.678 <0.001 -1.00; -0.36
1.5-2 years 11 3.55 -0.545 0.052 -1.10; 0.01
Item 11. Are you able to accept you bodily appearance?
Not at all (1) – a little (2) – moderately (3) – mostly (4) – completely (5)
Baseline 48 3.77 4.36 -0.589 <0.001 -0.89; -0.29
Half year 22 3.86 -0.496 0.007 -0.84; -0.15
1 year 17 3.88 -0.478 <0.001 -0.65; -0.31
1.5-2 years 11 3.73 -0.633 0.024 -1.16; -0.10
Item 16. How satisfi ed are you with your ability to perform daily living activities?
Very dissatisfi ed (1) – dissatisfi ed (2) – neither satisfi ed nor dissatisfi ed (3) – satisfi ed (4) 
– very satisfi ed (5)
Baseline 49 2.88 3.81 -0.932 <0.001 -1.24; -0.63
Half year 22 3.18 -0.628 0.006 -1.05; -0.20
1 year 17 3.24 -0.575 0.018 -1.04; -0.11
1.5-2 years 11 3.55 -0.265 0.231 -0.73; 0.20
Item 18. How satisfi ed are you with yourself?
Very dissatisfi ed (1) – dissatisfi ed (2) – neither satisfi ed nor dissatisfi ed (3) – satisfi ed (4) 
– very satisfi ed (5)
Baseline 49 3.57 3.97 -0.399 0.002 -0.65; -0.15
Half year 22 3.82 -0.152 0.240 -0.41; 0.11
1 year 17 3.82 -0.146 0.270 -0.42; 0.13
1.5-2 years 11 3.73 -0.243 0.116 -0.56; 0.07
Item 25. How well are you able to get around?
Very poor (1) – poor (2) - neither poor nor good (3) – good (4) – very good (5)
Baseline 47 2.49 3.70 -1.211 <0.001 -1.56; -0.87
Half year 22 3.32 -0.382 0.058 -0.78; 0.01
1 year 17 3.53 -0.171 0.433 -0.62; 0.28
1.5-2 years 11 3.36 -0.366 0.255 -0.96; 0.28
Data presented as mean; n = number of patients; CI = confi dence interval
The value of the general elderly population is based on reference 27 
One sample t-tests were used to compare the mean QoL estimates to corresponding estimates in 
the general elderly population
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1 year 17 3.35 0.043 0.852 -0.44; 0.52
1.5-2 years 11 3.45 0.145 0.380 -0.21; 0.50
Item 10. Do you have enough energy for everyday life?
Not at all (1) – a little (2) – moderately (3) – mostly (4) – completely (5)
Baseline 49 3.29 4.09 -0.804 <0.001 -1.10; -0.51
Half year 22 3.64 -0.454 <0.001 -0.67; -0.24
1 year 17 3.41 -0.678 <0.001 -1.00; -0.36
1.5-2 years 11 3.55 -0.545 0.052 -1.10; 0.01
Item 11. Are you able to accept you bodily appearance?
Not at all (1) – a little (2) – moderately (3) – mostly (4) – completely (5)
Baseline 48 3.77 4.36 -0.589 <0.001 -0.89; -0.29
Half year 22 3.86 -0.496 0.007 -0.84; -0.15
1 year 17 3.88 -0.478 <0.001 -0.65; -0.31
1.5-2 years 11 3.73 -0.633 0.024 -1.16; -0.10
Item 16. How satisfi ed are you with your ability to perform daily living activities?
Very dissatisfi ed (1) – dissatisfi ed (2) – neither satisfi ed nor dissatisfi ed (3) – satisfi ed (4) 
– very satisfi ed (5)
Baseline 49 2.88 3.81 -0.932 <0.001 -1.24; -0.63
Half year 22 3.18 -0.628 0.006 -1.05; -0.20
1 year 17 3.24 -0.575 0.018 -1.04; -0.11
1.5-2 years 11 3.55 -0.265 0.231 -0.73; 0.20
Item 18. How satisfi ed are you with yourself?
Very dissatisfi ed (1) – dissatisfi ed (2) – neither satisfi ed nor dissatisfi ed (3) – satisfi ed (4) 
– very satisfi ed (5)
Baseline 49 3.57 3.97 -0.399 0.002 -0.65; -0.15
Half year 22 3.82 -0.152 0.240 -0.41; 0.11
1 year 17 3.82 -0.146 0.270 -0.42; 0.13
1.5-2 years 11 3.73 -0.243 0.116 -0.56; 0.07
Item 25. How well are you able to get around?
Very poor (1) – poor (2) - neither poor nor good (3) – good (4) – very good (5)
Baseline 47 2.49 3.70 -1.211 <0.001 -1.56; -0.87
Half year 22 3.32 -0.382 0.058 -0.78; 0.01
1 year 17 3.53 -0.171 0.433 -0.62; 0.28
1.5-2 years 11 3.36 -0.366 0.255 -0.96; 0.28
Data presented as mean; n = number of patients; CI = confi dence interval
The value of the general elderly population is based on reference 27 
One sample t-tests were used to compare the mean QoL estimates to corresponding estimates in 
the general elderly population
 Table 5. WHOQOL-BREF compared to normal values for elderly




p value 95% CI
Item 1. How would you rate your quality of life?
Very poor (1) – poor (2) – neither poor nor good (3) – good (4) – very good (5)
Baseline 49 3.33 4.06 -0.733 <0.001 -1.01; -0.46
Half year 22 3.27 -0.787 <0.001 -1.10; -0.48
1 year 17 3.65 -0.413 0.027 -0.77; -0.05
1.5-2 years 11 3.45 -0.605 0.003 -0.96; -0.25
Item 3. To what extend do you feel that physical pain prevents you from doing what you 
need to do? 
Not at all (1) – a little (2) – a moderate amount (3) – very much (4) – an extreme amount (5)
Baseline 48 3.23 2.46 0.769 <0.001 0.47; 1.06
Half year 21 1.86 -0.603 0.022 -1.11; -0.10
1 year 16 1.56 -0.898 0.002 -1.41; -0.38
1.5-2 years 11 1.64 -0.824 0.024 -1.51; -0.13
Item 5. How much do you enjoy life?
Not at all (1) – a little (2) – a moderate amount (3) – very much (4) – an extreme amount (5)
Baseline 49 3.10 3.31 -0.208 0.083 -0.44; 0.03
Half year 22 3.48 0.166 0.360 -0.20; 0.54
1 year 17 3.35 0.043 0.852 -0.44; 0.52
1.5-2 years 11 3.45 0.145 0.380 -0.21; 0.50
Item 10. Do you have enough energy for everyday life?
Not at all (1) – a little (2) – moderately (3) – mostly (4) – completely (5)
Baseline 49 3.29 4.09 -0.804 <0.001 -1.10; -0.51
Half year 22 3.64 -0.454 <0.001 -0.67; -0.24
1 year 17 3.41 -0.678 <0.001 -1.00; -0.36
1.5-2 years 11 3.55 -0.545 0.052 -1.10; 0.01
1. Are y  able to ccept yo  bodily appearance?
Not at all (1) – a little (2) – mod rately (3) – m stly (4) – c mpletely (5)
8 77 3 589 0 89 29
86 496 0. 7 0 84 15
1 year 88 78 < .001 65 31
73 33 24 1 1 10
16. How satisfi ed are  with your ability to perform dail  living activities?
V ry dissatisfi ed (1) – dissatisfi ed (2) – neither satisfi ed nor dissatisfi ed (3) – satisfi ed (4) 
– very satisfi ed (5)
9 2 88 3 81 -0.932 -1.24; - . 3
2 3 18 28 06 05 2
7 3 24 575 18 04 11
3 55 265 231 0 73 0.20
18. How satisfi ed are you w th yourself?
Very dissatisfi ed (1) – dissatisfi e  (2) – neither satisfi ed nor dissatisfi ed (3) – satisfi ed (4) 
– very satisfi ed (5)
Baseline 49 3.57 3.97 -0.399 0.002 -0.65; -0.15
Half year 22 3.82 -0.152 0.240 -0.41; 0.11
1 year 17 3.82 -0.146 0.270 -0.42; 0.13
1.5-2 years 11 3.73 -0.243 0.116 -0.56; 0.07
Item 25. How well are you able to get around?
Very poor (1) – poor (2) - neither poor nor good (3) – good (4) – very good (5)
Baseline 47 2.49 3.70 -1.211 <0.001 -1.56; -0.87
Half year 22 3.32 -0.382 0.058 -0.78; 0.01
1 year 17 3.53 -0.171 0.433 -0.62; 0.28
1.5-2 years 11 3.36 -0.366 0.255 -0.96; 0.28
Data presented as mean; n = number of patients; CI = confi dence interval
The value of the general elderly population is based on reference 27 
One sample t-tests were used to compare the mean QoL estimates to corresponding estimates in 




Patient-reported outcomes have become a very important outcome of treatment in 
the elderly CLTI patients. (10–12) Considering that a quarter of CLTI patients undergo 
lower limb amputation during the first year after disease onset, there is a surprising 
lack of PROs in the vascular patients with a lower limb amputation. (15) Compared 
to other multicentre studies, we assessed a relatively large number of CLTI patients 
with a lower limb amputation, aged 70 and older, on PROs and clinical outcomes in a 
prospective observational cohort two-center study. A selection of questions from the 
WHOQOL-BREF questionnaire, relevant for patients with a lower limb amputation, 
was compared to the corresponding values of their elderly peers. (27) 
The main finding was that physical QoL and physical HS significantly improved after 
amputation in elderly CLTI patients. Mental HS also improved but only in the long-
term. This study also demonstrated that CLTI patients experienced less symptoms of 
depression after amputation compared to baseline. Mortality rates were also analysed. 
The one-year mortality rate was 39% and two-year was 55%.
Reduced physical functioning and QoL characterize CLTI patients. (2) Therefore, one 
of the goals of the treatment of CLTI is to improve their physical function and QoL. 
(2,28) Primary lower limb amputation, without an attempt at revascularization, is not 
often performed because we believe that these treatment goals cannot be achieved 
with lower limb amputation. Still, a large proportion of CLTI patients must undergo 
secondary lower limb amputation at some point in the course of their disease because 
of inadequate perfusion. Our cohort shows that improved physical QoL and physical 
HS are possible in the long-term. Moreover, the ability to enjoy life, the amount of 
energy elderly patients had, and/or the satisfaction in performing daily living activities 
is comparable to that of the Dutch elderly. Understandably, CLTI patients with a lower 
limb amputation report less pain symptoms than their peers. Still, these patients rate a 
poorer QoL and poorer acceptance of bodily appearance in these specific questions of 
the WHOQOL-BREF questionnaire. However, their scores of the acceptance of bodily 
appearance did not differ from their pre-amputation scores. In terms of personalized 
medicine and shared-decision making, it is important to understand the changes 




Suckow et al stated that QoL assessment in CLTI patients should incorporate patient 
preference. (15) In this study, the WHOQOL-BREF questionnaire was used. Though 
a consensus still has to be reached on a specific QoL measure for CLTI patients with 
a lower limb amputation, the WHOQOL-BREF has the benefit of taking patients’ 
evaluation or satisfaction with functioning into consideration. (14,27) Therefore, we 
argue that the WHOQOL-BREF is an appropriate instrument to measure QoL in CLTI 
patients with a lower limb amputation. In this study, QoL did not deteriorate after 
lower limb amputation. Even more so, patients indicated they were significantly more 
satisfied with their physical QoL after amputation compared with before amputation. 
Other questionnaires, such as the SF-36, lack discriminatory power in CLTI patients 
characterized by their many comorbidities. (15,29,30) Since the SF-12 is an abbreviated 
version of the SF-36; our results of HS improvement, after lower limb amputation, 
should be interpreted with care. Still, the scores on the physical and mental HS scale 
did not deteriorate after lower limb amputation. These results are in line with the 
placebo patient group with a lower limb amputation of Peeters et al in their study 
investigating the effect on HS of bone marrow derived mononuclear cell administration 
in CLTI patients without treatment options. (31) 
The prevalence of depression in PAD patients has a range between 3% and 48%.32 
Arya et al and McDermott et al stated that depression in PAD patients leads to a 
significantly higher risk of mortality. (16,33) Moreover, Arya et al described an increased 
amputation rate in PAD patients with symptoms of depression. (16) A review on 
depression in patients with a lower limb amputation, from varying etiologies, concluded 
that depression rates are relatively high up to 2 years after lower limb amputation. (34) 
However, little is known about depression after lower limb amputation due to CLTI in 
the elderly alone. (35) Our study demonstrated that CLTI patients experienced less 
symptoms of depression after lower limb amputation. A possible explanation for the 
decrease in scores of symptoms of depression can be the relief of ischemic rest pain 
in the limb after lower limb amputation in the elderly CLTI patients. So, from a mood-
disorder point of view, improved outcome is possible with lower limb amputation. 
Therefore, screening for symptoms of depression is important to complement the 
shared-decision making process in elderly CLTI patients.
In patients undergoing lower limb amputation, from any cause, mortality rates are 
extremely high. The 30-day mortality rates and the in-hospital mortality rates range 
between 4% and 22%. (5) After 1 year, mortality rates in CLTI patients are even higher; 
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up to 44% in patients aged 70 or older. (7,36–39) Within 2 years’ time, 1 in 2 patients will 
have deceased after lower limb amputation. (7,38,39) Our results are in line with these 
previously mentioned studies. The 30-day mortality rate was 16%, one-year was 39% 
and two-year was 55%. These high mortality rates raise the question of what outcome 
is more important to achieve after lower limb amputation. Along this line, one should 
consider patients who may benefit from having an earlier lower limb amputation. 
Shared-decision making concerning this topic is important, since each patient may 
value his/her limb salvage differently. 
Clearly, this study has limitations. First, the sample size of CLTI patients with a lower 
limb amputation decreases over time. Due to high mortality rates in this particular 
patient population, the sample size can be considered fairly large for a two-center 
study and also compared to other studies. However, attrition due to mortality could 
have biased our conclusions. Secondly, symptoms of depression were measured by 
self-report questionnaires. Self-report questionnaires are not yet part of standard care. 
The gold standard in diagnosing depression is the use of diagnostic interviews. (40,41) 
However, if one wants to assess symptoms of depression quickly in routine care, the 
CES-D questionnaire is a frequently used and accurate instrument in elderly patients. 
(42) Third, because there was no control group to compare the patients with a lower 
limb amputation to, any changes in QoL, HS and depression following amputation can 
be confounded by other factors not related to the intervention, such as spontaneous 
recovery.
CONCLUSION
Elderly CLTI patients with a lower limb amputation are a fragile population with high 
short and long-term mortality rates. In this study, we concluded that QoL and HS did 
not diminish after lower limb amputation, neither in the short-term or the long-term. 
Moreover, our results show that lower limb amputation in the elderly CLTI patients 
in the long term gives an acceptable QoL, which, in some aspects, is comparable 
to the QoL of their peers. Individual treatment goal setting plays an important role 
when undergoing hospital care, especially in elderly patients. In order to accomplish 
a good shared-decision making process that does not delay the timing of lower limb 
amputation, patients and family should not only be informed about the mortality rates 
but also about the fact that QoL and HS does not seem to diminish in CLTI patients 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
In 2050, 26% of the Dutch population will be older than 65 years. More importantly, one 
out of ten will be aged 80 or older. (1) Cardiovascular pathology, such as chronic limb-
threatening ischemia (CLTI; the end stage of peripheral arterial disease), is related 
to elderly age. Accordingly, the number of elderly patients with CLTI will increase. 
Therefore, providing insights into the treatment outcomes in this specific population is 
an important topic. The focuses of this thesis were these treatment outcomes for the 
elderly CLTI patient population. 
OUTCOME AFTER TREATMENT FOR CHRONIC LIMB-
THREATENING ISCHEMIA IN THE ELDERLY
For the public, providing cost-effective care has a high priority. (2) This is certainly the 
case in the treatment of CLTI, which is laborious and costly. (3) In Chapter 2, the cost-
effectiveness of the treatment for elderly CLTI patients in which surgical treatment is not 
preferred was analyzed. In this study, elderly CLTI patients undergoing endovascular 
treatment or conservative treatment had similar patient characteristics in contrast to the 
patients undergoing surgery. Despite the higher cost of endovascular revascularization, 
this study demonstrated a reasonable cost-effectiveness over conservative treatment. 
Still absolute differences in costs and health state effects were small: €3,825.99 and 
0.10003 QALY. Individual outcomes can easily be influenced by these small differences 
in the execution of endovascular revascularization and conservative treatment and the 
frailty of patients. This leaves room for physicians to ask patients about what they want, 
thus using the shared decision making in the choice of treatment for the fragile elderly 
CLTI patients.
In elderly CLTI patients, the individual circumstances are often mentioned in the 
literature when discussing best treatment options. (4,5) Surgical revascularization 
is incomparable to other treatments in case of objective and traditional outcomes. 
However, outcome of surgery remains limited and costly in a patient population with 
high mortality and morbidity rates. (6–8) So currently, there is a transition from surgical 
revascularization to another treatment options, especially in the elderly CLTI patient 
group. Conclusively, our findings may suggest that conservative treatment is justified 
in some elderly patients without ischemic rest pain and that shared decision making 
may play an important role in personalized medicine.
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Still, a treatment choice cannot be made on the consideration of costs and health 
state alone. Patient-reported outcome measures (PROMS), such as quality of life (QoL) 
and health status (HS) are also very important outcome measurements. (8,9) In daily 
clinical practice, the use of PROMS could involve patients more in their treatment 
and could improve the shared decision-making process. In Chapter 3, long-term QoL 
and HS outcomes are determined in 195 elderly CLTI patients after primary therapy 
(endovascular, surgical, or conservative treatment). In all treatment groups, these 
patients experienced an increase of their physical QoL compared to the baseline 
measurement. Furthermore, 2-year QoL scores were similar to the corresponding 
values of their elderly peers. (10) Interestingly, the physical HS domain also improved in 
scores, except for patients treated conservatively. However, conservative treatment did 
not lead to a deterioration of HS after 2 years. So, surviving CLTI patients experience a 
better QoL and a similar or increased HS 2 year after the start of any treatment. Similar 
to the BASIL study, no significant difference in QoL was detected between treatment 
groups. (11,12) Other studies with long-term QoL and HS outcomes after various 
treatments in CLTI patients are lacking. 
Moreover, QoL and HS can be associated with patient characteristics, such as 
sociodemographic variables, clinical variables and treatment. (13) The course of a 
measured variable (e.q. QoL or HS) over time is called a trajectory. Insight in variables, 
that can influence the trajectory of elderly CLTI patients’ QoL and HS, can aid the 
shared decision-making process when selecting treatment and also gives health care 
providers the opportunity to monitor specific patients more carefully with regard to 
patients’ treatment goals. The trajectories of elderly CLTI patients’ QoL and HS were 
also studied in the 195 elderly CLTI patients after primary therapy. To our knowledge, 
no studies have focused previously on the course of elderly CLTI patients’ QoL or HS 
after treatment. The aim was to find patient characteristics that may help us recognize 
CLTI patients that may need contemplation of the intended treatment. Supplementary 
care can be facilitated when there is insight into the variables that make a patient prone 
to better or worse QoL or HS outcomes. However, no sociodemographic or clinical 
variables significantly influenced the lowest QoL and HS trajectories. Perhaps more 
predictors should have been included in this study. Quality of life and HS can also be 
influenced by anxiety, depression and the presence of family and/or friends. This study 
hopes to encourage further analysis of the influence of biopsychosocial characteristics 
on QoL and HS in elderly CLTI patients. With respect to shared decision making, these 
distinctive variables will provide a very important facet in personalized medicine. In 
order to achieve this, QoL and HS should be implemented in standard medical care.
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Another important facet of the disease CLTI is that patients have a limited life 
expectancy. The 2-year mortality rate after diagnosis is almost as high as 50%. (14) In 
this thesis, the 2-year mortality rate was 42.1%. In Chapter 4, results focus on QoL and 
HS of the elderly CLTI patients who died during follow-up. Results show that QoL and 
HS are no predictors of death. Moreover, except for the mental HS domain, there was 
no difference in QoL and HS between the treatment groups: surgery, endovascular 
revascularization and conservative therapy. This indicates that treatment given to elderly 
CLTI patients does not harm their QoL and HS. Even at the last measurement before 
death, elderly CLTI patients were still equally satisfied with their QoL and HS compared 
to the previous measurement. These results can be of great interest for patients who 
are repetitive revascularized without favorable objective outcomes. Exactly this patient 
population can be facilitated with other treatment options that result in similar QoL 
and HS outcomes. Treatment selection can alter in a shared decision-making process, 
where PROMs are considered of great importance.   
THE EFFECT OF LOWER LIMB AMPUTATION IN THE 
ELDERLY PATIENT
One year after the onset of CLTI, 25% of patients undergone a lower limb amputation 
(15,16) and approximately 35% to 67% of CLTI patients have an amputated limb within 
four years.  (17,18) Although amputation rates remain high despite treatment, little is 
known about PROMs in elderly CLTI patients with a lower limb amputation specifically. 
(19,20) In Chapter 5, short-term QoL and HS were evaluated in the CLTI patients with a 
lower limb amputation in relation to CLTI patients without a lower limb amputation. This 
study showed that patients without a lower limb amputation had statistically significant 
improvement of both physical domains of QoL and HS. Patients with a lower limb 
amputation only had statistically significant improvement of the physical domain of 
the QoL and did not show any statistically significant difference in HS. Although health 
care providers presume that disability in physical functioning, such as walking and 
climbing chairs, equals impaired QoL, we found something different. (19,21) Instead, 
QoL (measured by WHOQOL-BREF) improved whereas HS did not. In our opinion, the 
explanation for this difference should be found in the concept of the questionnaires.  
Health status is an assessment of disability that measures objective physical, 
psychological, and social functioning rated by the patient him/herself (e.g., whether 
a patient is able to adequately engage in specific activities). However, HS does not 
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measure a patient’s subjective wellbeing concerning his/her physical, psychological, 
and social functioning of CLTI patients. (19,22–28) The WHOQOL-BREF questionnaire 
is more suitable for these topics. It provides the opportunity to assess the patient’s 
evaluation of physical, psychological, and social functioning. (29,30) Rather than asking 
a patient whether he/she is able to perform daily activities, the WHOQOL-BREF 
questionnaire asks patients if they are satisfied with their ability to perform certain 
daily living activities.  Though a consensus still has to be reached on a specific QoL 
measure for CLTI patients with a lower limb amputation, Suckow et al. stated that QoL 
assessment in CLTI patients should incorporate patient preference. (19) According 
to this definition, the disease-specific VascuQol questionnaire, used in the PREVENT 
and BASIL trials is a measure of disability, hence HS.  It does not measure QoL in 
CLTI patients with a lower limb amputation. (8,24,31) With respect to shared decision 
making, distinctive QoL questionnaires, like the WHOQOL-BREF, are appropriate 
instruments to measure QoL in CLTI patients with a lower limb amputation and should 
be used in future research.
Other mental health disorders, like depression and anxiety, are not evaluated freq-
uently after amputation in CLTI patients. In patients with PAD, an association is 
assumed between depression and worse outcome, such as lower limb amputation. 
(32,33) Moreover, a higher incidence of lower limb amputation has been described in 
diabetes patients with a depression. (33) In Chapter 6, the symptoms of depression 
and anxiety were studied to explore the effect on lower limb amputation. Based on our 
data, we did not find support for higher amputation rates in patients with greater trait 
anxiety of more symptoms of depression before treatment start. Moreover, symptoms 
of depression and state anxiety did not increase after lower limb amputation. 
When other revascularization options fail and conservative treatment is not sufficient, 
lower limb amputation is a last-resort treatment for CLTI. According to current clinical 
practice, this last-resort treatment needs to be prevented. In contrast to this opinion 
of the health care provider, depressive symptoms seem to decrease over time and 
symptoms of anxiety do not seem to be affected in patients after lower limb amputation 
in our study cohort. A possible explanation for less symptoms of depression after 
lower limb amputation may be the fact that our patient cohort experienced chronic 
ischemic limb pain prior to amputation. Of course, amputation choice cannot be made 
on the consideration of symptoms of depression and anxiety alone. But especially 
in the elderly, expectations and demands after lower limb amputation are lower. So, 
lower limb amputation may not be as harmful for the patient’s wellbeing in terms of 
symptoms of depression and anxiety.
Chapter 8
140
In patients undergoing lower limb amputation from any cause, mortality rates are 
extremely high. In 30 days and in hospital mortality rates range between 4% and 22%. 
(34)and reported factors that might influence these mortality outcomes. Methods 
Embase, PubMed, Cinahl and Psycinfo were searched for publications in any language 
on 30 day or in hospital mortality after major lower limb amputation in population/
regional based studies. PRISMA guidelines were followed. A self developed checklist 
was used to assess quality and susceptibility to bias. Summary data were extracted 
for the percentage of the population who died; pooling of quantitative results was 
not possible because of methodological differences between studies. Results Of the 
9,082 publications identified, results were included from 21. The percentage of the 
population undergoing amputation who died within 30 days ranged from 7% to 22%, 
the in hospital equivalent was 4-20%. Transfemoral amputation and older age were 
found to have a higher proportion of early post-operative mortality, compared with 
transtibial and younger age, respectively. Other patient factors or surgical treatment 
choices related to increased early post-operative mortality varied between studies. 
Conclusions Early post-operative mortality rates vary from 4% to 22%. There are very 
limited data presented for patient related factors (age, comorbidities After 1 year, 
mortality rates in CLTI patients are even higher; up to 44% in CLTI patients aged 70 or 
older. (18,35–38) In two years’ time, 1 in 2 patients will have deceased after lower limb 
amputation. (35,37,38) As mentioned previously, PROMs have become a very important 
outcome of treatment in the elderly CLTI patients. (21,29,39) Surprisingly, there is a lack 
of PROMs in vascular patients with a lower limb amputation. (19) In Chapter 7, CLTI 
patients with a lower limb amputation aged 70 and older were assessed on PROMs 
and mortality rate. The results show that this patient population has a high mortality 
rate of 55% after two years. Nevertheless, physical QoL and HS (both the physical as 
the mental domain) significantly improved in the long term in surviving CLTI patients 
after lower limb amputation. Moreover, our results show that lower limb amputation 
in the elderly CLTI patient in the long term gives an acceptable QoL, which, in some 
aspects, is comparable to the QoL of their healthy peers.
The current guidelines are an advocate of preventing lower limb amputation. (15,40) 
Dutch guidelines even make a case against lower limb amputation in elderly patients. 
(40) The inter-society TASC guidelines give nuances to this statement and acknowledge 
that amputation may offer an expedient return to QoL. (15) The recently published 
global vascular guidelines on the management of chronic limb-treatening ischemia 
recognises five major indications for primary amputation. (41) These indications are 
nonreconstructible arterial disease, destruction of the major weight-bearing portions 
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of the foot, the need for multiple surgical procedures with high morbidity to restore 
a viable lower extremity, and non-functional lower extremity, severe comorbid 
conditions or limited life expectancy. (41) In these last two indications, patients have 
an unchanging or improving QoL after amputation. (41) In our cohort, QoL and HS 
do not deteriorate after lower limb amputation in the short-term and long-term. Even 
more so, patients indicate to be significantly more satisfied with their physical QoL 
and HS after lower limb amputation. Along this line, one should consider patients who 
may benefit from having an earlier lower limb amputation. Shared decision making 
concerning this topic is important to incorporate in the guidelines since each patient 
may value his/her limb salvage differently.
FUTURE PERSPECTIVES
A special focus in CLTI should be on the elderly. Elderly CLTI patients are extremely 
vulnerable, because of frailty and an impaired life expectancy. In this specified CLTI 
patient group, a consensus on treatment has not been reached.  Still, revascularization 
is recommended for all CLTI patients. (15) However, revascularization is not always 
possible. Furthermore, lower limb amputation is often necessary after revascularization 
due to infection or remaining severe ischemic pain. (42) Traditional outcome 
measurements, such as patency- and limb salvage rates, are abundantly researched in 
revascularized CLTI patients. On the other hand, prospective data related to suitable 
PROMS that reflect on the elderly CLTI population are scarce. Especially for elderly CLTI 
patients with a lower limb amputation PROMS and costs are lacking. This thesis gives 
more insight in cost-effective care for frail elderly CLTI patients and PROMS of elderly 
CLTI patients and CLTI patients with a lower limb amputation. When life expectation is 
limited, patency- and limb salvage rates cannot solely determine treatment strategies 
and QoL becomes of great importance. So in daily practice, the focus should not be 
on the revascularization procedure, but on the disease process and PROMs in order to 
discuss with the elderly patient what he/she wants given the various treatment options 
and knowledge about their pros and cons. Only then, a valid shared decision-making 
process can be accomplished in vascular clinics’ daily practice.
In frail elderly, the application of shared decision making is an ongoing process. 
Cognitive impairment, multimorbidities and complex care situations provide for a 
multifaceted shared decision making that is not easily achieved. (43) In the elderly, an 
important aspect of shared decision making is a patient goal orientation. (44) These 
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patient goals focus on the patient’s most urgent problems and not on the underlying 
disease. (45) Therefore, these goals can be individually different in the elderly. 
Future studies should reflect on the entire elderly CLTI population and not only on 
patients that are eligible for revascularization. A special focus should be on elderly 
CLTI patients with a lower limb amputation. Because absolute numbers of elderly CLTI 
patients with a lower limb amputation are low per hospital, Dutch hospitals will have 
to join forces in a prospective multicenter lower limb amputation study to provide 
the currently missing data on elderly CLTI patients with a lower limb amputation. 
Moreover, tools for and studies into shared decision making in the elderly CLTI patients 
are needed. Surgeons should be trained in applying a shared decision-making process 
that is patient goal oriented driven and takes into account patient’s frailty. 
Given the results reported and discussed in this thesis, studies into this very timely 
and relevant topic should be done in order to empower these patients. With insight 
into variables that cause frailty and a diminished QoL and HS course during treatment, 
patients may be selected for pre-operative optimization programs in order to 
improve treatment outcome. Consequently, post-operative care can also be altered. 
In conclusion, a good shared decision-making process can only be accomplished if 
there is a better insight in PROMs for elderly CLTI patients as well as the relationship 
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In 2050 zal 26% van de Nederlandse bevolking ouder zijn dan 65 jaar en 10% ouder 
dan 80 jaar. Hart- en vaatziekten, zoals kritieke ischemie, zijn gerelateerd aan oudere 
leeftijd. Kritieke ischemie is het eindstadium van perifeer arterieel vaatlijden – een 
aandoening veroorzaakt door vernauwing in de bloedvaten van de benen op basis van 
atherosclerose. Kritieke ischemie is invaliderend voor patiënten en heeft grote invloed 
op de kwaliteit van leven en gezondheidstoestand van de patiënt. Het verkrijgen van 
inzicht in de resultaten van de behandelingen in deze groeiende patiëntenpopulatie 
is belangrijk. 
BEHANDELRESULTATEN BIJ KRITIEKE ISCHEMIE IN DE 
OUDERE PATIËNT
Kosteneffectiviteit van zorg is een belangrijk vraagstuk in het maatschappelijk 
debat. De behandeling van kritieke ischemie is arbeidsintensief en kostbaar. (3) In 
dit proefschrift wordt de kosteneffectieve behandeling van oudere patiënten met 
kritieke ischemie, die een endovasculaire of conservatieve behandeling ondergaan, 
geanalyseerd. Ondanks hogere kosten van deze behandeling, is een endovasculaire 
behandeling kosteneffectiever dan een conservatieve behandeling (hoofdstuk 2). De 
absolute verschillen in gezondheidswinst zijn echter klein. Individuele resultaten van de 
behandelingen kunnen beïnvloed worden door dit kleine verschil en de kwetsbaarheid 
van een oudere patiënt. Een chirurgische behandeling kent vaak de beste objectieve 
resultaten. Deze resultaten zijn echter beperkt en onrendabel in een kwetsbare 
patiëntenpopulatie met hoge mortaliteit en morbiditeit. Onze studie concludeert dat 
een conservatieve behandeling soms geoorloofd is in oudere patiënten met kritieke 
ischemie, als er geen sprake is van ischemische rustpijn (hoofdstuk 2). 
Een behandelingskeuze kan niet gemaakt worden op basis van kosten en 
gezondheidswinst alleen. Patiënt-gerapporteerde uitkomsten, zoals kwaliteit van leven 
en gezondheidstoestand, zijn ook belangrijke uitkomstmaten. Gezondheidstoestand 
is een evaluatie van de invloed van ziekte op het lichamelijk, sociaal en psychisch 
functioneren. De patiënt beoordeelt zelf of hij/zij in staat is om bepaalde activiteiten 
te verrichten. Gezondheidstoestand geeft geen subjectief welbevinden omtrent 
lichamelijk, sociaal en psychisch functioneren weer. De WHOQOL-BREF is wel in 
staat om het subjectieve welbevinden van een patiënt weer te geven. In plaats van 
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vragen aan een patiënt of hij/zij dagelijkse activiteiten kan uitvoeren, wordt er in de 
WHOQOL-BREF gevraagd of de patiënt tevreden is met de mate waarin hij/zij deze 
activiteiten kan uitvoeren. Het gebruik van patiënt-gerapporteerde uitkomsten kan 
een patiënt meer betrekken bij zijn/haar behandeling en kan gedeelde besluitvorming 
(shared decision-making) verbeteren in de klinische praktijk. 
In hoofdstuk 3 worden de kwaliteit van leven en gezondheidstoestand op de lange 
termijn bepaald in 195 oudere patiënten met kritieke ischemie na chirurgische, 
endovasculaire en conservatieve behandeling. Patiënten met kritieke ischemie 
ervaren na 2 jaar een betere kwaliteit van leven en een gelijkaardige of verbeterde 
gezondheidstoestand ongeacht welke behandeling gestart was. In een analyse van 
sociodemografische en medische factoren bij 195 patiënten met kritieke ischemie zijn 
geen factoren aan het licht gekomen die de kwaliteit van leven en gezondheidstoestand 
beïnvloeden (hoofdstuk 3). 
In dit proefschrift was de 2-jaars mortaliteit 42,1%. In hoofdstuk 4 van dit proefschrift 
is er aandacht voor de kwaliteit van leven en gezondheidstoestand van de patiënten 
die gedurende follow-up zijn gestorven. De resultaten laten zien dat kwaliteit van 
leven en gezondheidstoestand niet zijn aangedaan in deze patiëntengroep. Ook is er 
geen verschil in kwaliteit van leven en gezondheidstoestand tussen de verschillende 
behandelingsgroepen (met uitzondering van mentale gezondheidstoestand). Deze 
resultaten zijn met name interessant voor patiënten die herhaaldelijk een chirurgische 
of endovasculaire behandeling ondergaan zonder gunstige objectieve resultaten. Juist 
deze patiëntencategorie kan gebaat zijn bij conservatieve therapie, die gekenmerkt 
wordt door een vergelijkbare kwaliteit van leven en gezondheidstoestand. 
HET EFFECT VAN AMPUTATIE VAN DE ONDERSTE 
EXTREMITEIT IN DE OUDERE PATIËNT
Er is weinig bekend over patiënt-gerapporteerde uitkomsten na beenamputatie in 
de oudere patiënt met kritieke ischemie. Oudere patiënten met kritieke ischemie 
hadden een significante verbetering van het fysieke domein van kwaliteit van leven 
zowel met als zonder amputatie van de onderste extremiteit (hoofdstuk 5). Ook al 
verwachten gezondheidsmedewerkers dat een beperking in het fysiek functioneren 
(zoals wandelen en traplopen) resulteert in een verminderde kwaliteit van leven, laat 
onze studie het tegenovergestelde zien. In patiënten met perifeer arterieel vaatlijden 
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wordt er een relatie vermoed tussen depressie en amputatie. In de onderzochte 
patiëntengroep van dit proefschrift is de kans op beenamputatie niet hoger als er 
symptomen zijn van angst of depressie aan het begin van de behandeling voor kritieke 
ischemie (hoofdstuk 6). Ook na een beenamputatie is er geen toename in angst of 
depressieve symptomen. 
De mortaliteit van patiënten met kritieke ischemie die een beenamputatie ondergaan 
blijft hoog. Na 2 jaar is 55% van de patiënten overleden (hoofdstuk 7). De patiënten 
die na een beenamputatie blijven leven hebben op de lange termijn een acceptabele 
kwaliteit van leven, die op sommige domeinen vergelijkbaar is met de kwaliteit van 
leven van hun Nederlandse leeftijdsgenoten (hoofdstuk 7).
TOEKOMSTPERSPECTIEVEN
De bevindingen van dit proefschrift willen een stimulus zijn voor verder onderzoek van 
de behandeling van de oudere patiënt met kritieke ischemie. Oudere patiënten met 
kritieke ischemie zijn extreem kwetsbaar en hebben een beperkte levensverwachting. 
Juist in deze kwetsbare patiëntengroep is er nog geen consensus over de behandeling. 
Toch wordt revascularisatie in alle patiënten met kritieke ischemie aanbevolen. 
Revascularisatie is echter niet altijd mogelijk en daarnaast is soms een amputatie van 
de onderste extremiteit noodzakelijk. Traditionele uitkomstmaten, zoals patency en 
behoud van het lidmaat, zijn ruimschoots onderzocht in gerevasculariseerde patiënten 
met kritieke ischemie. Er is echter een gebrek aan patiënt-gerapporteerde uitkomsten 
in deze patiëntengroep. Dit geldt eens te meer voor patiënten met kritieke ischemie 
die een beenamputatie ondergaan. Als de levensverwachting van een patiënt beperkt 
is, kunnen traditionele uitkomstmaten alléén geen behandelingsstrategie bepalen 
en worden patiënt-gerapporteerde uitkomsten, zoals kwaliteit van leven, belangrijk. 
Dit proefschrift pleit voor integratie van patiënt-gerapporteerde uitkomsten in de 
dagelijkse praktijk, zodat de patiënt en arts een weloverwogen keuze kunnen maken 
voor een behandelingsstrategie. Alleen in dat geval, kan een gedeelde besluitvorming 
plaatsvinden op de polikliniek van de vaatchirurgie.
Bij kwetsbare ouderen is het bereiken van een gedeelde besluitvorming bemoeilijkt 
door cognitieve stoornissen, multipele co-morbiditeiten en zorgbehoefte. Voor oudere 
patiënten wordt de gedeelde besluitvorming gedreven door de behandeldoelen 
van de patiënt. Deze behandeldoelen zijn vaak gefocust op symptoombestrijding. 
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Toekomstig onderzoek zal ook deze kwetsbare oudere patiënt met kritieke ischemie 
moeten includeren in de studies. Speciale aandacht zal uit kunnen gaan naar de 
oudere patiënt met kritieke ischemie die een beenamputatie ondergaat. Nederlandse 
ziekenhuizen zullen hiervoor hun krachten moeten bundelen in een prospectieve 
multicenter studie. Een volgende logische stap is het ontwikkelen van handvaten om 
gedeelde besluitvorming met de oudere kwetsbare patiënt te verbeteren. Chirurgen 
zullen getraind moeten worden een gedeelde besluitvorming die gedreven is door 
de behandeldoelen van de patiënt en zijn/haar kwetsbaarheid te implementeren in 
de klinische praktijk. Inzicht in factoren die kwetsbaarheid en een slechte kwaliteit van 
leven veroorzaken kan resulteren in een programma voor kwetsbare oudere patiënten 
met kritieke ischemie om behandeluitkomsten te verbeteren.
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